UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 10-K
____________________
(Mark One)
xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
For the fiscal year ended December 31, 2017
¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission File No.: 001-16753
amn-20201231_g1.jpg
AMN HEALTHCARE SERVICES, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware06-1500476
(State or Other Jurisdiction of

Incorporation or Organization)
(I.R.S. Employer

Identification No.)
12400 High Bluff Drive, 8840 Cypress Waters Boulevard
Suite 100
San Diego, California
300
92130
DallasTexas75019
(Address of principal executive offices)(Zip Code)

Registrant’s Telephone Number, Including Area Code: (866) 871-8519
____________________

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of each exchange on which registered
Common Stock, $0.01 par valueAMNNew York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:
None.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes  x  No  ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.  Yes  ¨  No  x
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  x  No  ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer  x
Accelerated Filer
Accelerated filero
Non-accelerated filero
Smaller reporting companyo

Emerging growth companyo

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  Yes  ☒  No  
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  ¨��  No  x
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of June 30, 2017,2020, was $1,844,580,240$2,111,094,202 based on a closing sale price of $39.05$45.24 per share.
As of February 14, 2018,24, 2021, there were 47,658,34847,180,479 shares of common stock, $0.01 par value, outstanding.
Documents Incorporated By Reference: Portions of the registrant’s definitive proxy statement for the annual meeting of stockholders scheduled to be held on April 18, 201821, 2021 have been incorporated by reference into Part III of this Form 10-K.





                        

TABLE OF CONTENTS
 
Item Page
PART I
1.
1A.
1B.
2.
3.
4.
PART II
5.
6.
7.
7A.
8.
9.
9A.
9B.
PART III
10.
11.
12.
13.
14.
PART IV
15.
16.


Item Page
   
 PART I 
   
1.
1A.
1B.
2.
3.
4.
   
 PART II 
   
5.
6.
7.
7A.
8.
9.
9A.
9B.
   
 PART III 
   
10.
11.
12.
13.
14.
   
 PART IV 
   
15.
 



                        

References in this Annual Report on Form 10-K to “AMN Healthcare,” “AMN,” the “Company,” “we,” “us” and “our” refer to AMN Healthcare Services, Inc. and its wholly owned subsidiaries. This Annual Report contains references to our trademarks and service marks. For convenience, trademarks, service marks and trade names referred to in this Annual Report do not appear with the ®, TM, or SM symbols, but the lack of references is not intended to indicate that we will not assert our right to these trademarks, service marks and trade names.


PART I
 
10-K Introduction & Summary


This section provides an overview of AMN Healthcare Services, Inc. It does not contain all of the information you should consider. Please read the entire Annual Report on Form 10-K carefully before voting or making an investment decision.


In Particular, Please See the Following Sections
Forward-Looking StatementsRisk
Factors
Risk
FactorsPage 8
Management’s Discussion & Analysis
Financial

Statements




Index of frequently requested 10-K information


Five-Year Performance Graph
Selected Financial DataResults of Operations
Results of Operations
Liquidity and Capital Resources
Financial Statement Footnotes


Item 1.Business
Item 1.    Business
 
Overview of Our Company and Business Strategy
We are the leader and innovator in total talent solutions for the healthcare workforce solutions and staffing servicessector in the United States. OurWe are passionate about all aspects of our mission is to deliverto:
Deliver the bestright talent and insights to help healthcare organizations optimize their workforce, provideworkforce.
Provide healthcare professionals opportunities to do their best work toward qualityhigh-quality patient care, and createcare.
Create a values-based culture of innovation in which our team members can achieve their goals. As the leader and innovator in workforce
Our solutions we enable our clients to optimize their workforce, to successfully reducesimplify staffing complexity, increase efficiency and enhanceelevate the patient experience. Through ourOur comprehensive suite of talent solutions we provideprovides management, staffing, recruitment, technology, analytics, and related services to build and manage all or a portionpart of our clients’ healthcare workforce needs,needs. We offer temporary, project, and permanent career opportunities to our healthcare professionals, from nurses, doctors, and allied health professionals to healthcare leaders and executives both onin a temporary and permanent basis.
Overvariety of clinical settings across the past several years, we have evolved from a traditional healthcare staffing provider into a strategic healthcare workforce solutions partner to our clients. We expanded our portfolio to serve a diverse and growing set of talent-related needs. This includes managed services programs (“MSP”), vendor management systems (“VMS”), predictive analytics, workforce optimization consulting, clinical scheduling, recruitment process outsourcing (“RPO”), permanent placement, interim executives and leaders, and remote medical coding. Our clients look to usnation to help them buildachieve their personal and develop high quality, flexible workforces that deliver great outcomesprofessional goals.
Our strategy is designed to support growth in the number and an engaged patient experience. Our networksize of talented clinicianscustomer relationships and leaders trust us to place them in an environment that helps them grow and leverage their skills and expertise.


When expanding our services and products, we consider the following key criteria: (1) addressing the most pressing current and future needs of our customers and talent network, (2) alignment with our core operations, expertise, and access to healthcare professionals, (3) strengthening and broadening of our client and healthcare professional relationships, (4) reduction in sensitivity to economic cycles and (5) enhancement of our long-term sustainable, differentiated business model. Since 2010, we have expanded, developed or acquired the following offerings:
Managed Services Programs. We acquired Medfinders, oneexpansion of the nation’s leading providers of clinical workforce MSP, accelerating our growth in this area and clearly establishing AMN Healthcare as the nation’s largest provider of clinical workforce management solutions.
Vendor Management Systems. Through our acquisitions of ShiftWise and Medefis,markets we offer two industry-leading SaaS-based, vendor neutral management systems, which allows our clients to utilize a technology-based approach to more efficiently manage their contingent staffing needs.
Interim Leadership Staffing and Executive Search Services. We acquired B.E. Smith (“BES”) and The First String Healthcare (“TFS”), which we believe made us the nation’s largest provider of interim healthcare leadership staffing, including clinical leaders and executive leaders, healthcare executive search services and other related advisory services.
Workforce Optimization Services.Through our acquisition of Avantas, we offer workforce optimization services, including consulting, data analytics, predictive modeling and SaaS-based scheduling technology. We believe Avantas’ proprietary scheduling software helps create more cost effective staffing plans for our clients as compared to traditional methodologies.
Recruitment Process Outsourcing. We continue to invest in our RPO service line, adding technologies and other capabilities to meet our clients’ growing needs for core staff recruitment expertise and services and to capitalize on the market opportunity as it evolves.
Health Information Management. Through our acquisition of Peak Provider Solutions (“Peak”), we offer remote medical coding, case management and related health information management auditing and consulting solutions to hospitals and physician medical groups nationwide.
Expanded Our Network of Qualified Healthcare Professionals. Through our Onward Healthcare acquisition, we increased our supply of healthcare professionals and recruiting capabilities in our traditional healthcare staffing areas of nurse, allied and locum tenens.
Per Diem Staffing. Our acquisition of Medfinders provided us an entry point into the local, or per diem, staffing market. We provide per diem staffing, often in conjunction with our larger MSP clients. Through investment in new technologies, we are streamlining the match of the right clinicians to the right assignment to meet these on-demand needs.
As a core component of our growth strategy and profitability, we also seek to strengthen and create efficiencies in our operational and technology capabilities. As a result, in 2015, we embarked on a multi-year investment in the modernization of our front office, back office and infrastructure domains. We have also increased our efforts to integrate technology-based solutions in recruitment through continued investment in our digital capabilities, mobile applications and data analytics. These efforts will provide a more seamless and efficient workflow for our team members, our healthcare professionals, and our clients. Further, updated business systems will help us realize greater scale and cost efficiencies when fully implemented.
Moving forward, we believe our strategy will enable us to continue to grow the number of customers and segments of the market we serve, while enhancing our profitability and operating leverage. This means drivingserve. Driving increased adoption of our existing workforcetalent solutions through cross-selling will deepen and staffing services through cross selling and deepeningbroaden our customer relationships as they grow and expand.relationships. We will continue to innovate, develop and invest in new, complementary solutions to our portfolio that optimize our clients’ workforce and better engage our talent networks.network. We expect this will help us expand our strategic customer relationships to help clients address their workforce pain points, while driving more recurring revenue, with an improved margin mix that, similar to our evolution to MSPs,leadership in managed services programs (“MSP”), will be less sensitive to economic cycles.

1

Over the past decade, our business has evolved beyond traditional healthcare staffing and recruitment services; we have become a strategic total talent solutions partner with our clients. We expanded our portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to our healthcare professional staffing and recruitment services, our suite of healthcare workforce solutions includes MSPs, vendor management systems (“VMS”), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, clinical labor scheduling, recruitment process outsourcing (“RPO”), revenue cycle solutions, and credentialing software services. We enable clients to build and optimize their healthcare talent to deliver great patient outcomes and experience. Our talent network includes thousands of highly skilled, experienced professionals who trust us to place them in environments that expand and leverage their qualifications and expertise.
When developing and acquiring talent solutions, both services and technology, we consider many important criteria: (1) identifying and addressing the most pressing current and future needs of our clients and talent network; (2) alignment with our core operations, expertise, and access to healthcare professionals; (3) ways to deepen and broaden our client and healthcare professional relationships; (4) talent and technology solutions that expand the markets we serve; (5) businesses that reduce our sensitivity to economic cycles; and (6) offerings that differentiate us from competitors.
Continuous improvement of our operations and business technology is a core component of our growth strategy and profitability goals. We have accelerated the integration of technology-based solutions in our core recruitment processes through targeted investment in digital capabilities, mobile applications and data analytics. These innovations provide a more seamless and efficient workflow for our team members, our healthcare professionals and our clients. Our investments in technology systems will help us realize greater scale, agility, and cost efficiencies.

Human Capital Management
Providing total talent solutions to our clients is our primary source of revenue generation, so development of a broad base of healthcare professionals and corporate team members who are valued, respected and supported is essential to drive shareholder value and achieve our long-term growth objectives. To support these objectives, our human capital management strategy generally focuses on talent recruitment, engagement and retention, diversity, equality and inclusion, and employee health and safety. The central components of our human capital management strategy and infrastructure are described in more detail in this section below.

The strength of our human capital management infrastructure and strategy was also instrumental to our COVID-19 response in 2020. When the COVID-19 pandemic hit, the Company and its teams worked quickly to assess the impact of the pandemic on our team members, healthcare professionals, communities, clients and their patients and took immediate action to mitigate the risks to all stakeholders. Throughout the pandemic, caring for the well-being of our team members and healthcare professionals has been a primary focus. We are working hard every day to ensure that all of our team members and healthcare professionals have the resources available to help them navigate the continued challenges and stresses associated with the pandemic.

The successful implementationcare, support and safety of our strategy reliesfrontline healthcare professionals was and remains at the forefront for us. We have provided our healthcare professionals with additional support from our corporate clinical staff, third party vendors providing mental health resources, sick pay while quarantined and other products and services to show our appreciation for them.

We quickly and effectively moved our roughly 3,000 corporate team members to a fully remote work environment in large part uponMarch 2020 and our offices remain closed. Our team members have continued to support our clients and healthcare professionals with the superior executionhighest level of service from their home offices without a disruption in our business operations. We have provided our team members with stipends and other resources in 2020 and 2021 to establish their new working environments.

As of December 31, 2020, we had approximately 3,000 corporate team members, which includes both full-time and part-time. During the fourth quarter of 2020, we had an average of (1) 10,084 nurses, allied and other healthcare professionals, (2) 314 executive and clinical leadership interim staff, and (3) 1,239 medically qualified interpreters working for us. This does not include independent contractors, such as our locum tenens and contract interpreters, who were not our employees in 2020.

Diversity, Equality and Inclusion
At AMN, our diversity, equality and inclusion philosophy is grounded in the belief that we should respect all voices, seek diverse perspectives, and succeed when we act together as a positive force for all of humanity. We have the opportunity to make an impact on each other, our industry, and other communities by fostering a diverse team with a passion for social justice and equity. We are committed to actively engaging in building an organization and society where equality is the norm, equity is achieved, and inclusion is universal so that we may all thrive.

We believe that our diverse workforce, and inclusive environment drives the innovation and better outcomes that have made us the leader in total talent solutions. While the diverse backgrounds and experiences we seek are broad, here is a snapshot of some of the diversity of our key initiativesteam as of January 2021: 65% of our team members are women; 64% of our supervisor
2

through senior manager roles are held by women; 56% of our management, salesboard of directors are women; 32% of our team members are non white; our team is 57% Millennials, 34% Generation X, 8% Baby Boomers, and operations teams. Accordingly,less than 1% other generations; and team members self-identified as veterans, disabled, and LGBTQ+, each represent approximately 2% of our employment value proposition is differentiated to attractteam. In 2019 and retain high-quality team members. We foster a growth-oriented, values-driven culture, talented leadership, and a collegial work environment that challenges us to develop and meet our personal and professional goals. In 2017,2020, AMN was recognized as #11 on the Fortune 100 Fastest Growing Companies list and was also named to the 2018 Human Rights Campaign Corporate Equality Index and 2018 Bloomberg Gender-Equality Index. AMN continuesalso received a top ranking – 95 out of 100 – in the Human Rights Campaign Foundation’s 2021 Corporate Equality Index. We believe that our robust human capital management infrastructure and commitment to bediversity, equality and inclusion is fundamental to our continued recognition as one of America’s Most Responsible Companies in 2020 and 2021. In addition, the Women’s Forum of New York and 2020 Women on Board recently recognized us for advancing gender parity in the boardroom.

Team Member Engagement
To assess the engagement of our team members and take action to mitigate risks associated with workforce engagement, development and retention, we conduct an annual survey to assess the engagement of our team members. While the format of our annual survey varies from year to year to best capture different measures of employee engagement, the results of each assessment are discussed with our board of directors, and is incorporated into our annual human capital management strategic planning process. In 2019, our overall employee engagement was measured at 80%. We did not conduct an annual engagement survey in 2020 due to the disruptions presented by the COVID-19 pandemic. In the Spring of 2020, we surveyed our team members to see how they were doing in the new environment and also solicited feedback on how they thought the Company was handling the pandemic. We were pleased with the results, with the team members providing high marks noting that the Company placed their safety as a leading employerparamount and was recognized as a 2017 Becker’s Hospital Review Top 150 Places to Workvery transparent in Healthcare and 2017 National Best & Brightest Companies to Work For lists. HRO Today awarded AMN Healthcare and our client, BJC HealthCare, as their 2017 Partnership

in Recruiting Excellence recipient, and Staffing Industry Analysts recognized AMN’s U.S. industry leadership naming us again ascommunications about the largest temporary healthcare staffing firm, the largest travel nurse staffing providercurrent situations and the largest allied healthcare staffing provider.evolving future.


In addition, during 2020, we focused our attention and efforts on increasing engagement through our growing number of employee resource groups. Best practice research indicates that team member engagement and retention is positively impacted if team members are connected to like-minded peers and leaders. To build an inclusive infrastructure of employee resource groups that closely aligns with the diverse interests and backgrounds of our team members, we believe we have invested into and dedicated the necessary resources. As of December 31, 2020, we actively supported seven employee resource groups and approximately 30% of our corporate team members are members of a resource group. Each of our employee resource groups is sponsored by members of our executive team.

Our Services
In 2017,2020, we conducted our business through three reportable segments: (1) nurse and allied solutions, (2) locum tenensphysician and leadership solutions and (3) othertechnology and workforce solutions. We set forthdescribe each segment’s revenue and operating incomeresults under “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations.” Through our business segments, we provide our healthcare clients with a wide range of workforce solutions and staffing services as set forth below.
(1)Travel Nurse Staffing.We provide clients with nurses, most of them registered nurses, to work temporary assignments under our flagship brand, American Mobile, as well as under our Onward Healthcare and Nurses Rx brands.brand. Assignments in acute-care hospitals, including teaching institutions, trauma centers and community hospitals, comprise the majority of our assignments. The length of the assignment varies with a typical travel nurse assignment of 13 weeks. Under our O’Grady-PeytonO’Grady Peyton brand, we also recruit nurses internationally from English speaking countries who immigrate to the United States under a permanent resident visa (Green Card) and who typically work for us for a period of 24 months.
(2)
Rapid Response Nurse Staffing and Labor Disruption Services.We provide a shorter-term staffing solution of typically up to eight weeks under our NurseChoice brand to address hospitals’ urgent need for registered nurses, including electronic medical records conversion projects. NurseChoice is targeted to recruit and staff nurses who can begin assignments within one to two weeks in contrast to the three to five week lead time that may be required for travel nurses. We also provide labor disruption services for clients involved in strikes of nurses and allied professional staff through our HealthSource Global Staffing brand.
(3)
Local, or Per Diem, Staffing. Through our Nursefinders brand, we provide our clients local staffing, often in support of our MSP clients. Local staffing involves the placement of locally-based healthcare professionals, predominantly nurses, on daily shift work on an as-needed basis. Hospitals and healthcare facilities often give only a few hours’ notice of their local staffing assignments that require a turnaround from their staffing agencies of generally less than 24 hours.
(4)
Locum Tenens Staffing. We place physicians of all specialties, advanced practice clinicians and dentists on an independent contractor basis on temporary assignments with all types of healthcare organizations throughout the United States, including hospitals, health systems, medical groups, occupational medical clinics, psychiatric facilities, government institutions and insurance companies. We recruit these professionals nationwide and typically place them on assignment lengths ranging from a few days up to one year. We market these services through our Staff Care and Locum Leaders brands.
(5)
Allied Staffing.We provide allied health professionals, both on a travel and local staffing basis, under the Med Travelers and Club Staffing brands to acute-care hospitals and other healthcare facilities such as skilled nursing facilities, rehabilitation clinics, and retail and mail-order pharmacies. Allied health professionals include such disciplines as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants and pharmacists.
(6)
Physician Permanent Placement Services. We provide physician permanent placement services to hospitals, healthcare facilities and physician practice groups throughout the United States. Using a distinct consultative approach that we believe is particularly client-oriented, we perform the vast majority of these services on a retained basis through our Merritt Hawkins and MillicanSolutions (“Millican”)brands. To a smaller degree, we also perform these services on a contingent basis through our Kendall & Davis brand. We also provide physician and executive leadership search services focused on serving academic medical centers and children’s hospitals nationwide through our MillicanSolutions brand. Our broad specialty offerings include over 70 specialist and sub-specialist opportunities such as internal medicine, family practice and surgery.
(7)
Interim Leadership Staffing and Executive Search Services.Through our recent acquisitions of BES and TFS, we provide executive and clinical leadership interim staffing, healthcare executive search services and advisory services. Practice areas include senior healthcare executives, physician executives, chief nursing officers and other clinical and operational leaders. This business line provides us greater access to the “C-suite” of our clients and prospective clients, which we believe helps improve our visibility as a strategic partner to them and helps provide us with cross-selling opportunities.
(8)
Managed Services Programs.Many of our clients and prospective clients use a number of healthcare staffing agencies to fulfill their nurse, allied and locum tenens staffing needs. We offer a comprehensive managed
(2)Rapid Response Nurse Staffing and Labor Disruption Services.We provide a shorter-term staffing solution of typically up to eight weeks under our NurseChoice and HealthSource Global Staffing brands to address hospitals’ urgent need for registered nurses. NurseChoice and HealthSource Global Staffing recruit and place nurses who can begin assignments within one to two weeks in contrast to the three to five week lead time that may be required for travel nurses. We also provide labor disruption services for clients involved in strikes of nurses and allied professional staff through our HealthSource Global Staffing brand.
(3)Local, or Per Diem, Staffing. Through our Nursefinders brand, we provide our clients local staffing, often in support of our MSP clients. Local staffing involves the placement of locally-based healthcare professionals on daily shift work on an as-needed basis. Hospitals and healthcare facilities often give only a few hours’ notice of their local staffing assignments that require a turnaround from their staffing agencies of generally less than 24 hours.
(4)Locum Tenens Staffing. We place physicians of all specialties, advanced practice clinicians and dentists on an independent contractor basis on temporary assignments with all types of healthcare organizations throughout the United States, including hospitals, health systems, medical groups, occupational medical clinics, psychiatric
3

                        

facilities, government institutions and insurance companies. We recruit these professionals nationwide and typically place them on assignment lengths ranging from a few days up to one year. We market these services through our Staff Care and Locum Leaders brands.
(5)Allied Staffing.We provide allied health professionals under the Med Travelers and Club Staffing brands to acute-care hospitals and other healthcare facilities such as skilled nursing facilities, rehabilitation clinics, schools, and retail and mail-order pharmacies. Allied health professionals include such disciplines as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants and pharmacists.
(6)Revenue Cycle Solutions. Our AMN Revenue Cycle Solutions brand provides skilled labor solutions for remote medical coding, clinical documentation improvement, case management, and clinical data registry, and also provides auditing and advisory services. Clients include hospitals and physician medical groups nationwide.
(7)Physician Permanent Placement Services. We provide retained search, physician permanent placement services to hospitals, healthcare facilities and physician practice groups throughout the United States through our Merritt Hawkinsbrand.
(8)Interim Leadership Staffing and Executive Search Services.Under the brand name B.E. Smith, we provide executive and clinical leadership interim staffing, healthcare executive search services and advisory services. Practice areas include senior healthcare executives, physician executives, chief nursing officers and other clinical and operational leaders. We also provide physician executive leadership search services focused on serving academic medical centers and children’s hospitals nationwide. This business line provides us greater access to the “C-suite” of our clients and prospective clients, which we believe helps improve our visibility as a strategic partner to them and helps provide us with cross-selling opportunities.
(9)Recruitment Process Outsourcing. We offer our clients RPO services, customized to their particular needs, in which we recruit, hire and/or onboard permanent clinical and nonclinical positions on behalf of the client. Our RPO program leverages our expertise and support systems to replace or complement a client’s existing internal recruitment functions for permanent hiring needs, providing cost-effective flexibility to our clients to determine how to best obtain and use recruiting resources.
(10)Managed Services Programs.Many of our clients and prospective clients use a number of healthcare staffing agencies to fulfill their healthcare professional needs. We offer a comprehensive managed services program, in which we manage all or a portion of a client’s contingent staffing needs. This service includes both the placement of our own healthcare professionals and the utilization of other staffing agencies to fulfill the client’s staffing needs. We believe an MSP reduces redundanciesincreases efficiencies and cost savings for our clients and allows them to optimize theirfacilities staffing utilization.optimization. We often use our own VMS technology as part of our MSP, which we believe further enhances the value of our service offering. In 2017,2020, we had approximately $1.2$1.7 billion in annualized gross billings under management under our MSPs and approximately 40%50% of our consolidated revenue flowed through MSP relationships, comparedwhich has steadily increased over the past decade.
(11)Language Interpretation Services.Through our acquisition of Stratus Video, our AMN Language Services division provides healthcare interpretation services via remote video, over the phone, and onsite in-person. These services are all supported by proprietary technology platforms, which enable real-time routing of video and audio calls, drive client efficiency with an in-person scheduling mobile application, and power interoperability with multiple telehealth platforms.
(12)Vendor Management Systems.Some clients and prospective clients prefer a vendor-neutral VMS technology that allows them to self-manage procurement of contingent clinical labor and their internal float pool. We provide three software as a service (“SaaS”)-based VMS technologies, ShiftWise, Medefis and b4health, to clients that desire this option. Our VMS technologies provide, among other things, control over a wide variety of tasks via a single system and consolidated reporting. In 2020, we had approximately 1%$1.9 billion in 2008.annualized gross billings flow through our VMS programs.
(9)
Vendor Management Systems.Some clients and prospective clients wish to utilize a vendor-neutral VMS technology that allows them to self-manage the procurement of their contingent clinical labor. We provide two VMS technologies, ShiftWise and Medefis, to clients that desire this option. Our VMS technology provides, among other things, control over a wide variety of tasks via a single system and consolidated reporting. In 2017, we had approximately $1.2 billion in annualized gross billings flow through our VMS programs, for which we typically earn a 4-5% fee.
(13)Workforce Optimization Services.We provide workforce optimization services, including consulting, data analytics, predictive labor demand modeling and SaaS-delivered scheduling technology. Our Avantas business provides proprietary scheduling software, Smart Square, that uses predictive analytics to create better, more accurate and timely staffing plans for a client, which has been demonstrated to reduce a client’s clinical labor spend.
(14)Credentialing Services. Through our acquisition of Silversheet, we provide innovative credentialing software solutions to clinicians and healthcare enterprises. Silversheet’s products help reduce the complexity and challenges of the clinician credentialing process, enhance our clients’ ability to provide safe, effective, and high-quality medical care for patients, and greatly improve the clinician experience.
4

(15)Digital Staffing. Through investment in new technologies, we are streamlining the match of the right clinicians to the right assignment to meet the on-demand needs of our clients. The AMN Passport and AMN hub mobile applications allow nurses and allied professionals to quickly search hundreds of jobs, book assignments that match their qualifications and availability, and receive instantaneous alerts and updates, helping our clients quickly fill workforce gaps.
(16)Flex Pool Management. We offer an innovative and comprehensive workforce solution that provides technology and services to build and manage dedicated resource pools. This regional workforce model utilizes standardized processes, integrated systems, and advanced scheduling technology to mobilize clinicians and meet the growing demand of our MSP clients.

We typically experience modest seasonal fluctuations during our fiscal year and they tend to vary among our business segments. These fluctuations can vary slightly in intensity from year to year. Over the past five years, these seasonal fluctuations have been muted in our consolidated results.

(10)
Recruitment Process Outsourcing. We offer our clients RPO services, customized to their particular needs, pursuant to which we recruit, hire and/or onboard permanent clinical and nonclinical positions on behalf of the client. Our RPO program leverages our expertise and support systems to replace or complement a client’s existing internal recruitment function for permanent staffing needs, providing flexibility to our clients to determine how to best garner the recruiting resources necessary to fill their permanent staffing needs.
(11)
Workforce Optimization Services.We provide workforce optimization services, including consulting, data analytics, predictive modeling and SaaS-based scheduling technology. Through the acquisition of Avantas, we acquired proprietary scheduling software, Smart Square, which utilizes predictive analytics to create better, more accurate and timely staffing plans for a client, which we believe effectively reduces the client’s aggregate clinical labor spend.
(12)
Health Information Management. Through our recent acquisition of Peak, we offer remote medical coding, case management and related health information management consulting solutions to hospitals and physician medical groups nationwide.
Our Healthcare Professionals
The recruitment and retention of a sufficient number of qualified healthcare professionals to work on temporary assignments on our behalfand for placement at healthcare organizations is critical to the success of our business. Healthcare professionals choose temporary assignments for a variety of reasons that include seeking flexible work opportunities, exploring diverse practice settings, building skills and experience by working at prestigious healthcare facilities, avoiding the demands and political environment of working as permanent staff, working through life and career transitions, and as a means of access into a permanent staff position.



We recruit our healthcare professionals, depending on the particular service line, under the following brands: American Mobile, Nursefinders, NurseChoice, NursesRx, HealthSource Global Staffing, Onward Healthcare, O’Grady Peyton International, Med Travelers, Club Staffing, Onward Healthcare,Staff Care, Locum Leaders, B.E. Smith, The First String Healthcare, O’Grady Peyton International, Staff CareMerritt Hawkins, and Locum Leaders. We believe that ourAMN Revenue Cycle Solutions. Our multi-brand recruiting strategy together with ouris supported by innovative and effective marketing programs that focus on lead management, including our digital presence on websites, social media, and mobile applications, and our word-of-mouthapplications. Word-of-mouth referrals from the thousands of current and former healthcare professionals who we have placed enhancesenhance our effectiveness at reaching a larger number of healthcare professionals. While we are committed

Our process to this multi-brand strategy, we regularly assess our brands to drive brand clarity and maximize efficiencies. As a result of this evaluation, during 2016 we consolidated our Linde Healthcare brand into the Locum Leaders brand that we acquired in 2015.

When recruiting for healthcare professionals, in addition to other recruitment and staffing firms, we also compete with hospital systems that have developed their own recruitment departments and interim staffing pools. We believe that we attract and retain healthcare professionals because of ourfor temporary assignments and permanent placement depends on (1) offering a large selection of assignment locations,assignments and placements in a variety of geographies and settings andwith opportunities providingfor career development, (2) creating attractive compensation packages, (3) developing passionate, knowledgeable recruiters and service professionals who understand the needs of our healthcare professionals and provide a personalized approach, and (4) excellent reputation.maintaining a reputation for service excellence. The attractive compensation package that we provide our temporary healthcare professionals includes a competitive wage, professional development opportunities, professional liability insurance, 401(k) plan and health insurance. In addition, we may provide reimbursements for meals and incidentals, travel and housing, or we may provide company housing if a healthcare professional elects not to receive reimbursement.

Our Geographic Markets and Client Base
During each of the past three years, (1) we generated substantially all of our revenue in the United States and (2) substantially all of our long-lived assets were located in the United States. We typically generate revenue in all 50 states. During 2017,2020, the largest percentages of our revenue were concentrated in California, Texas and New York.


OverMore than half of our temporary and contract healthcare professional assignments occur at acute-care hospitals. In addition to acute-care hospitals, we provide services to sub-acute healthcare facilities, physician groups, rehabilitation centers, dialysis clinics, pharmacies,schools, home health service providers and ambulatory surgery centers. Our clients, many of the largest and most prestigious and progressive health care systems in the country, include Kaiser Foundation Hospitals, New York Presbyterian Health System, MedStar Health, HCA, Stanford Hospital and Clinics, Johns Hopkins Health System, Providence Health, PeaceHealth and Partners Healthcare.country. Kaiser Foundation Hospitals (and its affiliates), to whom we provide clinical managed services, comprised approximately 13%14% of our consolidated revenue and 18%17% of our nursingnurse and allied solutions segment’s revenue for the twelve months ended December 31, 2017.2020. No other client healthcare system or single client facility comprised more than 3%5% of our consolidated revenue for the twelve months ended December 31, 2017. Our success in winning MSP contracts means some larger health systems have grown and may continue to grow more significantly relative to our other revenue sources. The dynamics could lead to a greater client concentration than we have historically experienced.2020.


Our Industry
The primary markets in which we compete are U.S. temporary and contract healthcare staffing, workforce solutions and workforce solutions.executive search. Staffing Industry Analysts (“SIA”) estimates that the segments of the target market in which we primarily operate have an aggregate 2018 estimated market sizehealthcare staffing markets of $17 billion, of which travel nurse, per diem nurse, locum tenens and allied healthcare comprise $5.4have an aggregate 2020 estimated market size of $17.3 billion, $3.7comprising $6.7 billion, $3.7$3.5 billion, $3.4 billion and $4.2$3.7 billion, respectively. We also operate within the interim leadership, executive search, physician permanent placement, RPO, VMS, revenue cycle solutions, and workforce optimization services, medical coding, case management and consulting services markets. We estimate the market potentialsize of these additional segmentsmarkets to be at least $5 billion.$5.0 billion in 2020.
5

Industry Demand Drivers
Many factors affect the demand for temporarycontingent and permanent healthcare staffing,talent, which, accordingly, affects the size of the markets in which we primarily operate. Of these many factors, we believe the following serve as some of the most significant drivers of demand.
Economic Environment and Employment Rate. The demandDemand for our services is affected by growth inof the U.S. economy, which impactsinfluences the employment rate. Growth in real U.S. gross domestic product generally correlates todrives rising employment rates. When these macro-drivers are positive, itFavorable macro drivers typically resultsresult in increased demand for our services and vice versa.services. Generally, we believe a positive economic environment and growing employment lead to increasing demand for healthcare services. As employment levels rise, healthcare facilities, like employers in many industries, experience higher levels of employee attrition and have a relatively morefind it increasingly difficult time findingto obtain and retain permanent staffing to fill their needs.
staff.

Supply of Healthcare Professionals. While reports differ on the existence and extent of current and future healthcare professional shortages, many regions of the United States are experiencing a shortage of physicians and nurses that we believe will persist in the future. According to the Association of American Medical Colleges, the physician shortage is expected to range from 61,70046,900 to 94,700121,900 physicians by 2025.2032. In nursing, geographic and specialty-based shortages are also expected through 2025.2030, and we believe have been exacerbated by the COVID-19 pandemic. Demand for our services is positively correlated with activity in the permanent labor market. When nurse vacancy rates increase, temporary nurse staffing orders typically increase as well.
General Demand for Healthcare Services. Changes in demand for healthcare services, particularly at acute healthcare hospitals and other inpatient facilities, like skilled nursing facilities, affect the demand for our services. According to the U.S. Department of Health and Human Services, with the passage of the Affordable Care Act, the uninsured population declined by more than 2018 million people between the passage of the Affordable Care Act in 2010 and 2017.2018. Growth of the insured population contributed to a relatively sharp increase in national healthcare expenditures beginning in 2014. Current administration policy efforts may negatively impact this trend. Additionally, the U.S. population continues to age, and medical technology advances are contributing to longer life expectancy. A pronounced shift in U.S. age demographics is expected to boost growth of health expenditures, projected by the Centers for Medicare & Medicaid Services at a 5.4% annual rate from 2019-2028. According to the U.S. Census Bureau, the number of adults age 65 or older whois on pace to grow an estimated 80% between 2020 and 2030. People over 65 are three times more likely to have a hospital stay and twice as likely to visit a physician office compared with the rest of the population, is on pace to grow an estimated 36% between 2015 and 2025. This maypopulation. These dynamics could place upward pressure on demand for the services we provide in the coming years. Not only does the age-demographic shift affect healthcare services demand, it also complicates the supply of skilled labor, as an increasing number of clinicians are aging out of the workforce.
Adoption of Workforce Solutions. We believe healthcare organizations are increasingly seekingseek sophisticated, innovative and economically beneficial workforcetotal talent solutions that improve patient outcomes. We believe the prevalence of workforce solutions, such as MSP, VMS, RPO and workforce optimization tools, in the healthcare industry is still underpenetrated in comparison with non-healthcare sectors. During 2017,2020, approximately 40%50% of our consolidated revenues were generated through MSP relationships, which we believeestimate is higher than the industry average.our competitors. The changes in reimbursement methodologies, coupled withtalent shortage and significance of clinical labor representing a significant portion of ain healthcare facility’sfacilities’ cost structure,structures may accelerate the adoption of strategic outsourced workforce solutions, which would likelycould place upward pressure on the demand for the services we provide.
6

Industry Competition


The healthcare temporary staffing and workforce solutions industry is highly competitive. We compete in national, regional and local markets for healthcare facilityorganization clients and healthcare professionals. We believe that our comprehensive suite of total talent solutions, our commitment to quality and service excellence, our execution capabilities, and our national footprint create a compelling value proposition for our existing and prospective clients that give us distinct, scalable advantages over smaller, local and regional competitors and companies whose solution offerings, sales and execution capabilities are not as robust. The breadth of our talent solutions allows us to provide even greater value through a more strategic and consultative approach to our clients. In addition, we believe that our size, scale and sophisticated candidate acquisition processes give us access to a larger pool of available, high quality candidates than most of our competitors, while substantial word-of-mouth referral networks and recognizable brand names enable us to attract, engage, and grow a diverse, high-quality network of healthcare professionals. We also believe that our comprehensive suite of workforce solutions, our commitment to quality and service excellence, our execution capabilities, our national footprint and our access to a wide network of high-quality talent create a compelling value proposition for our clients and prospective clients. We believe that our size, geographic scope, broad spectrum of workforce solutions, talented and passionate team members and brand reputation give us distinct, scalable advantages over smaller, local and regional competitors and companies whose service offerings, sales and execution capabilities are not as robust. The breadth of our services allows us to provide even greater value through a more strategic, consultative and solution-oriented approach to our clients.

Larger firms, such as us, also generally have a deeper, more comprehensive infrastructure with a more established operating model and processes that provide the long-term stability and foundation for quality standards recognition, such as the Joint Commission staffing agency certification and National Committee for Quality Assurance Credentials Verification Organization certification. HRO Today named AMN Healthcare the number one position among all MSP providers in size of deals, and we also were honored in the Baker’s Dozen for quality of services, breadth of services and overall MSP capabilities. Once again, in 2020, Staffing Industry Analysts recognized AMN’s U.S. industry leadership naming us as the largest temporary healthcare staffing firm, the largest travel nurse staffing provider and the largest allied healthcare staffing provider.


We are the largest provider of nurse and allied healthcare staffing in the United States. In the nurse and allied healthcare staffing business, we compete with a few national competitors together with numerous smaller, regional and local companies, particularly in the per diem business.companies. We believe we are the third largest provider of locum tenens staffing services in the United States. The locum tenens staffing market consists of many small- to mid-sized companies with only a relatively small number of national competitors of which we are one. The healthcare interim leadership staffing, healthcare executive search services, and physician permanent placement services marketmarkets, where we believe we hold a strong leading position ispositions, are also highly fragmented and consistsconsist of many small- to mid-sized companies that do not have a national footprint. We also believe we have a market-leading share in managed services solutions, including VMS and MSP, and healthcare language interpretation services, which is the fastest growing market segment, after our acquisition of Stratus Video. Our leading competitors vary by segment and include CHG Healthcare Services, Jackson Healthcare, Medical Solutions, RightSourcing, Cross Country Healthcare, Jackson Healthcare, Aya Healthcare, HealthTrust Workforce Solutions, and Aureus Medical Group.WittKieffer. When recruiting for healthcare professionals, in addition to other executive search and staffing firms, we also compete with hospital systems that have developed their own recruitment departments.

Licensure For Our Business
Some states require state licensure for businesses that employ, assign and/or place healthcare professionals. We believe we are currently licensed in all states that require such licenses and take measures to ensure compliance with all state licensure requirements. In addition, the healthcare professionals who we employ or independently contract with are required to be individually licensed or certified under applicable state laws. We believe we take appropriate and reasonable steps to validate that our healthcare professionals possess all necessary licenses and certifications. We design our internal processes to ensure

that the healthcare professionals that we directly place with clients have the appropriate experience, credentials and skills. Our travel nurse, and allied healthcare staffing divisions, all of ourand locum tenens brands and all of our local staffing officesdivisions have received Joint Commission certification. We have also obtained our Credentials Verification Organization certification from the National Committee for Quality Assurance.

EmployeesGovernment Regulation
AsWe are subject to the laws of December 31, 2017,the United States and certain foreign jurisdictions in which we operate and the rules and regulations of various governing bodies, which may differ among jurisdictions. Compliance with these laws, rules and regulation has not had, approximately 2,980 corporate employees. During the fourth quarterand is not expected to have, a material effect on our capital expenditures, results of 2017, we had an average of (1) 9,234 nurses, allied and other clinical healthcare professionals, (2) 384 executive and clinical leadership interim staff, and (3) 349 medical coding professionals and case managers contracted to work for us. This does not include our locum tenens, all of whom are independent contractors and not our employees.operations, or competitive position.


Additional Information
We incorporated in the state of Delaware on November 10, 1997. We maintain a corporate website at www.amnhealthcare.com. We make available our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to these reports, as well as proxy statements and other information free of charge through our website as soon as reasonably practicable after being filed with or furnished to the Securities and Exchange Commission (“SEC”). Such reports, proxy statements and other information are also available on the SEC’s website, http://www.sec.gov. The information found on our website and the SEC’s website is not part of this Annual Report on Form 10-K or any other report we file with or furnish to the SEC.

7


Special Note Regarding Forward-Looking Statements
This Annual Report on Form 10-K, including the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains, and certain oral statements made by management from time to time, may contain, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are subject to safe harbors under the Securities Act and the Exchange Act. We base these forward-looking statements on our current expectations, estimates, forecasts and projections about future events and the industry in which we operate. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “should,” “would,” “project,” “may,” variations of such words and other similar expressions. In addition, statements that refer to projections of financial items; anticipated growth; future growth and revenue; future economic conditions and performance; plans, objectives and strategies for future operations; and other characterizations of future events or circumstances, are forward-looking statements. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ from those implied by the forward-looking statements in this Annual Report on Form 10-K are described under the caption "Risk Factors"“Risk Factors” below, elsewhere in this Annual Report on Form 10-K and in our other filings with the SEC. Shareholders,Stockholders, potential investors, and other readers are urged to consider these factors in evaluating the forward-looking statements and cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


Item 1A.Risk Factors

Item 1A.    Risk Factors

You should carefully read the following risk factors in connection with evaluating us and the forward-looking statements contained in this Annual Report on Form 10-K. Any of the following risks could materially adversely affect our business or our consolidated operating results, financial condition or cash flows, which, in turn, could cause the price of our common stock to decline. The risk factors described below and elsewhere in this Annual Report on Form 10-K are not the only risks we face. Factors we currently do not know, factors that we currently consider immaterial or factors that are not specific to us, such as general economic conditions, may also materially adversely affect our business or our consolidated operating results, financial condition or cash flows. The risk factors described below qualify all forward-looking statements we make, including forward-looking statements within this section entitled “Risk Factors.”


To develop and prioritize the following risk factors, we review risks to our business that are informed by our formal Enterprise Risk Management program, industry trends, the external market and financial environment as well as dialogue with leaders throughout our organization. Our risk factor descriptions are intended to convey our assessment of each applicable

risk and such assessments are integrated into our strategic and operational planning.
 
Risk Factors that May Affect the Demand for Our Services
The widespread outbreak of illness or other public health crisis could have an adverse effect on our business, financial condition and results of operations.

We could be negatively affected by the widespread outbreak of an illness or any other public health crisis. The COVID-19 pandemic has negatively impacted the global economy and created significant volatility and disruption of financial markets. There remains a significant risk that the “shelter-in-place” orders, quarantines, restrictions in and access to non-emergency healthcare services and restrictions on travel and mass gatherings that were ordered throughout 2020 and into 2021 to slow the spread of the virus may, once relaxed, be reinstituted if COVID-19 rates climb in parts of the country. In addition, many “non-essential” businesses continue to restrict their operations or have shifted to a remote working environment, which restricts, and may continue to restrict, the delivery of non-emergency healthcare.

Demand for our staffing services and workforce technology solutions has fluctuated significantly over the course of the COVID-19 pandemic. Demand for non-essential and elective healthcare has been negatively impacted by the COVID-19 pandemic. During 2020, many hospitals and other healthcare entities significantly decreased, and may continue to restrict, their utilization of certain temporary healthcare professionals, interpreters, coders and permanent recruitment and placement services, which resulted, and may continue to result, in decreased demand for many of our service offerings and utilization of our workforce technology platforms. Many individuals may continue to forgo non-essential and elective healthcare even after “safer at home” restrictions and recommendations are lifted, which could negatively impact healthcare utilization and demand for our services. We expect that any decreased demand resulting from decreased healthcare utilization will have an adverse effect on our business, financial condition and results of operations. We are unable to predict the duration and extent to which demand for our services will be negatively impacted by the COVID-19 pandemic.
8

                        
In addition, the significant spike in unemployment that has resulted, and may continue to result, from the COVID-19 pandemic will likely cause an increase in under- and uninsured patients, which generally results in a reduction in overall healthcare utilization and a decrease in demand for our services. At this time, we are unable to predict the duration and extent to which our businesses will be negatively impacted by the increased unemployment and under- and uninsured rates resulting from the COVID-19 pandemic.
The COVID-19 pandemic, and any other outbreak of illness or other public health crises, may also disrupt our operations due to the unavailability of our corporate team members or healthcare professionals due to illness, risk of illness, quarantines, travel restrictions or other factors that limit our existing or potential workforce and pool of candidates. In addition, we may experience negative financial effects related to the COVID-19 pandemic due to higher workers’ compensation and health insurance costs, for which we are largely self-insured. We may also be subject to claims regarding the health and safety of our healthcare professionals and our corporate team members.
Given the economic impact the COVID-19 pandemic has had on the financial condition of many hospitals and healthcare systems, many of our clients have experienced cash flow issues and difficulty gaining access to sufficient credit, which has, in some cases, impaired their ability to make payments to us, timely or otherwise, for services rendered and we experienced an increase to our allowance for credit losses for accounts receivable in 2020 that may continue due to the uncertainly caused by the COVID-19 pandemic. We may also be subject to claims from these clients relating to the ability to provide services under terms and conditions that they believe are fair and reasonable.

The foregoing and other continued disruptions to our business as a result of COVID-19 could have an adverse effect on our business, financial condition and results of operations. The extent of the impact of COVID-19 on our operational and financial performance will depend on future developments, including the duration and spread of the COVID-19 outbreak, which is highly uncertain and cannot be predicted at this time.

Economic downturns and slow recoveries could result in less demand from clients and pricing pressure that could negatively impactour financial condition.
Demand for staffing services is sensitive to changes in economic activity. As economic activity slows, hospitals and other healthcare entities typically experience decreased attrition and reduce their use of temporary employees before undertaking layoffs of their regular employees, which results in decreased demand for many of our service offerings. In times of economic downturn and high unemployment rates, permanent full-time and part-time healthcare facility staff are generally inclined to work more hours and overtime, resulting in fewer available vacancies and less demand for our services. Fewer placement opportunities for our temporary clinicians, physicians and physiciansleaders also impairs our ability to recruit and place them both on a temporary and permanent basis.
In addition, many healthcare facilities utilize temporary healthcare professionals to accommodate an increase in hospital admissions. Conversely, when hospital admissions decrease in economic downturns, due to reduced consumer spending, a rise in unemployment causing an increase in under- and uninsured patients or other factors, the demand for our temporary healthcare professionals typically declines. This may have an even greater negative effect on demand for physicians in certain specialties such as surgery, radiology and anesthesiology. In addition, we may experience more competitive pricing pressure during periods of decreased patient occupancy and hospital admissions, negatively affecting our revenue and profitability.


During challenging economic times, our clients, in particular those that rely on state government funding, may face issues gaining access to sufficient credit, which could result in an impairment of their ability to make payments to us, timely or otherwise, for services rendered. If that were to occur, we may increase our allowance for doubtful accounts and our days sales outstanding would be negatively affected.


If we are unable to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement and client needs, we may not remain competitive.
Patient delivery settings continue to evolve, giving rise to alternative modes of healthcare delivery, such as retail medicine, telemedicine and home health. In addition, changes in reimbursement models and government mandates are also impacting the healthcare environments.


Our success depends upon our ability to develop innovative workforce solutions, and quickly adapt to changing marketplace conditions, such as reimbursement changes, and evolving client needs, come into compliancecomply with new federal or state regulations and differentiate our services and abilities from those of our competitors. The markets in which we compete are highly competitive, and our competitors may respond more quickly to new or emerging client needs and marketplace conditions. The development of new service lines and business models requires close attention to emerging trends and proposed federal and state legislation
9

related to the healthcare industry. If we are unable to anticipate changing marketplace conditions, adapt our current business model to adequately meet changing conditions in the healthcare industry and develop and successfully implement innovative services, we may not remain competitive.


Consolidation of healthcare delivery organizations could negatively affect pricing of our services and increase our concentration risk.
Healthcare delivery organizations are consolidating, providing them with greater leverage in negotiating pricing for services. Consolidations may also result in us losing our ability to work with certain clients because the party acquiring or consolidating with our client may have a previously established service provider they elect to maintain. In addition, our clients may increase their use of intermediaries such as vendor management service companies and group purchasing organizations that may enhance their bargaining power. These dynamics each separately or together could negatively affect pricing for our services and our ability to maintain certain clients.

Hospital concentration coupled with our success in winning managed services contracts means our revenues from some larger health systems have grown and may continue to grow substantially relative to our other revenue sources. For example, Kaiser Foundation Hospitals (and its affiliates) (collectively, “Kaiser”) comprised approximately 14% of our consolidated revenue in 2020. If we were to lose Kaiser as a client or were unable to provide a significant amount of services to Kaiser, whether directly or as a subcontractor, such loss may have a material adverse effect on our revenue, results of operations and cash flows.

Intermediary organizations may impede our ability to secure new and profitable contracts with our clients.
 
Our business depends upon our ability to maintain our existing contracts and secure new, profitable contracts. Outside of our managed services contracts, our client contracts are not typically exclusive and our clients are generally free to offer temporary staffing assignments to our competitors. Additionally, our clients may choose to purchase these services through intermediaries such as group purchasing organizations or competitors offering MSP services, with whom we establish relationships in order to continue to provide our staffing services to certain of our healthcare facilities. These intermediaries may negatively affect our ability to obtain new clients and maintain our existing client relationships by impeding our ability to access and contract directly with clients and may also negatively affect the profitability of these client relationships. In addition, our inability to establish relationships with these intermediaries may result in us losing our ability to work with certain healthcare facilities.
 
Consolidation of healthcare delivery organizations could negatively affect pricing of our services and increase our concentration risk.

Healthcare delivery organizations are consolidating, providing them with greater leverage in negotiating pricing for services. In addition, we have seen an increase in our clients’ use of intermediaries such as vendor management service companies and group purchasing organizations that may also provide organizations with enhanced bargaining power. These dynamics each separately or together could negatively affect pricing for our services.

Hospital concentration coupled with our success in winning managed services contracts means our revenues from some larger health systems have grown and may continue to grow substantially relative to our other revenue sources. For example, Kaiser Foundation Hospitals (and its affiliates) (collectively, "Kaiser") comprised approximately 13% of our consolidated revenue in 2017. If we were to lose Kaiser as a client or were unable to provide a significant amount of services to Kaiser, whether directly or as a subcontractor, such loss may have a material adverse effect on our revenue, results of operations and cash flows.
The ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts through predictive analytics, online recruiting or otherwise, may affect the demand for our services whichthat could negatively affect our revenue, results of operations and cash flows.business.
 
If our clients are able to increase the effectiveness of their staffing and recruitment functions through analytics, automation or otherwise, their need for our services may decline. With the advent of technology and more sophisticated staffing management and recruitment processes, clients may be able to successfully increase the efficiency and effectiveness of their internal staffing management and recruiting efforts, through more effective planning and analytic tools, internet- or social media-based recruiting or otherwise. Such new technologies and processes could reduce the demand for our services, which could negatively affect our revenue, results of operations and cash flows.business.


The repeal or significant erosion of the Patient Protection and Affordable Care Act (“ACA”)without a corresponding replacement may negatively affect the demand for our services.

10

In 2010, the adoption of the ACA brought significant reforms to the health care system that included, among other things, a requirement that all individuals have health insurance (with limited exceptions). As a result of the ACA, the uninsured population declined by more than 2018 million through 2016.people between 2010 and 2018. In December 2017, the individual mandate was repealed. If there is a rollback of aspects of the individual mandate repeal actually leadsACA, such as Medicaid expansion, it may lead to a significant reduction in demand for the healthcare services and the demand for our services may decline. If members of the investor community believe that a further repeal of, or significant changes to, the ACA are forthcoming, and that such actions may significantly reduceincluding court rulings repealing the number of insured or the demand for our services,entire ACA, it may have negative effect on the price of our common stock.

Regulatory and Legal Risk Factors
Investigations, claims and legal proceedings alleging medical malpractice, anti-competitive conduct, violations of employment, privacy and wage regulations and other theories of liability asserted against us could subject us to substantial liabilities.

Like all employers, we must also comply with various laws and regulations relating to employment and pay practices and from time to time may be subject to individual and class action lawsuits related to alleged wage and hour violations under California and Federal law. We are subject to possible claims alleging discrimination, sexual harassment and other similar activities in which we or our hospital and healthcare facility clients and their agents have allegedly engaged. We are also subject to examination of our payroll practices from various federal and state taxation authorities from time to time. While we believe that our employment and pay practices materially comply with all applicable laws and regulations, we are nonetheless named as defendants in these lawsuits and actions.Because of the nature of our business, the impact of these employment and payroll laws and regulations may have a more pronounced effect on our business. There is a risk that we could be subject to payment of significant additional wages, insurance and employment, and payroll-related taxes and sizeable statutory penalties negatively impacting our financial position, results of operations and cash flows. These laws and regulations may also impede our ability to grow the size and profitability of our operations. In addition, our involvement in these matters and any related adverse rulings may result in increased costs and expenses, cause us from time to time to significantly increase our legal accruals and/or modify our pay practices, all of which would likely have an adverse impact on our financial performance and profitability.

We, along with our clients and healthcare professionals, are subject to investigations, claims and legal actions alleging malpractice or related legal theories. At times, plaintiffs name us in these lawsuits and actions regardless of our contractual obligations, the competency of the healthcare professionals, the standard of care provided by the healthcare professionals, the quality of service that we provided or our actions. In certain instances, we are contractually required to indemnify our clients against some or all of these potential legal actions.

The size and nature of our business requires us to collect substantial personal information of healthcare professionals and other team members that is subject to a myriad of privacy-related laws from multiple jurisdictions that regulate the use and disclosure of such information. In addition, many of our healthcare professionals have access to client proprietary information systems and patient confidential information. We may be required to incur significant costs to comply with mandatory privacy and security standards and protocols imposed by law, regulation, industry standards or contractual obligations with our clients. In addition, an inherent risk of the collection and access to such information includes possible claims from unintentional or intentional misuse, disclosure or use of this information. Such claims may result in negative publicity, injunctive relief, criminal investigations or charges, civil litigation, payment by us of monetary damages or fines, or other adverse effects on our business, which may be material.

We are also subject to certain laws and regulations applicable to recruitment and employment placement agencies with which we must comply in order to continue to conduct business in that specific state.

As we grow and increase our leadership position, we are at greater risk for anti-competitive conduct claims and investigations, such as violation of federal and state antitrust laws, unfair business practices and “price-gouging.”

We maintain various types of insurance coverage for these types of claims, including professional liability, errors and omissions, employment practices and cyber, through commercial insurance carriers and a wholly-owned captive insurance company and for other claims such as wage and hour practices we are uninsured. The cost of defending such claims, even if groundless, could be substantial and the associated negative publicity could adversely affect our ability to attract, retain and place qualified employees and healthcare professionals in the future. We may also experience increased insurance premiums and retention and deductible accruals that we may not be able to pass on to our clients, thereby reducing our profitability. Moreover, our insurance coverage and reserve accruals may not be sufficient to cover all claims against us.
11


We are subject to federal and state healthcare industry regulation including conduct of operations, costs and payment for services and payment for referrals as well as laws regarding employment practices and government contracting.

The healthcare industry is subject to extensive and complex federal and state laws and regulations related to conduct of operations, costs and payment for services and payment for referrals. We provide workforcetalent solutions and servicestechnologies on a contract basis to our clients, who pay us directly. Accordingly, Medicare, Medicaid and insurance reimbursement policy changes generally do not directly impact us. Nevertheless, reimbursement changes in government programs, particularly Medicare and Medicaid, can and do indirectly affect the demand and the prices paid for our services. For example, our clients could receive reduced or no reimbursements because of a change in the rates or conditions set by federal or state governments whichthat would negatively affect the demand and the prices for our services. Moreover, our hospital, healthcare facility and physician practice group clients could suffer civil and criminal penalties, and be excluded from participating in Medicare, Medicaid and other healthcare programs for failure to comply with applicable laws and regulations whichthat may negatively affect our profitability.

A portion of our hospital and healthcare facility clients are state and federal government agencies, where our ability to compete for new contracts and orders, and the profitability of these contracts and orders, may be affected by government legislation, regulation or policy. Additionally, in providing services to state and federal government clients and to clients who participate in state and federal programs, we are also subject to specific laws and regulations, which government agencies have broad latitude to enforce. If we were to be excluded from participation in these programs or should there be regulatory or policy changes or modification of application of existing regulations adverse to us, it would likely materially adversely affect our brand, business, results of operations and cash flows.

The success of our business depends on our ability to quickly and efficiently assist in obtaining licenses and privileges for our healthcare professionals. The costs to provide these credentialing services impact the revenue and profitability of our business.


We are also subject to certain state laws and regulations applicable to recruitment and placement agencies. Like all employers,“nursing pools” with which we must also comply with various laws and regulations relatingin order to employment and pay practices. There is a riskcontinue to conduct business in that we could be subject to payment of additional wages, insurance and employment and payroll-related taxes. Because of the nature of our business, the impact of these employment and payroll laws and regulations may have a more pronounced effect on our business. These laws and regulations may also impede our ability to grow the size and profitability of our operations.particular state.
 
The challenge to the classification of certain of our healthcare professionals as independent contractors could adversely affect our profitability.
 
We treatHistorically, we have treated our locum tenens, which include physicians and certain advanced practitioners, such as certified nurse anesthetists, nurse practitioners and physician assistants, as independent contractors. Certain state laws regarding classification of independent contractors have been modified in the past few years and as a result, we have altered our classification of certain locum tenens providers in certain instances.Other states and/or the Federal government may choose to adopt similar restrictions that may require us to expand our employee classifications for locum tenens. If this occurs, it could increase our employee costs and expenses and could negatively impact our profitability.

In addition, Federal or state taxing authorities may take the position that such professionalslocum tenens are employees exposing us to additional wage and insurance claims and employment and payroll-related taxes. A reclassification of our locum tenens clinicians and physicians to employees from independent contractors could result in liability that would have a significant negative impact on our profitability for the period in which such reclassification was implemented, and would require changes to our payroll and related business processes, which could be costly. In addition, many states have laws that prohibit non-physician owned companies from employing physicians, referred to as the “corporate practice of medicine.” If our independent contractor physicians were classified as employees in states that prohibit the corporate practice of medicine, we may be prohibited from conducting our locum tenens staffing business in those states under our current business model, which may have a substantial negative effect on our revenue, results of operations and profitability.
Investigations, claims and legal proceedings alleging medical malpractice, violation of employment and wage regulations and other theories of liability asserted against us could subject us to substantial liabilities.
We, along with our clients and healthcare professionals, are subject to investigations, claims and legal actions alleging malpractice or related legal theories. At times, plaintiffs name us in these lawsuits and actions regardless of our contractual obligations, the competency of the healthcare professionals, the standard of care provided by the healthcare professionals, the quality of service that we provided or our actions. In certain instances, we are contractually required to indemnify our clients against some or all of these potential legal actions.
Additionally, we may be subject to various employment claims, including state and federal wage and hour claims, by our corporate employees and our employed healthcare professionals that could require us to pay significant additional compensation to such employees and professionals while also exposing us to sizable statutory penalties. We are also subject to possible claims alleging discrimination, sexual harassment and other similar activities in which we or our hospital and healthcare facility clients and their agents have allegedly engaged. As we grow and increase our leadership position, we are at greater risk for anti-competitive conduct claims such as violation of federal and state antitrust laws and unfair business practices arising from our agreements with our employees, contractors, clients and vendors.
The nature of our business requires us to place our healthcare professionals in the workplaces of other businesses. Many of these individuals have access to client proprietary information systems and confidential information. An inherent risk of such activity includes possible claims of intentional misconduct, release, misuse or misappropriation of client intellectual property, confidential information, funds or other property, cybersecurity breaches affecting our clients or us, criminal activity, torts or other claims. Such claims may result in negative publicity, injunctive relief, criminal investigations or charges, civil litigation, payment by us of monetary damages or fines, or other adverse effects on our business, which may be material.
We maintain various types of insurance coverage for these types of claims, including professional liability and employment practices, through commercial insurance carriers and a wholly-owned captive insurance company. The cost of defending such claims, even if groundless, could be substantial and the associated negative publicity could adversely affect our ability to attract, retain and place qualified employees and healthcare professionals in the future. We may also experience increased insurance premiums and retention and deductible accruals that we may not be able to pass on to our clients, thereby reducing our profitability. Moreover, our insurance coverage and reserve accruals may not be sufficient to cover all claims against us.

We are also subject to examination of our payroll practices from various federal and state taxation authorities from time to time and an unforeseen negative outcome from such an exam could have a negative impact on our financial position, results of operations and cash flows.

Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer and could subject us to substantial liabilities.
In the ordinary course of our business, we collect and store sensitive data, such as our proprietary business information and that of our clients as well as personally identifiable information of our healthcare professionals and employees, including full names, social security numbers, addresses, birth dates and payroll-related information, in our data centers, on our networks and in hosted SaaS-based solutions provided by third parties. Our employees may also have access to, receive and use personal health information in the ordinary course of our business. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures and business controls, our information technology and infrastructure, including the third party SaaS-based technology in which we store personally identifiable information and other sensitive information of our healthcare professionals and employees, may be vulnerable to attacks by hackers, breached due to employee error, malfeasance or other disruptions or subject to the inadvertent or intentional unauthorized release of information. Any such occurrence could compromise our networks and the information stored thereon could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could (1) result in legal claims or proceedings, liability under laws that protect the privacy of personal information and regulatory penalties, (2) disrupt our operations and the services we provide to our clients and (3) damage our reputation, any of which could adversely affect our profitability, revenue and competitive position.
Additionally, the possession and use of personal information and data in conducting our business subjects us to legislative and regulatory burdens in the United States and other countries. We may be required to incur significant costs to comply with mandatory privacy and security standards and protocols imposed by law, regulation, industry standards or contractual obligations with our clients.


Risk Factors Related to Our Operations, Personnel and Information Systems
Our inability to implement new infrastructure and technology systems and technology disruptions may adversely affect our operating results and ability to manage our business effectively.
We have technology, operations and human capital infrastructures to support our existing business. Our ability to deliver services to our clients and to manage our commercial technologies, internal systems and data depends largely upon our access to and the performance of our management information and communications systems, including our VMS, client relationship management systems and client/healthcare professional-facing self-service websites. These technology systems also maintain accounting and financial information upon which we depend to fulfill our financial reporting obligations. We must continue to invest in this infrastructure and we have embarked on a multi-year plan to upgrade and convert our infrastructure, back office and front office network platforms to support our growth, enhance our management and utilization of data and improve our efficiency. Implementing new systems is costly and involves risks inherent in the conversion to a new technology platform, including loss of information, disruption to our normal operations, changes in accounting procedures and internal control over financial reporting, as well as problems achieving accuracy in the conversion of electronic data. Failure to properly or adequately address these issues could result in increased costs, the diversion of management’s and employees’ attention and resources and could materially adversely affect our operating results, internal controls over financial reporting and ability to manage our business effectively. Furthermore, if we are unable to continue to improve our technology and operations processes to gain efficiency and support our growth, our financial results will be adversely affected.

Although we have risk mitigation measures, these systems, and our access to these systems, are not impervious to floods, fire, storms, or other natural disasters, or service interruptions. There also is a potential for intentional and deliberate attacks to our systems, which may lead to service interruptions, data corruption or data theft. Additionally, these systems are subject to other non-environmental risks, including technological obsolescence and lack of strategic alignment with our evolving business. If our current or planned systems do not adequately support our operations, are damaged or disrupted or if we are unable to replace, repair, maintain or expand them, it may adversely affect our business operations and our profitability.

Disruption to or failures of our SaaS-based technology or our inability to adequately protect our intellectual property rights with respect to such technology could reduce client satisfaction, harm our reputation and negatively affect our business.

The performance, reliability and security of the SaaS-based technologies, such as ShiftWise, Medefis and Avantas Smart Square, are critical to such offerings’ operations, reputation and ability to attract new clients. Some of our clients rely on our SaaS-based technology to perform certain of their operational functions. Accordingly, any degradation, errors, defects, disruptions or other performance problems with our SaaS-based technology could damage our or our clients’ operations and reputations and negatively affect our business. We are converting to new instances of our vendor management system technologies with the platform conversion heightening our risk of business disruption. If any of these problems occur, our

clients may, among other things, terminate their agreements with us or make indemnification or other claims against us, which may also negatively affect us.

Additionally, if we fail to protect our intellectual property rights adequately with respect to our SaaS-based technology, our competitors might gain access to it, and our business might be harmed. Moreover, any of our intellectual property rights protecting our SaaS-based technology, including our newly developed vendor management platforms, may be challenged by others or invalidated through litigation, and defending our intellectual property rights might also entail significant expense. Accordingly, despite our efforts, we may be unable to prevent third parties from using or infringing upon or misappropriating our intellectual property with respect to our SaaS-based technology, which may negatively affect our business as it relates to our SaaS-based offerings.

Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations.
Cyber incidents can result from deliberate attacks or unintentional events. These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these incidents or techniques, timely discover them, or implement adequate preventative measures. Our information technology may not provide sufficient protection, and as a result we may lose significant information about us or our employees or clients. Other results of these incidents could include, but are not limited to, disrupted operations, liability for stolen assets or the disclosure of personally identifiable information of our employees or independent contractors, misstated financial data, increased cybersecurity protection costs, litigation and reputational damage adversely affecting customer or investor confidence.
 
If we do not continue to recruit and retain sufficient quality healthcare professionals at reasonable costs, it could increase our operating costs and negatively affect our business and our profitability.
We rely significantly on our ability to recruit and retain a sufficient number of healthcare professionals who possess the skills, experience and licenses necessary to meet the requirements of our clients. With rising clinician burnout rates resulting from the COVID-19 pandemic, an ongoing shortage of certain qualified nurses and physicians in many areas of the United States and low unemployment rates for nurses and physicians, competition for the hiring of these professionals remains intense. We compete with healthcare staffing companies, recruitment and placement agencies, including online staffing and recruitment agencies, and with hospitals, healthcare facilities and physician practice groups to attract healthcare professionals based on the quantity, diversity and quality of assignments offered, compensation packages, and the benefits that we provide.provide and speed and quality of our service. We rely on our human capital intensive, relationship-oriented approach and national infrastructure to enable us to compete in all aspects of our business. We must continually evaluate and expand our temporary and permanent healthcare professional network to serve the needs of our clients.

12

With a current shortage of certain qualified nurses and physicians in many areas of the United States, competition for the hiring of these professionals remains intense. Our ability to recruit and retain temporary and permanent healthcare professionals depends on several factors, including our ability to provide our healthcare professionals with assignments and placements that they view as attractive and to provide competitive compensation packages.
The costs of attractingrecruitment of quality healthcare professionals and providing them with attractive compensation packages may be higher than we anticipate, or we may be unable to pass these costs on to our hospital and healthcare facility clients, which may reduce our profitability. Moreover, if we are unable to recruit temporary and permanent healthcare professionals, our service execution may deteriorate and, as a result, we could lose clients. Our inability to recruit temporary and permanent healthcare professionals may be exacerbated by continued low levels of unemployment.

Our inability to implement new infrastructure and technology systems and technology disruptions may adversely affect our operating results and ability to manage our business effectively.

We have technology, operations and human capital infrastructures to support our existing business. Our ability to deliver services to our clients and to manage our commercial technologies, internal systems and data depends largely upon our access to and the performance of our management information and communications systems, including our SaaS-based solutions, client relationship management systems and client/healthcare professional-facing self-service websites. These technology systems also maintain accounting and financial information upon which we depend to fulfill our financial reporting obligations. We must continue to invest in this infrastructure to support our growth, enhance our management and utilization of data and improve our efficiency.

Upgrading current systems and implementing new systems is costly and involves inherent risks, including loss of information, disruption to our normal operations, changes in accounting procedures and internal control over financial reporting, as well as problems achieving accuracy in the conversion of electronic data. Failure to properly or adequately address these issues could result in increased costs, loss of clients and talent, the diversion of management’s and employees’ attention and resources and could materially adversely affect our growth, financial and operating results, internal controls over financial reporting and ability to manage our business effectively.

Additionally, the current legacy systems are subject to other non-environmental risks, including technological obsolescence for which there may not be sufficient redundancy or backup. These systems, and our access to these systems, are not impervious to floods, fire, storms, or other natural disasters, or service interruptions. There also is a potential for intentional and deliberate attacks to our systems that may lead to service interruptions, data corruption or data theft. If our current or planned systems do not adequately support our operations, are damaged or disrupted or if we are unable to replace, repair, maintain or expand them, it may adversely affect our business operations and our profitability.

Our business could be harmed if we fail to further develop and evolve our current talent solutions technology offerings and capabilities.

To achieve our strategic objectives and to remain competitive, we must continue to develop and enhance our talent solutions technology offerings and capabilities. This may require the acquisition of equipment and software and the development of new proprietary software and capabilities, either internally or through independent consultants. If we are unable to design, develop, implement and utilize, in a cost-effective manner, technology and information systems that provide the capabilities necessary for us to compete effectively, or for any reason any interruption or loss of our information processing capabilities occurs, this could harm our business, results of operations and financial condition.

Disruption to or failures of our SaaS-based or technology-enabled services, or our inability to adequately protect our intellectual property rights with respect to such technologies, could reduce client satisfaction, harm our reputation and negatively affect our business.

The performance, reliability and security of our technology-enabled services, including our language interpretation services and SaaS-based technologies, such as AMN Language Services, ShiftWise, Medefis, b4health, Avantas Smart Square and Silversheet, are critical to such offerings’ operations, reputation and ability to attract new clients. Some of our clients rely on our SaaS-based technologies to perform certain of their operational functions. Accordingly, any degradation, errors, defects, disruptions or other performance problems with our SaaS-based technologies could damage our or our clients’ operations and reputations and negatively affect our business. If any of these problems occur, our clients may, among other things, terminate their agreements with us or make indemnification or other claims against us, which may also negatively affect us.

Additionally, if we fail to protect our intellectual property rights adequately with respect to our SaaS-based technologies, our competitors might gain access to it, and our business might be harmed. Moreover, if any of our intellectual property rights associated with our SaaS-based technologies are challenged by others or invalidated through litigation, and defending our intellectual property rights might also entail significant expense. Accordingly, despite our efforts, we may be unable to prevent third parties from using or infringing upon or misappropriating our intellectual property with respect to our SaaS-based
13

technologies, which may negatively affect our business as it relates to our SaaS-based and technology-enabled service offerings.

Security breaches and cybersecurity incidents could compromise our information and systems adversely affecting our business operations and reputation subject us to substantial liabilities.
Security breaches, including cyber incidents can result from deliberate attacks or unintentional events. These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. In the ordinary course of our business, we collect and store sensitive data, such as our proprietary business information and that of our clients as well as personally identifiable information of our healthcare professionals and team members, including full names, social security numbers, addresses, birth dates and payroll-related information, in our data centers, on our networks and in hosted SaaS-based solutions provided by third parties. Our employees may also have access to, receive and use personal health information in the ordinary course of our business. The secure processing, maintenance and transmission of this information is critical to our operations.

Despite our security measures and business controls, our information technology and infrastructure, including the third party SaaS-based technology in which we store personally identifiable information and other sensitive information of our healthcare professionals may be vulnerable to attacks by hackers, breached due to employee error, malfeasance or other disruptions or subject to the inadvertent or intentional unauthorized release of information. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these incidents or techniques, timely discover them, or implement adequate preventative measures. Our information technology and other security protocols may not provide sufficient protection, and as a result a security reach could compromise our networks and significant information about us, our employees, healthcare professionals, patients or clients may be accessed, disclosed, lost or stolen.

Any such access, disclosure or other loss of information could (1) result in legal claims or proceedings, liability under laws that protect the privacy of personal information and regulatory penalties, (2) disrupt our operations and the services we provide to our clients and (3) damage our reputation, any of which could adversely affect our profitability, revenue and competitive position.
 
The inability to quickly and properly screencredential and match quality healthcare professionals with suitable placements may negatively affect demand for our services.
 
Our success depends on the quality of our healthcare professionals and our ability to quickly and efficiently assist in obtaining licenses and privileges for our healthcare professionals. The speed with which our healthcare professionals can obtain the appropriate licenses, and we can credential them depends in part, on state licensing laws. Roughly 30 states are part of the Enhanced Nurse Compact and over 20 states are part of the Physical Therapy Licensure Compact and Interstate Medical Compact Acts. A decline or change in interstate compact laws can impact our business.

Our ability to ensure the quality of our healthcare professionals also relies heavily on the effectiveness of our data and communication systems as well as properly trained and competent operational employeesteam members that screencredential and match healthcare professionals in suitable placements. An inability to properly screen,credential, match, and monitor healthcare professionals for acceptable credentials, experience and performance may cause clients to lose confidence in our services whichthat may damage our brand and reputation and result in clients opting to utilize competitors’ services or rely on their own internal resources. The costs to provide these credentialing services impact the revenue and profitability of our business.
 
Our operations may deteriorate if we are unable to continue to attract, develop and retain our sales and operations team members.
 
Our success depends heavily upon the recruitment, performance and retention of ourdiverse sales and operations team members who share our values, passion and commitment to customer focus. The number of individuals who meet our qualifications for these positions is limited, and we may experience difficulty in attracting qualified candidates, especially as we diversify our offerings and our business becomes more complex. In addition, we commit substantial resources to the training, development

and support of our team members. Competition for qualified sales and operational team members in the line of business in which we operate is strong, and we may not be able to retain a sufficient number of team members after we have expended the time and expense to recruit and train them. In addition, these team members may leave to establish competing businesses.
 
We are increasingly dependent on third parties for the execution of certain critical functions.
14

We have outsourced and offshored certain critical applications or business processes to external providers, including cloud-based, credentialing and data processing services. We exercise care in the selection and oversight of these providers. However, the failure or inability to perform or adhere to law, regulation and our policies on the part of one or more of these critical suppliers could cause significant disruptions and increased costs to our business as well as reputational damage.

The loss of key officers and management personnel could adversely affect our business and operating results.
 
We believe that the success of our business strategy and our ability to maintain our recent levels of profitability depends on the continued employment of our senior executive team. We have an employment agreement with Susan R. Salka, our President and Chief Executive Officer, through May 4, 2019,2022, which is renewable on an annual basis. Other executive members of the management team are employees at will with standard severance agreements. If members of our executive team become unable or unwilling to continue in their present positions, our business and financial results could be adversely affected.
Our inability to maintain our positive brand awareness and identity may adversely affect our results of operations.
 
We have invested substantial amounts in acquiring, developing and maintaining our brands, and our success depends on our ability to maintain positive brand awareness identities for existing servicesacross business lines and effectively buildingbuild up or consolidate our brand awareness and image for new services. We cannot assure that additional expenditures, and our continuing commitment to marketing and improving our brands and executing on our brand and marketing strategies will have the desired effect on our brands’ value whichand may adversely affect our results of operations.operations and also result in an impairment of the fair market value of intangible assets associated with acquired tradenames. In addition, our brands may suffer reputational damage that could negatively affect our short- and long-term financial results. The poor performance, reputation or negative conduct of competitors may have a spillover effect adversely affecting the industry and our brand.


Our inability to consummate and effectively incorporate acquisitions into our business operations may adversely affect our long-term growth and our results of operations.
We invest time and resources in carefully assessing opportunities for acquisitions, and acquisitions are a key component of our growth strategy. We have made acquisitions in the past several years to broaden the scope and depth of our workforce solutions and bolster our workforce services.talent solutions. If we are unable to consummate additional acquisitions, we may not achieve our long-term growth goals.
Despite diligence and integration planning, acquisitions still present certain risks, including the time and economic costs of integrating an acquisition’s technology, control and financial systems, unforeseen liabilities, and the difficulties in bringing together different work cultures and personnel. Difficulties in integrating our acquisitions, including attracting and retaining talent to grow and manage these acquired businesses, may adversely affect our results of operations.


FutureBusinesses we acquire may have liabilities or adverse operating issues which could harm our operating results.

    Businesses we acquire may have liabilities or adverse operating issues, or both, that we either fail to discover through due diligence or underestimate prior to the consummation of the acquisition. These liabilities and/or issues may include the acquired business’ failure to comply with, or other violations of, applicable laws, rules, or regulations or contractual or other obligations or liabilities. As the successor owner, we may be financially responsible for, and may suffer harm to our reputation or otherwise be adversely affected by, such liabilities and/or issues. These and any other costs, liabilities, issues, and/or disruptions associated with any past or future acquisitions could harm our reputation and operating results.

    In addition, future acquisitions are accompanied by the risk that the obligations and liabilities of an acquired company may not be adequately reflected in the historical financial statements of that company and the risk that those historical financial statements may be based on assumptions that are incorrect or inconsistent with our assumptions or approach to accounting policies. Any of these material obligations, liabilities or incorrect or inconsistent assumptions could adversely impact our results of operations and financial condition.


As we develop new services and clients, enter new lines of business, and focus more of our business on providing a full range of talent solutions, the demands on our business and our operating risks may increase.
    As part of our strategy, we plan to extend our services to new healthcare settings, clients, and new lines of business. As we focus on developing new services, capabilities, clients, practice areas and lines of business, and engage in business in new geographic locations, our operations may be exposed to additional as well as enhanced risks.

    In particular, our growth efforts place substantial additional demands on our management and other team members, as well as on our information, financial, administrative, compliance and operational systems. We may not be able to manage these demands successfully. Growth may require increased recruiting efforts, increased regulatory and compliance efforts, increased
15

business development, selling, marketing and other actions that are expensive and entail increased risk. We may need to invest more in our people and systems, controls, compliance efforts, policies and procedures than we anticipate. As our business continues to evolve and we provide a wider range of services, we will become increasingly dependent upon our employees, particularly those operating in business environments less familiar to us. Failure to identify, hire, train and retain talented employees who share our values could have a negative effect on our reputation and our business.

    The demands that our current and future growth place on our people and systems, controls, compliance efforts, policies and procedures may exceed the benefits of such growth, and our operating results may suffer, at least in the short-term, and perhaps in the long-term.

The expansion of social media platforms presents new risks and challenges that can cause damage to our brand and reputation.

    There has been an increase in the use of social media platforms, including blogs, social media websites and other forms of internet-communication in our industry that allows access to a broad audience of interested parties. The inappropriate and/or unauthorized use of certain media vehicles by our clients, vendors, employees and contractors could increase costs, cause damage to our brand, or result in information leakage that could lead to legal implications, including improper collection and/or dissemination of personally identifiable information of candidates and clients. In addition, negative or inaccurate posts or comments about us on any social networking website could damage our reputation, brand image and goodwill.

We maintain a substantial amount of goodwill and indefinite-lived intangibles on our balance sheet that may decrease our earnings or increase our losses if we recognize an impairment to goodwill or indefinite-lived intangibles.
 
We maintain goodwill on our balance sheet, which represents the excess of the total purchase price of our acquisitions over the fair value of the net assets and indefinite-lived intangibles we acquired. We evaluate goodwill and indefinite-lived intangibles for impairment annually, or when evidence of potential impairment exists. If we identify an impairment, we record a charge to earnings. An impairment charge to goodwill or indefinite-lived intangibles would decrease our earnings or increase our losses, as the case may be.
 

Risk Factors Related to Our Indebtedness and Other Liabilities
 
Our indebtedness could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, and expose us to interest rate risk to the extent of any variable rate debt.
As of December 31, 2017,2020, our total indebtedness, lessnet of unamortized fees and premium, equaled $319.8$862.6 million. Our substantial indebtedness could have important consequences, including:
increasingincrease our vulnerability to adverse economic, industry or competitive developments, including:

requiring a portion of our cash flows from operations to be dedicated to the payment of principal and interest on our indebtedness, therefore reducing our ability to use our cash flows to fund operations, capital expenditures and future business opportunities,
making it more difficult for us to satisfy our obligations with respect to our indebtedness,
restricting us from making strategic acquisitions or causing us to make non-strategic divestitures,
limiting our ability to obtain additional financing for working capital, capital expenditures, product and service development, debt service requirements, acquisitions, and general corporate or other purposes, and
limiting our flexibility in planning for, or reacting to, changes in our business or market conditions and placing us at a competitive disadvantage compared to our competitors who are less leveraged and who, therefore, may be able to take advantage of opportunities that our substantial indebtedness may prevent us from exploiting.pursuing.

Our ability to service our indebtedness will depend on our ability to generate cash in the future. We cannot provide assurance that our business will generate sufficient cash flow from operations or that future borrowings will be available in an amount sufficient to enable us to service our indebtedness or to fund other liquidity needs. Additionally, if we are not in compliance with the covenants and obligations under our debt instruments, we would be in default, and the lenders could call the debt, which would have a material adverse effect on our business.

16


The terms of our debt instruments impose restrictions on us that may affect our ability to successfully operate our business.
Our debt instruments contain various covenants that could adversely affect our ability to finance our future operations or capital needs and to engage in other business activities that may be in our best interest. These covenants limit our ability to, among other things:
incur or guarantee additional indebtedness or issue certain preferred equity,
pay dividends on, redeem, repurchase, or make distributions in respect of our capital stock, prepay, redeem, or repurchase certain debt or make other restricted payments,
make certain investments,
create, or permit to exist, certain liens,
sell assets,
enter into sale/leaseback transactions,
enter into agreements restricting restricted subsidiaries’ ability to pay dividends or make other payments,
consolidate, merge, sell, or otherwise dispose of all or substantially all of our assets,
enter into certain transactions with affiliates, and
designate restricted subsidiaries as unrestricted subsidiaries.


Our ability to comply with these covenants may be affected by events beyond our control, such as prevailing economic conditions and changes in regulations, and if such events occur, we cannot be sure that we will be able to comply. A breach of these covenants could result in a default under our debt instruments (including as a result of cross-default provisions) and, in the case of our revolversenior credit facility under our credit agreement, permit the lenders thereunder to cease making loans to us. If there were an event of default under any of our debt instruments, holders of such defaulted debt could cause all amounts borrowed under the applicable instrument to be due and payable immediately. Our assets or cash flow may not be sufficient to repay borrowings under our outstanding debt instruments in the event of a default thereunder.
In addition, the restrictive covenants in our credit agreement require us to maintain specified financial ratios and satisfy other financial condition tests. Although we were in compliance with the financial ratios and financial condition tests set forth in our credit agreement on December 31, 2017,2020, we cannot provide assurance that we will continue to be. Our ability to meet those financial ratios and tests will depend on our ongoing financial and operating performance, which, in turn, will be subject to economic conditions and to financial, market, and competitive factors, many of which are beyond our control. A breach of

any of these covenants could result in a default under our credit agreement (and our other debt instruments to the extent the default triggers a cross default provision) and, in the case of the revolver under our credit agreement, permit the lenders thereunder to cease making loans to us. Upon the occurrence of an event of default under the credit agreement, the lenders could elect to declare all amounts outstanding thereunder to be immediately due and payable and terminate all commitments to extend further credit. Such action by the lenders could cause cross-defaults under our other debt instruments.
Variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly.

Borrowings under our credit agreement are at variable rates of interest and expose us to interest rate risk. If interest rates increase, our debt service obligations on certain of our variable rate indebtedness will increase even though the amount borrowed remains the same, and our net income and cash flows, including cash available for servicing our indebtedness, will correspondingly decrease. In addition, in July 2017, the U.K. Financial Conduct Authority announced that it intends to stop collecting LIBOR rates from banks after 2021. The announcement indicates that LIBOR will not continue to exist on the current basis. We are unable to predict the effect of any changes to LIBOR, the establishment and success of any alternative reference rates, or any other reforms to LIBOR or any replacement of LIBOR that may be enacted in the United Kingdom or elsewhere. Such changes, reforms or replacements relating to LIBOR could have an adverse impact on the market for or value of any LIBOR-linked securities, loans, derivatives or other financial instruments or extensions of credit held by us. As such, LIBOR-related changes could affect our overall results of operations and financial condition.

We have substantial insurance-related accruals and legal accruals on our balance sheet, and any significant adverse adjustments may decrease our earnings or increase our losses and negatively impact our cash flows.
 
We maintain accruals related to legal matters, our captive insurance company and self-insured retentions for various lines of insurance coverage, including professional liability, employment practices, health insurance and workers compensation on our balance sheet. We determine the adequacy of our accruals by evaluating legal matters, our historical experience and trends,
17

related to both insurance claims and payments, information provided to us by our insurance brokers, attorneys, third-party administrators and actuarial firms as well as industry experience and trends. If such information collectively indicates that our accruals are understated, we provide for additional accruals; a significant increase to these accruals would decrease our earnings.


Item 1B.Unresolved Staff Comments
Item 1B.    Unresolved Staff Comments
 
None.
Item 2.    Properties
 
We lease all of our properties, which consist of office-type facilities. We believe that our leased space is adequate for our current needs and that we can obtain adequate space to meet our foreseeable business needs. We have pledged substantially all of our leasehold interests to our lenders under our credit agreement to secure our obligations thereunder. We set forth below our principal leased office spaces as of December 31, 20172020 together with our business segments that utilize them:
LocationSquare Feet
San Diego, California (corporate headquarters and all(all segments)175,672
Dallas, Texas (all segments)108,502
 
Item 3.Legal Proceedings
Item 3.    Legal Proceedings
From timeInformation with respect to time, we are involved in various lawsuits, claims, investigations and proceedings that arise in the ordinary course of business. These matters typically relate to professional liability, tax, payroll, contract, competitor disputes and employee-related matters and include individual and collective lawsuits, as well as inquiries and investigations by governmental agencies regarding our employment practices. Additionally, some of our clientsthis item may also become subject to claims, governmental inquiries and investigations and legal actions relating to services provided by our healthcare professionals. Depending upon the particular facts and circumstances, we may also be subject to indemnification obligations under our contracts with such clients relating to these matters. We record a liability when management believes an adverse outcome from a loss contingency is both probable and the amount, or a range, can be reasonably estimated. Significant judgment is required to determine both probability of loss and the estimated amount. We review our loss contingencies at least quarterly and adjust our accruals and/or disclosures to reflect the impact of negotiations, settlements, rulings, advice of legal counsel or other new information, as deemed necessary. The most significant matters for which we have established loss contingencies are class actions related to wage and hour claims under California and Federal law. Specifically, among other claims in these lawsuits, it is alleged that certain expense reimbursements should be included in the regular rate of pay for purposes of calculating overtime rates, and that employees were not afforded required breaks or compensated for all time worked. While we believe that our wage and hour practices conform with law in all material respects, litigation is always subject to inherent uncertainty, and we are not able to reasonably predict if any matter will be resolved in a manner that is materially adverse to us beyond the amounts accrued. See additional informationfound in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (12), Commitments and Contingencies—(a) Legal.Contingencies, which is incorporated herein by reference.

With regard to outstanding loss contingencies as of December 31, 2017, we believe that such matters will not, either individually or in the aggregate, have a material adverse effect on our business, consolidated financial position, results of operations or cash flows.
Item 4.Mine Safety Disclosures
Item 4.    Mine Safety Disclosures
 
Not applicable.
18

                        

PART II
 
Item 5.Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Item 5.    Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
 
Our common stock trades on the New York Stock Exchange under the symbol “AMN.” The last reported sale of our common stock on February 14, 2018 on the New York Stock Exchange was $53.90 per share. The following table sets forth, for the periods indicated, the high and low sales prices reported by the New York Stock Exchange.
 Sales Price
 High Low
Year Ended December 31, 2016   
First Quarter$34.10
 $21.24
Second Quarter$41.38
 $33.02
Third Quarter$44.99
 $30.96
Fourth Quarter$40.40
 $26.00
Year Ended December 31, 2017   
First Quarter$43.85
 $33.61
Second Quarter$42.70
 $34.71
Third Quarter$45.95
 $34.85
Fourth Quarter$51.75
 $37.71
As of February 14, 2018,24, 2021, there were 19 stockholders of record of our common stock, one of which was Cede & Co., a nominee for The Depository Trust Company. All of our common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are considered to be held of record by Cede & Co., which is considered to be one stockholder of record. A substantially greater number of holders of our common stock are “street name” or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions. Because such shares are held on behalf of stockholders, and not by the stockholders directly, and because a stockholder can have multiple positions with different brokerage firms, banks and other financial institutions, we are unable to determine the total number of stockholders we have without undue burden and expense.


During the fiscal year ended December 31, 2017,2020, we did not sell any equity securities that were not registered under the Securities Act.


From time to time, we may repurchase our common stock in the open market pursuant to programs approved by our Board. We may repurchase our common stock for a variety of reasons, such as acquiring shares to offset dilution related to equity-based incentives and optimizing our capital structure. On November 1, 2016, our Board authorized us to repurchase up to $150.0 million of our outstanding common stock in the open market. Under the repurchase program announced on November 1, 2016 (the “Company Repurchase Program”), share purchases may be made from time to time beginning in the fourth quarter of 2016, depending on prevailing market conditions and other considerations. The Company Repurchase Program has no expiration date and may be discontinued or suspended at any time.


During the fourth quarter ofSince 2016, we have repurchased 443,3532,561,546 shares of our common stock at an average price of $29.88$46.48 per share, resulting in an aggregate purchase price of $13.3$119.1 million.

During 2017,2020, we purchased 486,543did not repurchase any shares of our common stock at an average price of $41.41 per share, resulting in an aggregate purchase price of $20.2 million.stock. See “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (10)(b), Capital Stock—Treasury Stock.” The following table presents the detail of shares repurchased during 2017. All share repurchases reflected in the table belowto date were made under the Company Repurchase Program, which is the sole repurchase program of the Company currently in effect.

     
Period
 
Total
Number of
Shares (or
Units)
Purchased 
 
Average
Price Paid
per Share
(or Unit) 
 
Total Number of
Shares (or Units)
Purchased as Part of
Publicly Announced
Program 
 
Maximum Dollar
Value of Shares (or Units)
that May Yet Be
Purchased Under the Program 
 
June 1 - 30, 20179,400
$34.929,400
$136,410,198
September 1 - 30, 2017177,143
$38.18177,143
$129,641,361
November 1 - 30, 2017300,000
$43.52300,000
$116,575,101
  
  
 
Total486,543
$41.41486,543
$116,575,101

We have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business, to pay down debt and potentially for share repurchases. Any future determination to pay dividends on common stock will be at the discretion of our board of directors and will depend upon our financial condition, results of operations, capital requirements and such other factors as the board deems relevant. In addition, our ability to declare and pay dividends on our common stock is subject to covenants restricting such actions in the instruments governing our debt. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” and “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement.”
 
The information required by Item 201(d) of Regulation S-K is incorporated by reference to the 2018 Annual Meeting Proxy Statement (as definedtable set forth in Item 10 below) under the heading “Equity Compensation Plan Information at December 31, 2017.”12 of this Annual Report on Form 10-K.
19

                        

Performance Graph
 
This performance graph shall not be deemed “filed” with the SEC or subject to Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any of our filings under the Exchange Act or the Securities Act.
The graph below compares the total return on our common stock with the total return of (i) the NYSE Composite Index, and (ii) the Dow Jones US Business Training & Employment Agencies Index (“BTEA”), assuming an investment of $100 on December 31, 20122015 in our common stock, the stocks comprising the NYSE Composite Index, and the stocks comprising the BTEA.
amn-20201231_g2.jpg
12/31/1512/31/1612/31/1712/31/1812/31/1912/31/20
AMN Healthcare Services, Inc.100.00 123.83 158.62 182.48 200.68 219.81 
NYSE Composite100.00 111.94 132.90 121.01 151.87 162.49 
BTEA100.00 90.72 120.76 90.09 113.78 120.40 

 12/31/12 12/31/13 12/31/14 12/31/15 12/31/16 12/31/17
AMN Healthcare Services, Inc.100.00
 127.27
 169.70
 268.83
 332.90
 426.41
NYSE Composite100.00
 126.28
 134.81
 129.29
 144.73
 171.83
BTEA100.00
 167.96
 176.46
 174.84
 158.61
 211.13

Item 6.Selected Financial Data
Item 6.    Selected Financial Data
 
You should read the selected financial and operating data presented below in conjunction with “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Item 8. Financial Statements and Supplementary Data” below. We derive our statements of operations data for the years ended December 31, 2017, 20162020, 2019 and 2015,2018, and the balance sheet data at December 31, 20172020 and 20162019 from the audited financial statements included elsewhere in this Annual Report on Form 10-K. We derive the statements of operations data for the years ended December 31, 20142017 and 20132016 and the balance sheet data at December 31, 2015, 20142018, 2017 and 20132016 from our audited financial statements of ours that do not appear herein.
20

                        

We completed our acquisitionacquisitions of (1) ShiftWise on November 20, 2013, (2) Avantas on December 22, 2014, (3) Onward Healthcare, including its two wholly-owned subsidiaries, Locum Leaders and Medefis (collectively “OH”), on January 7, 2015, (4) TFS on September 15, 2015, (5) Millican on October 5, 2015, (6) BESB.E. Smith on January 4, 2016, (7) HSG(2) HealthSource Global on January 11, 2016, and (8)(3) Peak Health on June 3, 2016.2016, (4) Phillips DiPisa and Leaders For Today on April 6, 2018, (5) MedPartners on April 9, 2018, (6) Silversheet on January 30, 2019, (7) Advanced on June 14, 2019, (8) b4health on December 19, 2019 and (9) Stratus Video on February 14, 2020. Our acquisitions affect the comparability of the selected financial data of the applicable pre-acquisition and post-acquisition time periods.
We have not paid any cash dividends during the past five fiscal years.



 Fiscal Years Ended December 31,
 20202019201820172016
 ( in thousands, except per share data)
Consolidated Statements of Operations:
Revenue$2,393,714 $2,222,107 $2,136,074 $1,988,454 $1,902,225 
Cost of revenue1,601,936 1,478,642 1,439,691 1,344,035 1,282,501 
Gross profit791,778 743,465 696,383 644,419 619,724 
Operating expenses:
Selling, general and administrative549,747 508,030 452,318 399,700 398,472 
Depreciation and amortization92,766 58,520 41,237 32,279 29,620 
Total operating expenses642,513 566,550 493,555 431,979 428,092 
Income from operations149,265 176,915 202,828 212,440 191,632 
Interest expense, net, and other57,742 28,427 16,143 19,677 15,465 
Income before income taxes91,523 148,488 186,685 192,763 176,167 
Income tax expense20,858 34,500 44,944 60,205 70,329 
Net income$70,665 $113,988 $141,741 $132,558 $105,838 
Net income per common share:
Basic$1.49 $2.44 $2.99 $2.77 $2.21 
Diluted$1.48 $2.40 $2.91 $2.68 $2.15 
Weighted average common shares outstanding:
Basic47,424 46,704 47,371 47,807 47,946 
Diluted47,690 47,593 48,668 49,430 49,267 



 As of December 31,
 20202019201820172016
 (in thousands)
Consolidated Balance Sheet Data:
Cash and cash equivalents$29,213 $82,985 $13,856 $15,147 $10,622 
Total assets2,353,507 1,931,646 1,492,721 1,253,957 1,186,881 
Total notes payable, including current portion, net of unamortized fees and premium862,649 617,159 320,607 319,843 362,942 
Total stockholders’ equity819,677 736,742 638,990 562,527 449,383 



21































                        

Item 7.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
 Fiscal Years Ended December 31,
 2017 2016 2015 2014 2013
 ( in thousands, except per share data)
Consolidated Statements of Operations:         
Revenue$1,988,454
 $1,902,225
 $1,463,065
 $1,036,027
 $1,011,816
Cost of revenue1,344,035
 1,282,501
 993,702
 719,910
 714,536
Gross profit644,419
 619,724
 469,363
 316,117
 297,280
Operating expenses:         
Selling, general and administrative399,700
 398,472
 319,531
 232,221
 218,233
Depreciation and amortization32,279
 29,620
 20,953
 15,993
 13,545
Total operating expenses431,979
 428,092
 340,484
 248,214
 231,778
Income from operations212,440
 191,632
 128,879
 67,903
 65,502
Interest expense, net, and other19,677
 15,465
 7,790
 9,237
 9,665
Income before income taxes192,763
 176,167
 121,089
 58,666
 55,837
Income tax expense60,205
 70,329
 39,198
 25,449
 22,904
Net income$132,558
 $105,838
 $81,891
 $33,217
 $32,933
Net income per common share:         
Basic$2.77
 $2.21
 $1.72
 $0.71
 $0.72
Diluted$2.68
 $2.15
 $1.68
 $0.69
 $0.69
Weighted average common shares outstanding:         
Basic47,807
 47,946
 47,525
 46,504
 45,963
Diluted49,430
 49,267
 48,843
 48,086
 47,787
 As of December 31,
 2017 2016 2015 2014 2013
 (in thousands)
Consolidated Balance Sheet Data:         
Cash and cash equivalents$15,147
 $10,622
 $9,576
 $13,073
 $15,580
Total assets1,253,957
 1,186,881
 880,432
 680,731
 604,288
Total notes payable, including current portion, less unamortized discount and fees319,843
 362,942
 135,990
 143,190
 147,347
Total stockholders’ equity562,527
 449,383
 347,860
 256,581
 217,742


Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
You should read the following discussion in conjunction with our consolidated financial statements and the notes thereto and other financial information included elsewhere in this Annual Report on Form 10-K. Certain statements in this “Management’s Discussion and Analysis (“MD&A”) of Financial Condition and Results of Operations” are “forward-looking statements.” See “Special Note Regarding Forward-Looking Statements” under Item 1, “Business.” We intend this MD&A section to provide you with a narrative from the perspective of our management on our financial condition, results of operations, liquidity and certain other factors that may affect our future results. The following sections comprise this MD&A:

Changes to Our Reportable Segments
Overview of Our Business
Recent Trends
Results of Operations
Liquidity and Capital Resources
Off-Balance Sheet and Other Financing Arrangements
Contractual Obligations
Critical Accounting Policies and Estimates
Recent Accounting Pronouncements

Changes to Our Reportable Segments

Effective March 8, 2020, we modified our reportable segments. We previously utilized three reportable segments, which we identified as follows: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. In light of our acquisitions as well as our organizational changes to better align our structure with our strategy, our management reorganized our reportable segments to better reflect how the business is evaluated by the chief operating decision maker. Beginning in the first quarter of 2020, we have disclosed the following three reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. The nurse and allied solutions segment includes our travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions businesses. The physician and leadership solutions segment includes our locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The technology and workforce solutions segment includes language interpretation, vendor management systems, workforce optimization, recruitment process outsourcing, education, credentialing and flex pool management businesses. Prior period data in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” has been reclassified to conform to the new segment reporting structure.

Overview of Our Business
 
We provide healthcare workforce solutions and staffing services to healthcare facilities across the nation. As an innovative workforcetotal talent solutions partner, our managed services programs, or “MSP,” vendor management systems, or “VMS,” recruitment process outsourcing, or “RPO,” workforce consulting services, predictive modeling, staff scheduling, remote medical coding, case managementcredentialing services, revenue cycle solutions, language interpretation services and the placement of physicians, nurses, allied healthcare professionals and healthcare executivesleaders into temporary and permanent positions enable our clients to successfully reduce staffing complexity, increase efficiency and lead their organizations within the rapidly evolving healthcare environment.
For the year ended December 31, 2017,2020, we recorded revenue of $1,988.5$2,393.7 million, as compared to $1,902.2$2,222.1 million for 2016.2019. We recorded net income of $132.6$70.7 million for 2017,2020, as compared to $105.8$114.0 million for 2016.2019. Nurse and allied solutions segment revenue comprised 62%71% and 70% of total consolidated revenue for the years ended December 31, 20172020 and 2016. Locum tenens2019, respectively. Physician and leadership solutions segment revenue comprised 22%19% and 25% of total consolidated revenue for the years ended December 31, 20172020 and 2016. Other2019, respectively. Technology and workforce solutions segment revenue comprised 16%10% and 5% of total consolidated revenue for the years ended December 31, 20172020 and 2016.2019, respectively. For a description of the services we provide under each of our business segments, please see, “Item 1. Business—Our Services.”
We believe we have becomeare recognized as the market-leading innovator in providing healthcare workforcetalent solutions and staffing services in the United States. We seek to advance our market-leading position through a number of strategies that focus on market growth,penetration, expansion of our talent solutions, increasing operational efficiency and scalability and increasing our supply of qualified healthcare professionals. Our market growth strategy continues to focus on broadening and investing, both organically and
22

through strategic acquisitions, in service and technology offerings beyond our traditional temporary staffing and permanent placement services, to include more strategic and recurring revenue sources from innovative workforcetalent solutions offerings such as MSP, VMS, RPO andcredentialing, workforce optimization services, which generally operate at higher margins than our traditional healthcare staffing businesses.service, and other technology-enabled services. We also seek strategic opportunities to expand into complementary service offerings to our staffing businesses that leverage our core capabilities of recruiting and credentialing healthcare professionals. Along those lines,
As part of our long-term growth strategy to add value for our clients, healthcare professionals, and stockholders, on February 14, 2020, December 19, 2019, June 14, 2019, January 30, 2019, April 9, 2018 and April 6, 2018, we acquired Peak during 2016,Stratus Video (which we have since rebranded as AMN Language Services), b4health, Advanced (which we have since rebranded as American Mobile and Med Travelers for the travel nurse staffing and allied staffing divisions, respectively), Silversheet, MedPartners (which we have since rebranded as AMN Revenue Cycle Solutions), and Phillips DiPisa and Leaders For Today (“PDA” and “LFT”, which we have since rebranded as B.E. Smith), respectively. Stratus Video is a remote video interpreting company that provides healthcare interpretation via remote medical coding, casevideo, over the phone, and onsite in-person, all supported by proprietary technology platforms. b4health is an innovative technology company and a leading provider of a web-based internal float pool management solution and related auditingVMS for healthcare facilities. Advanced is a national healthcare staffing company that specializes in placing therapists and consulting services.nurses across multiple settings, including hospitals, schools, clinics, skilled nursing facilities, and home health. Silversheet provides innovative credentialing software solutions to clinicians and healthcare enterprises. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (2), Acquisitions.”

Operationally, our strategic initiatives focus on investing in and further developing our processes and systems to achieve market leading efficiency and scalability, which we believe will provide operating leverage as our revenue grows. From a healthcare professional supply perspective, we continue to invest in new candidate recruitment and engagement initiatives and technologies to access and effectively utilize our network of qualified healthcare professionals to capitalize on the demand growth we are experiencing, which we expect to continue in the future due to the combined effects of healthcare reform, the aging population and labor shortages within certain regions and disciplines.
Over the last several years, we have worked to execute on our management strategies and intend to continue to do so in the future. Over the past five years, we have grown our business both organically and as a result of a number of acquisitions.

We typically experience modest seasonal fluctuations during our fiscal year and they tend to vary among our business segments. These fluctuations can vary slightly in intensity from year to year. Over the last fourpast five years, steadily and progressively increasing demand muted the effects of these quarterly fluctuations.fluctuations have been muted in our consolidated results.

Recent Trends
 
Demand for our temporary and permanent placement staffing services is driven in part by U.S. economic and labor trends.trends, and in 2020 through present, demand has been significantly impacted by the COVID-19 pandemic. In December 2020, we experienced historically high demand for nurses and certain allied healthcare professionals and our demand for these disciplines continues to be elevated. However, when the imposition of “shelter-in-place” orders and the suspension of elective and “non-essential” healthcare services occurred in March 2020 in response to the COVID-19 health crisis, demand for many of our businesses declined significantly. Although most of these “shelter-in-place” orders and service suspensions have been lifted, general utilization of healthcare continues to be below the pre-COVID-19 levels, which continues to negatively impact demand for many of our business lines other than nursing, certain allied disciplines, language interpretation services and our vendor management technology solutions. With the increase in unemployment, related economic concerns, healthcare professional “burnout” and the uncertainty surrounding the COVID-19 pandemic, we are unable to predict the extent and duration to which demand for our businesses will continue to be impacted by the COVID-19 pandemic.

In our nurse and allied solutions segment, prior to the COVID-19 pandemic, our ability to recruit enough nurses to meet the then-current demand levels was impacted by the tight labor market and modest bill rate increases. Demand for nurses in specialties including ICU, telemetry, and medical surgical nurses is particularly strong, and needs are high across the country. With the higher demand, and urgent need to quickly fill positions, bill rates and wages for these nurses are currently well above prior year levels. Demand for nurses peaked in December 2020, and has declined along with COVID-19 hospitalizations. Bill rates also remain well above historic levels, though recently have started to trend down along with the demand decline. Although the number of nurses on travel assignments has been increasing each month since July 2020, our ability to adequately meet the high client demand is constrained by the tight labor market along with nurse burnout and other issues related to the pandemic. In addition, as a result of the significant increase in COVID-19 infection and hospitalization rates throughout the third quarter and into October, our workers’ compensation insurance costs have increased.

23

The U.S. Bureau of Labor Statistics’ survey data reflect near recorddemand in our allied staffing division significantly varies by discipline. We have seen a significant increase in demand for respiratory therapists and lab technicians due to the high COVID-19 infections and hospitalizations across the country. Like nursing, the demand for respiratory therapy has declined from its peak as COVD-19 hospitalizations have declined, but still remains at elevated levels. Demand for our imaging and lab specialties has steadily recovered and is now well above prior year levels. For speech language therapists contracted to work with schools, the uneven levels of in-person education has slowed in growth, but this slowdown in growth has been partially mitigated by the fact that many therapists have been able to deliver care through the adoption of our teletherapy platform.

Prior to the COVID-19 public health crisis, our allied staffing division experienced a decline in demand for physical therapists from skilled nursing facility and home health clients resulting from Medicare reimbursement changes. This decline in demand was further exacerbated by the impact of COVID-19 in March. Although the utilization of physical therapists has been slowly increasing with the general recovery in healthcare, job openingsdemand and quits. We viewplacements for this data,discipline are still well below prior year.

In our physician and leadership solutions segment, our locum tenens division started 2020 well, with recruiter productivity and revenue increasing after disruptions resulting from process and technology changes made during 2018. However, in mid-March, as a result of COVID-19, our locum tenens business experienced a significant increase in order cancellations and a decrease in overall demand due to the suspension of elective procedures and non-essential healthcare services. In the latter half of the year, locum tenens experienced a spike in demand related to COVID-19, although this has more recently declined along with lower hospitalizations. Although the placements for locum tenens has been slowly improving along with increases in general healthcare utilization, the recovery is inconsistent across specialties.

For our interim leadership division, demand decreased as providers reacted to lower patient volumes and focused on cost containment. More recently, demand for our interim leadership services surged due to both needs related to increased COVID-19 hospitalizations and an increased level of burnout and turnover of healthcare leadership roles. Our physician permanent placement and healthcare executive search businesses experienced a nearly 20-year-low unemployment ratedecline in overall search demand as many clients suspended filling open roles due to uncertainty from the COVID-19 public health crisis. Since June, demand for permanent placement services has improved from their lowest levels, but clients remain cautious in hiring in this uncertain environment.

In our technology and continued economic growth as positive trends for the healthcare staffing industry. The low unemployment rate has led to some wage growth to attract healthcare professionals. We work to pass these increases on to our clients but have experienced margin pressure in some divisions, particularly locum tenens.

We continue to see the benefits of our workforce solutions strategy, particularlysegment, our VMS technologies initially experienced increased growth following the outbreak of the COVID-19 public health crisis as clients utilized our technologies to effectively manage their increased demand for nurses. As demand for nurses declined during the second quarter, utilization of the VMS technologies also declined. However, more recently, orders, placements and bill rates in the technologies have risen significantly, and new clients are also adopting the platforms to engage with contingent labor.

In early March, the utilization in our language interpretation business declined as a result of the COVID-19-related suspension or restriction of elective and “non-essential” healthcare services. However, utilization started to increase in late April as many of these restrictions were lifted and healthcare utilization resumed more normal activities. By mid-June, weekly interpretation minutes utilized were above pre-COVID-19 levels and have continued to steadily increase from both existing and new clients.

At the onset of the COVID-19 pandemic, we experienced a delay in discussions with clients regarding new contracts or expansions. As clients have recently begun to resume normal operations, we have contracted for several new managed services programs.programs and service line expansions. As
a result of our ongoing focus on these types of strategic MSP relationships, we continue to increase the percentage of our nurse and allied
staffing revenue derived from our managed services program clients.MSP clients continues to increase.


In our nurseresponse to the COVID-19 pandemic, we implemented new service offerings such as contact tracing services and alliedreturn to work healthcare workforce solutions segment, demand is favorable. Althoughto support non-healthcare clients and the communities we serve. Through these services, we help clients ensure the health and well-being of their employees and take necessary steps to implement new safety protocols such as COVID-19 screening, testing, temperature checks, on-site clinical support and contact tracing. More recently, we have been providing staffing and management services related to vaccination sites, and expect this support will continue to negotiate bill rate increases with clients, we are experiencing a decrease inthrough all or the utilizationmajority of premium bill rates, which is dampening the overall average bill rate in this segment.2021.


In our locum tenens solutions segment, we have seen a decline inresponse to the reduced demand from some large physician practice management firms that has negatively impacted our hospitalist volumes and,for services as a result revenue in this segment. Additionally, we are inof the process of making operating model changes and implementing new front and back office technologies in locum tenens. Although these changes are expected to have a long-term positive impact on our growth and profitability, in the short-term, these changes are expected to be disruptive to our productivity and revenue, and we expect this to continue throughCOVID-19 pandemic, throughout the second quarter, of 2018. Outside of the above influences,we took actions to reduce our selling, general and administrative expenses. Cost reduction actions taken included, among other things, suspending employer contributions under our 401(k) retirement savings plan and deferred compensation plan, reducing our workforce to correspond to reduced demand, in most specialties has remained strong.

Inand reducing variable compensation, travel, professional services and marketing expenses. As our other workforce solutions segment, our interim leadership, vendor management systems, workforce consulting, and medical coding businesses are growing. We experienced declines in our permanent placement businesses during 2017 that we believe are primarily relatedcontinue to operational execution. In response,recover, we have made organizationalbeen increasing our workforce to support our clients’ needs, increasing spending in certain areas and operational changes designed to improvehave fully restored our performance in 2018.retirement matching benefits.

24


Results of Operations
 
The following table sets forth, for the periods indicated, certain statements of operations data as a percentage of revenue. Our results of operations include three reportable segments: (1) nurse and allied solutions, (2) locum tenensphysician and leadership solutions, and (3) othertechnology and workforce solutions. The acquisitions during 20162020, 2019 and 20152018 impact the comparability of the results between the years presented. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (2), Business Combinations.Acquisitions.” Our historical results are not necessarily indicative of our results of operations to be expected in the future.
 
Years Ended December 31,  Years Ended December 31,
2017 2016 2015  202020192018
Consolidated Statements of Operations: Consolidated Statements of Operations:
Revenue100.0%100.0%100.0%Revenue100.0 %100.0 %100.0 %
Cost of revenue67.6 67.4 67.9 Cost of revenue66.9 66.5 67.4 
Gross profit32.4 32.6 32.1 Gross profit33.1 33.5 32.6 
Selling, general and administrative20.1 20.9 21.8 Selling, general and administrative23.0 22.9 21.2 
Depreciation and amortization1.6 1.6 1.4 Depreciation and amortization3.9 2.6 1.9 
Income from operations10.7 10.1 8.8 Income from operations6.2 8.0 9.5 
Interest expense, net, and other1.0 0.8 0.5 Interest expense, net, and other2.4 1.3 0.8 
Income before income taxes9.7 9.3 8.3 Income before income taxes3.8 6.7 8.7 
Income tax expense3.0 3.7 2.7 Income tax expense0.8 1.6 2.1 
Net income6.7%5.6%5.6%Net income3.0 %5.1 %6.6 %
 
Comparison of Results for the Year Ended December 31, 20172020 to the Year Ended December 31, 20162019
 
Revenue. Revenue increased 5%8% to $1,988.5 million for 2017 from $1,902.2$2,393.7 million for 2016, driven by 4% organic growth along with $12.42020 from $2,222.1 million offor 2019, primarily attributable to additional revenue resultingof $194.2 million from our Peak acquisitionStratus Video, Advanced, b4health, and Silversheet acquisitions and higher organic revenue in June 2016.our nurse and allied solutions segment, partially offset by lower revenue in our physician and leadership solutions segment. Excluding the additional revenue from acquisitions, revenue decreased 1%.

Nurse and allied solutions segment revenue increased 5%9% to $1,238.5 million for 2017 from $1,185.1$1,699.3 million for 2016.2020 from $1,562.6 million for 2019. The $53.4$136.7 million increase was primarily attributable to additional revenue of $72.2 million in connection with the Advanced acquisition. Excluding the impact from the Advanced acquisition, the increase was also attributable to an approximately 15% increase in the average bill rate, partially offset by a 5% increase12% decrease in the average number of healthcare professionals on assignment and a 2% increasean approximately $29.0 million decrease in the average bill ratelabor disruption revenue during the year ended December 31, 2017. The increase was partially offset by an approximately $37.0 million decrease in labor disruption revenue2020.
Physician and the impact of one less calendar day due to 2016 being a leap year.
Locum tenensleadership solutions segment revenue increased 2%decreased 17% to $430.6 million for 2017 from $424.2$466.6 million for 2016.2020 from $562.8 million for 2019. The $6.4$96.1 million increasedecrease was primarily attributable to the impact of the COVID-19 pandemic on the segment’s businesses. The locum tenens business experienced a 4% increase13% decrease in the number of days filled and a 1% decrease in the revenue per day filled during the year ended December 31, 2017, partially offset2020. In addition, revenue in our interim leadership and permanent placement businesses declined collectively by approximately 20% during 2020 due to a 3% decrease in overall demand as some clients cancelled searches and placed new searches on hold due to the number of days filled.public health crisis.
OtherTechnology and workforce solutions segment revenue increased 9%135% to $319.3 million for 2017 from $292.9$227.8 million for 2016.2020 from $96.8 million for 2019. Of the $26.4$131.0 million increase, $12.4$122.0 million was attributable to the additional revenue in connectionfrom our Stratus Video, b4health, and Silversheet acquisitions, with the Peak acquisition in June 2016, along withremainder primarily attributable to growth in our organic VMS interim leadership, and workforce optimization businesses, partially offset by declines in our permanent placement business during the year ended December 31, 2017.2020.

For 2020 and 2019, revenue under our MSP arrangements comprised approximately 50% and 45% of our consolidated revenue, 65% and 57% for nurse and allied solutions segment revenue and 17% and 20% for physician and leadership solutions segment revenue, respectively.

Gross Profit. Gross profit increased 4%6% to $644.4 million for 2017 from $619.7$791.8 million for 2016,2020 from $743.5 million for 2019, representing gross margins of 32.4%33.1% and 32.6%33.5%, respectively. The decreasedecline in in consolidated gross margin for the year ended December 31, 2020 was primarily due to lower bill-to-pay spreads in the locum tenens solutions segment and an unfavorable change in business mix in our other workforce solutions segment, offset by a higherlower gross margin in theour nurse and allied solutions segment, driven primarily by lower direct costs duringbill-to-pay spreads and higher workers’ compensation insurance expenses due to the year ended December 31, 2017.COVID-19 pandemic, partially offset by the change in sales mix resulting from our Stratus Video and b4health acquisitions and their higher margins as compared to our staffing
25


businesses. Gross margin by reportable segment for 20172020 and 20162019 was 27.6%27.4% and 26.9%28.5% for nurse and allied solutions, 30.0%36.7% and 31.1%37.0% for locum tenensphysician and leadership solutions, and 54.5%67.9% and 57.8%92.8% for othertechnology and workforce solutions, respectively. The year-over-year gross margin decline in the technology and workforce solutions segment was primarily due to the change in sales mix resulting from the addition of lower margin Stratus Video as compared to our SaaS-based technologies within the segment.
 
Selling, General and Administrative Expenses. Selling, general and administrative (“SG&A”) expenses were $399.7$549.7 million, representing 20.1%23.0% of revenue, for 2017,2020, as compared to $398.5$508.0 million, representing 20.9%22.9% of revenue, for 2016.2019. The increase in SG&A expenses was primarily due to $1.9$31.3 million of additional SG&A expenses from the PeakStratus Video, Advanced, b4health, and Silversheet acquisitions and a $31.0 million increase related to acquisition, $1.7integration, changes in the fair value of earn-out liabilities from acquisitions, restructuring, and extraordinary legal expenses, which included a $20.0 million lower favorable actuarial-based decreasesincrease in our professional liability reserves, and other expenses associated with our revenue growth,legal accruals during the fourth quarter of 2020. The overall increase was partially offset by a $2.8 millioncost reduction measures that were initiated during the second quarter of 2020, which was also the primary driver of the decrease in acquisitionthe physician and integration costs as compared to last year.leadership solutions segment. The decreaseincrease in the technology and workforce solutions segment was primarily driven by $22.2 million of additional expenses from the Stratus Video, b4health, and Silversheet acquisitions. The increase in unallocated corporate overhead was primarily attributable to lowerhigher acquisition, integration, changes in the fair value of earn-out liabilities from acquisitions, restructuring, and integration costs.extraordinary legal expenses. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:
 (In Thousands)
Years Ended
December 31,
 20202019
Nurse and allied solutions$233,564 $225,707 
Physician and leadership solutions109,117 136,684 
Technology and workforce solutions62,959 45,935 
Unallocated corporate overhead123,642 83,463 
Share-based compensation20,465 16,241 
$549,747 $508,030 
 
(In Thousands)
Years Ended
December 31,
 2017 2016
Nurse and allied solutions$158,480
 $156,676
Locum tenens solutions77,778
 73,126
Other workforce solutions92,793
 91,936
Unallocated corporate overhead60,412
 65,335
Share-based compensation10,237
 11,399
 $399,700
 $398,472
Depreciation and Amortization Expenses. Amortization expense increased 2%75% to $18.6$63.8 million for 20172020 from $18.3$36.5 million for 2016,2019, primarily attributable to a full year ofadditional amortization expenseexpenses related to the intangible assets acquired in the Peak acquisition.Advanced, b4health, and Stratus Video acquisitions, the shortened useful life of tradename intangible asset acquired in the MedPartners acquisition during the third quarter of 2019, and the shortened useful lives of the tradename intangible assets during the third quarter of 2020. Depreciation expense increased 21%31% to $13.7$28.9 million for 20172020 from $11.3$22.0 million for 2016,2019, primarily attributable to fixed assets acquired as part of the Peak acquisition and an increase in purchased and developed hardware and software placed in service in large part fromfor our ongoing information technology investments to support our total talent solutions initiatives and to optimize our internal front and back office information technology initiatives.systems. Additionally, $1.4 million of depreciation expense for Stratus Video, which was acquired in February 2020, is included in cost of revenue for 2020.


Interest Expense, Net, and Other. Interest expense, net, and other, was $19.7$57.7 million for 20172020 as compared to $15.5$28.4 million for 2016.2019. The increase is primarily due to (1) a higher interest bearingaverage debt outstanding balance during 2020, which resulted from (a) borrowings under our Amended Credit Agreement (as defined below in this Item 7) used to finance the Stratus Video and Advanced acquisitions, (b) the issuance of our Existing 2027 Notes (as defined below in this Item 7) forin October 2019, (c) the year ended December 31, 2017, as comparedissuance of our New 2027 Notes (as defined below in this Item 7) in August 2020, and (d) the issuance of our 2029 Notes (as defined below in this Item 7) in October 2020, (2) $8.3 million premium payment associated with the redemption of the 2024 Notes (as defined below in this Item 7) in November 2020, and (3) $5.0 million of write-offs of unamortized financing fees during 2020. The proceeds from the issuances of the higher interest bearing senior notes were used to repay, in whole in the term loansfourth quarter of 2019 and revolver in 2016.part in the third and fourth quarters of 2020, our indebtedness under the lower interest bearing Credit Facilities (as defined below in this Item 7).
Income Tax Expense. Income tax expense was $60.2$20.9 million for 20172020 as compared to $70.3$34.5 million for 2016,2019, reflecting effective income tax rates of 31.2%22.8% and 39.9%23.2% for these periods, respectively. The differencedecrease in the effective income tax rate was primarilypartially attributable to (1) recording athe recognition of discrete net tax benefitbenefits of $14.0$4.7 million and $7.3 million in relation to income before income taxes of $91.5 million and $148.5 million for the year ended December 31, 2017

resulting from our initial analysis of the impact of the Tax Cuts2020 and Jobs Act, and (2) the relationship of pre-tax income to permanent differences related to unrecognized tax benefits and excess tax benefit from the adoption of ASU 2016-09, “Stock Compensation - Improvements to Employee Share-Based Payment Accounting” in the first quarter of 2017, which resulted in recording a $5.4 million reduction in income tax expense for the year ended December 31, 2017. Prior to the adoption, this amount would have been recorded as additional paid-in capital. This change could create future volatility in our effective tax rate depending upon the amount of exercise or vesting activity from our share-based awards.2019, respectively. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (7), Income Taxes, and Note (1), Summary of Significant Accounting Policies.”
 
26


Comparison of Results for the Year Ended December 31, 20162019 to the Year Ended December 31, 20152018
 
Revenue. Revenue increased 30%4% to $1,902.2$2,222.1 million for 20162019 from $1,463.1$2,136.1 million for 2015, due2018, primarily attributable to additional revenue of approximately $194$117.6 million from our HSG, BES, Millican, TFS, OHAdvanced, MedPartners, PDA, LFT, and PeakSilversheet acquisitions withand higher organic revenue in our nurse and allied solutions segment, partially offset by lower organic revenue in our physician and leadership solutions segment. Excluding the remainder of the increase driven by 17% organic growth.additional revenue from acquisitions, revenue decreased 1%.


Nurse and allied solutions segment revenue increased 24%9% to $1,185.1$1,562.6 million for 20162019 from $953.3$1,431.0 million for 2015. Of the $231.82018. The $131.6 million increase $45.7 million was primarily attributable to the additional revenue of $110.8 million in connection with the HSG acquisitionAdvanced and $2.0 millionMedPartners acquisitions. Excluding the impact from acquisitions, the increase was also attributable to the prior year having one less week of revenue from the OH acquisition as it was consummated on January 7, 2015 (the “OH Stub Period”), with the remainder primarily attributable to a 13% increase in the average number of healthcare professionals on assignment and a 6%an approximately 1% increase in the average bill rate during the year ended December 31, 2016.2019.

Physician and leadership solutions segment revenue decreased 9% to $562.8 million for 2019 from $617.5 million for 2018. The $54.7 million decrease was primarily attributable to a 17% decrease in the number of days filled in our locum tenens business, which was partially offset by additional revenue of $5.7 million in connection with the PDA and LFT acquisition and growth in our permanent placement and organic interim leadership businesses.
Locum tenensTechnology and workforce solutions segment revenue increased 10% to $424.2$96.8 million for 20162019 from $385.1$87.6 million for 2015. Of the $39.22018. The $9.2 million increase $0.6 million was attributable to the additional revenue of Locum Leaders over the OH Stub Period with the remainder primarily attributable to a 3% increasegrowth in the number of days filled and a 7% increase in the revenue per day filledour VMS business during the year ended December 31, 2016.2019.
Other workforceFor 2019 and 2018, revenue under our MSP arrangements comprised approximately 45% and 42% of our consolidated revenue, 57% and 57% for nurse and allied solutions segment revenue increased 135% to $292.9 millionand 20% and 15% for 2016 from $124.7 million for 2015. Of the $168.2 million increase, $145.5 million was attributable to the additionalphysician and leadership solutions segment revenue, in connection with the BES, Millican, TFS, and Peak acquisitions and the additional revenue of Medefis over the OH Stub Period, with the remainder primarily attributable to an increase in billable active searches and the average placement value in the physician permanent placement business as well as growth in our VMS and workforce optimization services revenue during the year ended December 31, 2016.respectively.

Gross Profit. Gross profit increased 32%7% to $619.7$743.5 million for 20162019 from $469.4$696.4 million for 2015,2018, representing gross margins of 32.6%33.5% and 32.1%32.6%, respectively. Gross margin by reportable segment for 2019 and 2018 was 28.5% and 27.7% for nurse and allied solutions, 37.0% and 35.5% for physician and leadership solutions, and 92.8% and 91.4% for technology and workforce solutions, respectively. The year-over-year gross margin increase in consolidated gross marginthe physician and leadership solutions segment was primarily due to the growthchange in oursales mix resulting from the addition of higher margin other workforce solutions segmentPDA and higher bill-to-pay spreads in theLFT as compared to our locum tenens solutions segment, partially offset by higher direct costsbusiness within the segment.

Selling, General and Administrative Expenses. The year-over-year increase in SG&A expenses in the nurse and allied solutions segment during the year ended December 31, 2016. Gross margin by reportable segment for 2016 and 2015 was 26.9% and 27.1% for nurse and allied solutions, 31.1% and 30.2% for locum tenens solutions, and 57.8% and 75.9% for other workforce solutions, respectively. The other workforce solutions segment decrease was primarily due to the change in the business mix resulting from the additions of BES, TFS and Peak during the year ended December 31, 2016.

Selling, General and Administrative Expenses. SG&A expenses were $398.5 million, representing 20.9% of revenue, for 2016, as compared to $319.5 million, representing 21.8% of revenue, for 2015. The increase in SG&A expenses was primarily due to $35.1driven by $17.1 million of additional SG&A expenses from the HSG, BES, Millican, TFS,Advanced and PeakMedPartners acquisitions and OH expenses over the OH Stub Period, as well as increased employee headcount, variable compensation, legal reserves, and other expenses associated with ourthe revenue growth. SG&A expense increases as a result of acquisitions in the nurse and allied solutions, locum tenens solutions and other workforce solutions segments were $4.5 million, $0.1 million and $30.5 million, respectively. The increase in unallocated corporate overhead was primarily attributable to higher employee and variable expenses to support our growth, along with higher legal reserve costs. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:
 (In Thousands)
Years Ended
December 31,
 20192018
Nurse and allied solutions$225,707 $195,219 
Physician and leadership solutions136,684 133,226 
Technology and workforce solutions45,935 38,622 
Unallocated corporate overhead83,463 74,436 
Share-based compensation16,241 10,815 
$508,030 $452,318 
 
(In Thousands)
Years Ended
December 31,
 2016 2015
Nurse and allied solutions$156,676
 $134,570
Locum tenens solutions73,126
 68,096
Other workforce solutions91,936
 54,327
Unallocated corporate overhead65,335
 52,254
Share-based compensation11,399
 10,284
 $398,472
 $319,531
Depreciation and Amortization Expenses. Amortization expense increased 55% to $18.3 million for 2016 from $11.8 million for 2015, primarily attributable to additional amortization expense related toWe describe in further detail the intangible assets acquired in the TFS, Millican, BES, HSG and Peak acquisitions. Depreciation expense increased 23% to $11.3 million for 2016 from $9.2 million for 2015, primarily attributable to fixed assets acquired as partcomparison of the TFS, Millican, BES, HSG and Peak acquisitions and an increase in purchased and developed hardware and software for our ongoing front and back office information technology initiatives.
Interest Expense, Net, and OtherInterest expense, net, and other was $15.5 million for 2016, as compared to $7.8 million for 2015. The increase is primarily due to a higher average debt outstanding balanceresults for the yearyears ended December 31, 2016, which resulted from (1) borrowings under our credit facilities that we used primarily2019 and 2018 in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Comparison of Results for the Year Ended December 31, 2019 to finance the BES and Peak acquisitions and (2) the consummation of the issuance and saleYear Ended December 31, 2018” of our Notes (as defined below in this Item 7) in October 2016.2019 Annual Report on Form 10-K.


Income Tax Expense. Income tax expense was $70.3 million for 2016, as compared to $39.2 million for 2015, reflecting effective income tax rates of 39.9% and 32.4% for these periods, respectively. During 2015, we recorded a discrete federal income tax benefit of $12.2 million resulting from the IRS federal audit settlement. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (7), Income Taxes.”
27

                        
Liquidity and Capital Resources
 
In summary, our cash flows were:
 
Year Ended December 31, Years Ended December 31,
2017 2016 2015 202020192018
(in thousands) (in thousands)
Net cash provided by operating activities$115,262
 $131,851
 $56,313
Net cash provided by operating activities$256,826 $224,862 $226,993 
Net cash used in investing activities(33,446) (257,362) (116,085)Net cash used in investing activities(538,172)(291,824)(279,337)
Net cash provided by (used in) financing activities(77,193) 126,290
 56,200
Net cash provided by financing activitiesNet cash provided by financing activities211,486 136,599 37,511 
Historically, our primary liquidity requirements have been for acquisitions, working capital requirements, and debt service under our credit facilities and the Notes.senior notes. We have funded these requirements through internally generated cash flow and funds borrowed under our credit facilities.facilities and senior notes. During the thirdfourth quarter of 2017,2020, we paid offredeemed the remaining balanceentire outstanding $325.0 million aggregate principal amount of our term debt.5.125% senior notes due 2024 (the “2024 Notes”). At December 31, 2017,2020, (1) the total of our Additional Term Loan (as defined below) outstanding (including both current and long-term portions) was $21.9 million, (2) zero was drawn with $256.0$378.1 million of available credit under our Revolverthe Senior Credit Facility (as defined below), and(2) the aggregate principal amount of our 5.125% Senior2027 Notes due 2024 (the “Notes”)(as defined below) outstanding equaled $325.0$500.0 million, and (3) the aggregate principal amount of our 2029 Notes (as defined below) outstanding equaled $350.0 million. We repaid in full our indebtedness under the Additional Term Loan in January 2021. We describe in further detail our Amended Credit Agreement (as defined below), under which our Revolver and Second Term Loan (and any other loans that may be made thereunder) areSenior Credit Facility is governed, in “Item 8. Financial Statements and Supplementary Data—Notes to

Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement.” On February 9, 2018, we replaced our Credit Agreement with a New Credit Agreement (as defined below).

In April 2015, we entered into an interest rate swap agreement to minimize our exposure to interest rate fluctuations on $100 million of our outstanding variable rate debt under one of our Term Loans (as defined below in this Item 7) for which we pay a fixed rate of 0.983% per annum and receive a variable rate equal to floating one-month LIBOR. This agreement was set to expire on March 30, 2018, and no initial investment was made to enter into this agreement. In connection with our issuance and sale of $325.0 million aggregate principal amount of the 2027 Notes, and the use of a portion of the proceeds thereof to repay $138.4 million of our Term Loans on October 3, 2016, we reduced the interest rate swap notional amount to $40.0 million. On May 3, 2017, we terminated the remaining interest rate swap. See additional information2029 Notes in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (3)(8), Derivative Instruments.Notes Payable and Credit Agreement.

We believe that cash generated from operations and available borrowings under our RevolverSenior Credit Facility will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond. We intend to finance potential future acquisitions with cash provided from operations, borrowings under our RevolverSenior Credit Facility, or other borrowingborrowings under our Amended Credit Agreement, bank loans, debt or equity offerings, or some combination of the foregoing. The following discussion provides further details of our liquidity and capital resources.
 
Operating Activities
 
Net cash provided by operating activities for 2017, 20162020, 2019 and 20152018 was $115.3$256.8 million,, $131.9 $224.9 million and $56.3$227.0 million, respectively. The decreaseincrease in net cash provided by operating activities for 20172020 from 20162019 was primarily attributable to (1) an increase in restricted cash, cash equivalentsother liabilities between periods of $47.7 million, and investments attributable to cash payments madea corresponding decrease in income tax receivable between periods of $4.1 million, primarily due to our captive insurance entity,election to defer employer payroll taxes in accordance with the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and an increase in accruals established in connection with a legal matter during the fourth quarter of 2020, which are restricted for usewas partially offset by the captivecontingent consideration earn-out payment for future claim paymentsthe Advanced acquisition (in excess of its acquisition-date fair value, which is noted below in financing activities), and to a lesser extent, its working capital needs, (2) a decrease in accounts payable and accrued expensesother assets between periods of $16.0 million due to timing of paymentslower long-term prepayments and (3) an increase in income taxes receivable.deposits. The overall decreaseincrease was partially offset by (1) improved operating results,a decrease in accrued compensation and benefits between periods of $6.9 million primarily due to higher distributions under the deferred compensation plan as compared to the prior year and (2) smalleran increase in accounts receivable and subcontractor receivable between periods of $14.3 million due to improved collections in 20172019 as compared to 2018, which stabilized in 2020, and a higher average receivable balance in the current year due to an increase in 2016, and (3) excess tax benefits on the vesting of employee equity awards resulting from the adoption of a new accounting pronouncement discussed in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (1), Summary of Significant Accounting Policies.”revenue. Our Days Sales Outstanding was 6355 and 6455 days at December 31, 20172020 and December 31, 2016,2019, respectively.
 
Investing Activities
 
Net cash used in investing activities for 2017, 20162020, 2019 and 20152018 was $33.4$538.2 million,, $257.4 $291.8 million and $116.1$279.3 million, respectively. The year-over-year decreaseincrease from 20162019 to 20172020 in net cash used in investing activities was primarily attributable to (1) no new$476.5 million used for acquisitions in 20172020 as compared to $216.5 million used for the acquisitions of BES and HSG in January 2016 and Peak in June 2016, (2) net proceeds of $5.2$247.9 million in 2017, as compared to2019 and (2) a net purchase of $11.2 million restricted investmentinvestments related to our captive insurance entitycompany of $15.5 million during 2016.2020, as compared to net proceeds of $5.8 million during 2019. The decreaseoverall increase was partially offset by $3.6$5.3 million additionalless payments made during 2017 as compared to 2016 to fund the deferred compensation plan.plan during 2020 as compared to 2019. Capital expenditures were $26.5$37.7 million,, $22.0 $35.2 million and $27.0$35.2 million for the years ended December 31, 2017, 20162020, 2019 and 2015,2018, respectively. Our capital expenditures in recent years were primarily to information technology investments to support the growth of the businessour total talent solutions initiatives and for investments made in conjunction with management initiativesefforts to updateoptimize our internal front and back office information technology platforms. We intend to continue our investment in these information technology initiatives, including investments of approximately $17 million in the next year, to standardize our staffing operations on PeopleSoft and Salesforce. We believe these investments will further differentiate our ability to deliver innovative workforce solutions in addition to delivering improved operating efficiency.systems.


Financing Activities

28


Net cash (used in) provided by financing activities for 2017, 20162020, 2019 and 20152018 was ($77.2 million), $126.3$211.5 million, $136.6 million and $56.2$37.5 million, respectively. Net cash used inprovided by financing activities for 20172020 was primarily due to (1) gross proceeds received in connection with the issuances of the New 2027 Notes (as defined below) and the 2029 Notes (as defined below) of $552.0 million and (2) borrowings of $245.0 million under the Senior Credit Facility (as defined below) and $250.0 million under the Additional Term Loan (as defined below), partially offset by (1) the repayments of $44.1$245.0 million under ourthe Senior Credit Facility and $228.1 million under the Additional Term Loans,Loan, (2) $20.2$333.3 million of payments related to the redemption of the 2024 Notes (as defined below), (3) $11.5 million of financing costs paid in connection with the repurchaseAmended Credit Agreement (as defined below) and the issuances of our common stock,the 2027 Notes and (3) $9.4the 2029 Notes, (4) $10.6 million of prior acquisition contingent consideration earn-out payments, and (5) $6.9 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards.
 

Credit Agreement Prior to February 9, 2018
We are party to a credit agreement (as amended to date, the “Credit Agreement”) with several lenders to provide for the following credit facilities: (A) a $275 million revolver facility (the “Revolver”), which includes a $40 million sublimit for the issuance of letters of credit and a $20 million sublimit for swingline loans, (B) a $150 million secured term loan credit facility (the “Original Term Loan”) and (C) a $75 million secured term loan facility (the “Second Term Loan,” and together with the Original Term Loan, the “Term Loans”). The Credit Agreement contains various customary affirmative and negative covenants, including restrictions on assumption of additional indebtedness, declaration and payment of dividends, dispositions of assets, consolidation into another entity and allowable investments. The Revolver and the Term Loans are secured by substantially all of our assets, including the common stock or equity interests of our domestic subsidiaries. For more detail regarding the terms of the Credit Agreement, including maturity dates, payment and interest terms, please see “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement.”

We repaid the entire Original Term Loan in 2016. As of December 31, 2016, the total of our Term Loans outstanding (including both the current and long-term portions), less unamortized fees, was $43.9 million. During 2017, we paid off the remaining balance of the Second Term Loan. There was zero and $82.5 million outstanding under the Revolver at December 31, 2017 and 2016, respectively.

NewAmended Credit Agreement
On February 9, 2018, we entered into a credit agreement (the “New Credit Agreement”) with several lenders to provide for a $400,000$400.0 million secured revolving credit facility (the “Senior Credit Facility”) to replace our then-existing credit agreement. On June 14, 2019, we entered into the first amendment to the New Credit Agreement.Agreement (the “First Amendment”) to provide for, among other things, a $150.0 million secured term loan credit facility (the “Term Loan”). In connection with our issuance of the Existing 2027 Notes (as defined below), we used a portion of the proceeds to repay our entire indebtedness under the Term Loan during the fourth quarter of 2019.
On February 14, 2020, we entered into the second amendment to the New Credit Agreement (the “Second Amendment”) to provide for, among other things, a $250.0 million secured term loan credit facility (the “Additional Term Loan” and, together with the Senior Credit Facility, the “Credit Facilities”). The Second Amendment (together with the New Credit Agreement and the First Amendment, collectively, the “Amended Credit Agreement”) extended the maturity date of the Senior Credit Facility to be coterminous with the Additional Term Loan. The Senior Credit Facility includes a $50,000$75.0 million sublimit for the issuance of letters of credit and a $50,000$75.0 million sublimit for swingline loans. Our obligations under the NewAmended Credit Agreement and the Senior Credit Facility are secured by substantially all of our assets. Borrowings under the Senior Credit Facility bear interest at floating rates, at our option, based upon either LIBOR plus a spread of 1.00% to 2.00% or a base rate plus a spread of 0.00% to 1.00%. The applicable spread is determined quarterly based upon our consolidated net leverage ratio. The Senior Credit Facility is available for working capital, capital expenditures, permitted acquisitions and general corporate purposes. The maturity dateterms of the SeniorAmended Credit Facility is February 9, 2023.Agreement, including maturity dates, payment and interest terms, are described in further detail in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement.”


5.125%4.625% Senior Notes Due 20242027


On October 3, 2016,August 13, 2020, AMN Healthcare, Inc., a wholly owned subsidiary of the Company, completed the issuance and sale of $325.0an additional $200.0 million aggregate principal amount of 4.625% senior notes due 2027 (the “New 2027 Notes”), which were issued at a price of 101.000% of the aggregate principal amount. The New 2027 Notes were issued pursuant to the existing indenture, dated as of October 1, 2019, under which we previously issued $300.0 million aggregate principal amount of 4.625% senior notes due 2027 (the “Existing 2027 Notes” and together with the New 2027 Notes, the “2027 Notes”). The New 2027 Notes will be treated as a single series with the Existing 2027 Notes and will have the same terms (other than issue price, issue date and the date from which interest accrues) as those of the Existing 2027 Notes. The 2027 Notes will mature on October 1, 2024.2027. Interest on the 2027 Notes is payable semi-annually in arrears on April 1 and October 1 of each year, and commenced Aprilcommencing October 1, 2017.2020 with respect to the New 2027 Notes. The 2027 Notes are fully and unconditionally and jointly guaranteed on a senior unsecured basis by us and all of our subsidiaries that guarantee the Amended Credit Agreement.


On and after October 1, 2019,2022, we may redeem all or a portion of the 2027 Notes upon not less than 30 nor more than 60 days’ notice, at the redemption prices (expressed in percentages of principal amount on the redemption date) set forth below, plus accrued and unpaid interest, if any, to (but excluding) the redemption date, if redeemed during the twelve month period commencing on October 1 of the years set forth below:
PeriodRedemption
Price
2019 103.844%
2020 102.563%
2021 101.281%
2022 and thereafter 100%
PeriodRedemption
Price
2022 102.313 %
2023 101.156 %
2024 and thereafter 100.000 %
Prior to October 1, 2019,2022, we may also redeem 2027 Notes with the net cash proceeds of certain equity offerings in an aggregate principal amount not to exceed 40% of the aggregate principal amount of the 2027 Notes issued, at a redemption price (expressed as a percentage of principal amount) of 105.125%104.625% of the principal amount thereof plus accrued and unpaid interest, if any, to (but excluding) the applicable redemption date.
29

In addition, we may redeem some or all of the 2027 Notes prior to October 1, 20192022 at a redemption price equal to 100% of the principal amount of the 2027 Notes redeemed, plus accrued and unpaid interest thereon, if any, to (but excluding) the applicable redemption date, plus a “make-whole” premium based on the applicable treasury rate plus 50 basis points.

Upon the occurrence of specified change of control events as defined in the indenture governing the 2027 Notes, we must offer to repurchase the 2027 Notes at 101% of the principal amount, plus accrued and unpaid interest, if any, to (but excluding) the purchase date.
The indenture governing the 2027 Notes contains covenants that, among other things, restrict our ability to:
sell assets,
pay dividends or make other distributions on capital stock, or make payments in respect of subordinated indebtedness or make other restricted payments,
make certain investments,
incur or guarantee additional indebtedness or issue preferred stock,
create or permit to exist, certain liens,
enter into agreements that restrict dividends or other payments from our restricted subsidiaries,
consolidate, merge or transfer all or substantially all of our assets,
engage in transactions with affiliates, and
create unrestricted subsidiaries.
These covenants are subject to a number of important exceptions and qualifications. The indenture governing the 2027 Notes contains affirmative covenants and events of default that are customary for indentures governing high yield securities. The 2027 Notes and the guarantees are not subject to any registration rights agreement.
We used the proceeds from the issuance and sale of the Existing 2027 Notes to (1) repay $131.3$149.1 million of our existing Originalindebtedness under the Term Loan, indebtedness, (2) repay $7.2$146.0 million under our Senior Credit Facility, and (3) pay fees and expenses related to the transaction during the fourth quarter of 2019. We used the proceeds from the issuance of the New 2027 Notes to repay $200.0 million of our existing Secondindebtedness under the Additional Term Loan during the third quarter of 2020.
4.000% Senior Notes Due 2029

On October 20, 2020, AMN Healthcare, Inc., a wholly owned subsidiary of the Company, completed the issuance of $350.0 million aggregate principal amount of 4.000% Senior Notes due 2029 (the “2029 Notes”). The 2029 Notes will mature on April 15, 2029. Interest on the 2029 Notes will be payable semi-annually in arrears on April 15 and October 15 of each year, commencing April 15, 2021.

At any time and from time to time on and after April 15, 2024, we will be entitled at our option to redeem all or a portion of the 2029 Notes upon not less than 10 nor more than 60 days’ notice, at the redemption prices (expressed in percentages of principal amount on the redemption date) set forth below, plus accrued and unpaid interest, if any, to (but excluding) the redemption date (subject to the right of holders of record of the 2029 Notes on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the twelve month period commencing on April 15 of the years set forth below:

PeriodRedemption
Price
2024102.000 %
2025101.000 %
2026 and thereafter100.000 %


At any time and from time to time prior to April 15, 2024, we may also redeem 2029 Notes with the net cash proceeds of certain equity offerings in an aggregate principal amount not to exceed 40% of the aggregate principal amount of the 2029 Notes issued, at a redemption price (expressed as a percentage of principal amount) of 104.000% of the principal amount thereof plus accrued and unpaid interest, if any, to (but excluding) the applicable redemption date.

30

In addition, we may redeem some or all of the 2029 Notes at any time and from time to time prior to April 15, 2024 at a redemption price equal to 100% of the principal amount of the 2029 Notes redeemed, plus accrued and unpaid interest thereon, if any, to (but excluding) the applicable redemption date, plus a “make-whole” premium based on the applicable treasury rate plus 50 basis points.

Upon the occurrence of specified change of control events as defined in the indenture governing the 2029 Notes, we must offer to repurchase the 2029 Notes at 101% of the principal amount, plus accrued and unpaid interest, if any, to (but excluding) the purchase date.

The indenture governing the 2029 Notes contains covenants that, among other things, restricts our ability to:

sell assets;
pay dividends or make other distributions on capital stock, make payments in respect of subordinated indebtedness or make other restricted payments;
make certain investments;
incur or guarantee additional indebtedness or issue preferred stock;
create certain liens;
enter into agreements that restrict dividends or other payments from our restricted subsidiaries to us;
consolidate, merge or transfer all or substantially all of their assets;
enter into transactions with affiliates; and
create unrestricted subsidiaries.

These covenants are subject to a number of important exceptions and qualifications. The indenture governing the 2029 Notes contains affirmative covenants and events of default that are customary for indentures governing high yield securities. The 2029 Notes and the guarantees are not subject to any registration rights agreement.

We used the proceeds from the issuance of the 2029 Notes, along with cash generated from operations, to redeem all of our outstanding $325.0 million aggregate principal amount of 2024 Notes on November 4, 2020, (2) pay the associated redemption premium and all accrued and unpaid interest on the 2024 Notes, (3) repay $182.5$40.0 million under our Revolver,the Senior Credit Facility, and (4) pay fees and expenses related to the transaction.


Letters of Credit
 
At December 31, 2017,2020, we maintained outstanding standby letters of credit totaling $22.0$24.1 million as collateral in relation to our professional liability insurance agreements, workers compensation insurance agreements and a corporate office lease agreement. Of the $22.0$24.1 million of outstanding letters of credit, we have collateralized $2.7$2.2 million in cash and cash equivalents and the remaining amount has been$21.9 million is collateralized by the Revolver.Senior Credit Facility. Outstanding standby letters of credit at December 31, 20162019 totaled $15.4$19.8 million.
 
Off-Balance Sheet and Other Financing Arrangements
 
At December 31, 20172020 and 2016,2019, we did not have any off-balance sheet arrangement that has or is reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

Contractual Obligations
 
The following table summarizes our contractual obligations as of December 31, 20172020 (in thousands):
 
Fiscal Year Fiscal Year
2018 2019 2020 2021 2022 Thereafter Total 20212022202320242025ThereafterTotal
Notes payable (1)$16,656
 $16,656
 $16,656
 $16,656
 $16,656
 $358,314
 $441,594
Notes payable (1)$59,000 $37,125 $37,125 $37,125 $37,125 $944,511 $1,152,011 
Senior Credit Facility (2)Senior Credit Facility (2)356 418 418 420 25,051 — 26,663 
Operating lease obligations (2)(3)16,962
 16,969
 16,913
 16,969
 16,777
 66,439
 151,029
19,108 18,552 18,207 17,030 15,160 18,733 106,790 
Total contractual obligations$33,618
 $33,625
 $33,569
 $33,625
 $33,433
 $424,753
 $592,623
Total contractual obligations$78,464 $56,095 $55,750 $54,575 $77,336 $963,244 $1,285,464 
 
(1)Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of 5.125%.
(2)Amounts represent minimum contractual amounts, with initial or remaining lease terms and license terms in excess of one year. We have assumed no escalations in rent or changes in variable expenses other than as stipulated in lease contracts.
(1)Amounts represent contractual amounts due under (a) the 2027 Notes and 2029 Notes, including interest based on the fixed rates of 4.625% and 4.000%, respectively, and (b) the Additional Term Loan, which was repaid in full during the first quarter of 2021.
(2)Amounts represent contractual amounts to be repaid under the Senior Credit Facility for borrowings made during the first quarter of 2021, including interest based on the rate in effect at December 31, 2020.
31

(3)Amounts represent minimum contractual amounts with initial lease terms in excess of one year, including any leases that were signed, but not yet commenced as of December 31, 2020 that create significant obligations. We have assumed no escalations in rent other than as stipulated in lease agreements.
In addition to the above disclosed contractual obligations, the unrecognized income tax benefits, including interest and penalties, was $5.3$5.4 million at December 31, 2017.2020. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (7), Income Taxes.”



Critical Accounting Policies and Estimates
 
Our critical accounting policies are described in Note (1) to our audited consolidated financial statements contained in Item 8 of this Annual Report on Form 10-K. Critical accounting policies are those that we believe are both important to the portrayal of our financial condition and results and require our most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The preparation of our consolidated financial statements in conformity with United States generally accepted accounting principles requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and base them on the information that is currently available to us and on various other assumptions that we believe are reasonable under the circumstances. Actual results could vary from these estimates under different assumptions or conditions. We believe that the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our consolidated financial statements:
 
Goodwill and Indefinite-lived Intangible Assets

Our business acquisitions typically result in the recording of goodwill and other intangible assets. The determination of the fair value of such intangible assets involves the use of appropriate valuation techniques and requires management to make estimates and assumptions that affect our consolidated financial statements. Significant judgments required to estimate the fair values include estimated future cash flows, growth rates, customer attrition rates, brand awareness and discount rates. Changes in these estimates and assumptions could materially affect the determination of fair value for each intangible asset. Management may engage independent third-party specialists to assist in determining the fair values. For intangible assets purchased in a business acquisition, the estimated fair values of the assets received are used to establish their recorded values, which may become impaired in the future.

In accordance with accounting guidance on goodwill and other intangible assets, we perform annual impairment analysis to assess the recoverability of goodwill and indefinite-lived intangible assets. We assess the impairment of goodwill of our reporting units and indefinite-lived intangible assets annually, or more often if events or changes in circumstances indicate that the carrying value may not be recoverable. We may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, we determine that it is more likely than not that the fair value of the reporting unit is greater than its carrying amount, the quantitative impairment test is unnecessary. If the reporting unit does not pass the qualitative assessment, then the reporting unit’s carrying value is compared to its fair value. The fair values of the reporting units are estimated using market and discounted cash flow approaches. Goodwill is considered impaired if the carrying value of the reporting unit exceeds its fair value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. Valuation techniques consistent with the market approach and income approach are used to measure the fair value of each reporting unit. Significant judgments are required to estimate the fair value of reporting units including estimating future cash flows, and determining appropriate discount rates, growth rates, company control premium and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value for each reporting unit. We perform our annual impairment test on October 31 of each year.

Intangible assets with estimable useful lives are required to be amortized over their respective estimated useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment evaluation is based on an undiscounted cash flow analysis at the lowest level at which cash flows of the long-lived assets are largely independent of other groups of assets and liabilities. We assess potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recovered. Our judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of our businesses, market conditions and other factors. Although there are inherent uncertainties in this assessment process, the estimates and assumptions we use, including estimates of future cash flows, volumes, market penetration and discount rates, are consistent with our internal planning. If these estimates or their related assumptions change in the future, we may be required to record an impairment charge on all or a
32

portion of our long-lived intangible assets. Furthermore, we cannot predict the occurrence of future impairment-triggering events nor the impact such events might have on our reported asset values. Future events could cause us to conclude that impairment indicators exist and that long-lived intangible assets associated with our acquired businesses are impaired.

Professional Liability Reserve
 
We maintain an accrual for professional liability that we include in accounts payable and accrued expenses and other long-term liabilities in our consolidated balance sheets. We determine the adequacy of this accrual by evaluating our historical experience and trends, loss reserves established by our insurance carriers, management and third-party administrators, and our independent actuarial studies. We obtain actuarial studies on a semi-annual basis that use our historical claims data and industry data to assist us in determining the adequacy of our reserves each year. For periods between the actuarial studies, we record our accruals based on loss rates provided in the most recent actuarial study and management’s review of loss history.

Contingent Liabilities
 
From time to time, weWe are involved in various lawsuits, claims, investigations, and proceedings that arise in the ordinary course of business. These matters typically relate to professional liability, tax, compensation, contract, competitor disputes and employee-related matters and include individual and class action lawsuits, as well as inquiries and investigations by governmental agencies regarding the Company’s employment and compensation practices. Additionally, some of our clients may also become subject to claims, governmental inquiries and investigations and legal actions relating to services provided by our healthcare professionals. From time to time, and depending upon the particular facts and circumstances, we may be subject to indemnification obligations under our contracts with such clients relating to these matters.

Certain of the above-referenced matters may include speculative claims for substantial or indeterminate amounts of damages. We record a liability when we believe that it is both probable that a loss has been incurred and the amount can be reasonably estimated. In assessing the probability of loss and the estimated amount, we consider the following factors, among others: (a) the nature of the matter and any related facts, circumstances and data; (b) the progress of the case; (c) the opinions or views of legal counsel and other advisers; (d) our experience, and the experience of other entities, in similar cases; (e) how we intend to respond to the matter; and (f) reasonable settlement values based on the foregoing factors. Significant judgment is required to determine both probability and the estimated amount. Where a range of loss can be reasonably estimated with no best estimate in the range, we record the minimum estimated liability. We review these provisions at least quarterly and adjust these provisions accordingly to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information. We believe that the amount or estimable range of reasonably possible loss beyond that accruals that we have established, will not, either individually or in the aggregate, have a material adverse effect on our business, consolidated financial position, results of operations, or cash flows with respect to loss contingencies for legal and other contingencies as of December 31, 2017.2020. However, the outcome of litigation is inherently uncertain. Therefore, if one or more of these legal matters were resolved against us for amounts in excess of management’s expectations, our results of operations and financial condition, including in a particular reporting period, could be materially adversely affected.

Income Taxes
 
We evaluate our unrecognized tax benefits in accordance with the guidance for accounting for uncertainty in income taxes. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.
 
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. In July 2015, the FASB voted to amend the guidance by approving a one-year delay in the effective date of the new standard to 2018. In addition, the FASB has also issued several amendments to the standard, which clarify certain aspects of the guidance, including principal versus agent consideration and identifying performance obligations. We have adopted this

standard effective January 1, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. Revenue from substantially all of our contracts with customers will continue to be recognized over time as services are rendered. We will recognize the cumulative effect of adopting this guidance as an adjustment to our opening balance of retained earnings, net of tax, primarily related to deferral of contract costs, which we expect to be approximately $2 million. Prior periods will not be retrospectively adjusted.
In February 2016,December 2019, the FASB issued ASU 2016-02, “Leases.2019-12, “Simplifying the Accounting for Income Taxes. The standard is expected to reduce cost and complexity related to accounting for income taxes. The new guidance eliminates certain exceptions and clarifies and amends existing guidance to promote consistent application among reporting entities. This standard requires organizations that lease assets to recognize the assets and liabilities created by those leases. The standard also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The ASU becomesis effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. We are required to adopt2020, with early adoption permitted. Depending on the guidanceamendment, adoption may be applied on a retrospective, modified retrospective basis and can elect to apply optional practical expedients. We are currently evaluating the approach we will take and the impact of adopting this new standard on our consolidated financial statements and related disclosures.
In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” The standard provides guidance on how certain cash receipts and payments are presented and classified in the statement of cash flows. For public entities, ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods, and requires a retrospective approach. Early adoption is permitted, including adoption in an interim period.or prospective basis. We have adopted this standard effective January 1, 20182021 and do not expect the adoption of this standard to have a material impact on our consolidated financial statements.
In November 2016,January 2020, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash.” The standard requires that a statement of cash flows explain2020-01, “Clarifying the change during the period in the total of cash, cash equivalents,Interactions between Topic 321, Topic 323, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.Topic 815.” The new guidance clarifies the interactions between accounting standards that apply to equity investments without readily determinable fair values. Specifically, it addresses the accounting for the transition into and out of the equity method. This standard is effective on a prospective basis for fiscal years, and interim and annual periods within those fiscal years, beginning after
33

December 15, 2017 and2020, with early adoption is permitted. The amendment will be adopted retrospectively. We have adopted this standard effective January 1, 20182021 and although it will change the historical presentation on the consolidated statements of cash flows, it will not have any other material impact on our consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.” The standard simplifies the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Further, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. This standard is effective for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019, with early adoption permitted for impairment tests performed after January 1, 2017. While we continue to assess the timing of adopting this standard, we do not expect the adoption of this standard to have a material impact on our consolidated financial statements.
There have been no other new accounting pronouncements issued but not yet adopted that are expected to materially affect our consolidated financial condition or results of operations.

Item 7A.Quantitative and Qualitative Disclosures about Market Risk
Item 7A.    Quantitative and Qualitative Disclosures about Market Risk
 
Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates and commodity prices. During 2017,2020, our primary exposure to market risk was interest rate risk associated with our variable interest debt instruments. During the third quarter of 2017, we paid off the remaining balance of the Term Loans. A 100 basis point increase in interest rates on our variable rate debt would not have resulted in a material effect on our consolidated financial statements for 2017.2020. During 2017,2020, we generated substantially all of our revenue in the United States. Accordingly, we believe that our foreign currency risk is immaterial.
34

                        

Item 8.Financial Statements and Supplementary Data

Item 8.    Financial Statements and Supplementary Data

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 
Page

35

                        

Report of Independent Registered Public Accounting Firm
 
TheTo the Stockholders and Board of Directors
AMN Healthcare Services, Inc.:
 
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of AMN Healthcare Services, Inc. and subsidiaries (the "Company")Company) as of December 31, 20172020 and 2016,2019, the related consolidated statements of comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-yearthree‑year period ended December 31, 2017,2020, and the related notes (collectively, the "consolidatedconsolidated financial statements")statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 20172020 and 2016,2019, and the results of its operations and its cash flows for each of the years in the three-yearthree‑year period ended December 31, 2017,2020, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB")(PCAOB), the Company’s internal control over financial reporting as of December 31, 2017,2020, based on criteria established in Internal Control - Integrated Framework (2013)issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 16, 201826, 2021 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
Change in Accounting Principle
As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for leases as of January 1, 2019, due to the adoption of Accounting Standards Update 2016-02, Leases, and related amendments.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters


The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
    Professional liability reserve
As discussed in Note 1(j) and 6 to the consolidated financial statements, the Company determines their professional liability accrual by evaluating historical experience, trends, loss reserves, and actuarial studies. As of December 31, 2020, the Company recorded professional liability reserves totaling $40,894 thousand.
We identified the evaluation of the professional liability reserve as a critical audit matter. A high degree of complex and subjective auditor judgment, including the involvement of actuarial professionals with specialized skills and knowledge, was required in evaluating the Company’s actuarial estimates and assumptions, specifically estimates for incurred but not reported claims. Changes in the actuarial estimates or assumptions could have a significant impact on the liability recognized.
36

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the process to estimate the professional liability reserve. This included a control related to the selection of expected loss rates used in the estimates for incurred but not reported claims. We tested the key inputs to determine the incurred but not reported estimate. This included testing data used by the Company’s actuarial specialist to determine the expected loss rates, specifically claims history used in the actuarial models, for consistency with the actual claims incurred and paid by the Company. We also involved actuarial professionals with specialized skills and knowledge, who assisted in evaluating the Company’s actuarial estimates and assumptions, specifically expected loss rates, by comparing them to the Company’s historical data, and industry and regulatory trends.
Fair value of intangible assets in acquisition of Stratus Video
As discussed in Note 2 to the consolidated financial statements, the Company acquired Stratus Video on February 14, 2020 for a purchase price of $485,568 thousand. In connection with the acquisition, the Company recorded various intangible assets, including customer relationships, tradenames and trademarks, and developed technology (collectively, the intangible assets). The acquisition-date fair value of the intangible assets was $227,000 thousand.
We identified the evaluation of fair value of the intangible assets acquired in the Stratus Video acquisition as a critical audit matter. A high degree of subjective auditor judgment, including the involvement of valuation professionals with specialized skills and knowledge, was required in evaluating the assumptions used in the valuation model for each acquired intangible asset. The discounted cash flow model included the following assumptions for which there was limited observable market information, and the calculated fair value of such assets was sensitive to possible changes to these key assumptions:
Revenue growth rates
Tradename/trademark royalty rate
Annual customer attrition rate
Developed Technology royalty rate
Earnings before interest, tax, depreciation, and amortization (EBITDA) margins
Weighted-average cost of capital (WACC), including the discount rate
The following are the primary audit procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s process to estimate the fair value of intangible assets. This included controls related to the development of the key assumptions listed above. We evaluated the Company’s forecasted revenue growth rates by comparing forecasted growth assumptions to those of Stratus Video’s peers and industry reports. We compared (1) the Stratus Video’s forecasted revenue growth rates and EBITDA margins to historical actual results for Stratus Video, and (2) forecasted annual customer attrition rate to historical customer sales data. In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in:
Evaluating the Company’s tradename/trademark and developed technology royalty rates assumption to licensing transactions for similar intellectual property;
Evaluating the Company’s WACC, including the discount rate, by comparing it against a discount rate range that was independently developed using publicly available market data for comparable peers;
Developing an estimate of the acquisition-date fair value of the intangible assets using the Company’s cash flow forecast and an independently developed discount rate and comparing the results to the Company’s fair value estimate.
/s/ KPMG LLP
 
We have served as the Company'sCompany’s auditor since 2000.


San Diego, California
February 16, 201826, 2021

37

                        

AMN HEALTHCARE SERVICES, INC.
 
CONSOLIDATED BALANCE SHEETS
(in thousands, except par value)
 
December 31,
December 31, 2017 December 31, 201620202019
ASSETS   ASSETS
Current assets:   Current assets:
Cash and cash equivalents$15,147
 $10,622
Cash and cash equivalents$29,213 $82,985 
Accounts receivable, net of allowances of $9,801 and $11,376 at December 31, 2017 and 2016, respectively350,496
 341,977
Accounts receivable, net of allowances of $7,043 and $3,332 at December 31, 2020 and 2019, respectivelyAccounts receivable, net of allowances of $7,043 and $3,332 at December 31, 2020 and 2019, respectively376,099 352,685 
Accounts receivable, subcontractor41,012
 49,233
Accounts receivable, subcontractor73,985 72,714 
Prepaid expenses16,505
 14,189
Prepaid expenses13,629 11,669 
Other current assets50,993
 34,607
Other current assets40,809 40,446 
Total current assets474,153
 450,628
Total current assets533,735 560,499 
Restricted cash, cash equivalents and investments64,315
 31,287
Restricted cash, cash equivalents and investments61,347 62,170 
Fixed assets, net of accumulated depreciation of $97,889 and $84,865 at December 31, 2017 and 2016, respectively73,431
 59,954
Fixed assets, net of accumulated depreciation of $161,752 and $132,900 at December 31, 2020 and 2019, respectivelyFixed assets, net of accumulated depreciation of $161,752 and $132,900 at December 31, 2020 and 2019, respectively116,174 104,832 
Operating lease right-of-use assetsOperating lease right-of-use assets77,735 89,866 
Other assets74,366
 57,534
Other assets135,120 120,254 
Goodwill340,596
 341,754
Goodwill864,485 595,551 
Intangible assets, net of accumulated amortization of $90,685 and $72,057 at December 31, 2017 and 2016, respectively227,096
 245,724
Intangible assets, net of accumulated amortization of $215,234 and $151,417 at December 31, 2020 and 2019, respectivelyIntangible assets, net of accumulated amortization of $215,234 and $151,417 at December 31, 2020 and 2019, respectively564,911 398,474 
Total assets$1,253,957
 $1,186,881
Total assets$2,353,507 $1,931,646 
LIABILITIES AND STOCKHOLDERS’ EQUITY   LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:   Current liabilities:
Accounts payable and accrued expenses$130,319
 $137,512
Accounts payable and accrued expenses$167,881 $156,140 
Accrued compensation and benefits121,423
 107,993
Accrued compensation and benefits213,414 170,932 
Current portion of notes payable
 3,750
Current portion of notes payable4,688 
Current portion of operating lease liabilitiesCurrent portion of operating lease liabilities15,032 13,943 
Deferred revenue8,384
 8,924
Deferred revenue11,004 11,788 
Other current liabilities5,146
 16,611
Other current liabilities10,938 25,302 
Total current liabilities265,272
 274,790
Total current liabilities422,957 378,105 
Notes payable, less unamortized fees319,843
 359,192
Notes payable, net of unamortized fees and premiumNotes payable, net of unamortized fees and premium857,961 617,159 
Deferred income taxes, net27,036
 21,420
Deferred income taxes, net67,205 46,618 
Operating lease liabilitiesOperating lease liabilities77,800 91,209 
Other long-term liabilities79,279
 82,096
Other long-term liabilities107,907 61,813 
Total liabilities691,430
 737,498
Total liabilities1,533,830 1,194,904 
Commitments and contingencies

 

Commitments and contingencies00
Stockholders’ equity:   Stockholders’ equity:
Preferred stock, $0.01 par value; 10,000 shares authorized; none issued and outstanding at December 31, 2017 and 2016
 
Common stock, $0.01 par value; 200,000 shares authorized; 48,411 issued and 47,481 shares outstanding, respectively, at December 31, 2017 and 48,055 shares issued and 47,612 shares outstanding, respectively, at December 31, 2016484
 481
Preferred stock, $0.01 par value; 10,000 shares authorized; NaN issued and outstanding at December 31, 2020 and 2019Preferred stock, $0.01 par value; 10,000 shares authorized; NaN issued and outstanding at December 31, 2020 and 2019
Common stock, $0.01 par value; 200,000 shares authorized; 49,614 issued and 47,053 outstanding at December 31, 2020 and 49,283 issued and 46,722 outstanding at December 31, 2019Common stock, $0.01 par value; 200,000 shares authorized; 49,614 issued and 47,053 outstanding at December 31, 2020 and 49,283 issued and 46,722 outstanding at December 31, 2019496 493 
Additional paid-in capital453,351
 452,491
Additional paid-in capital468,726 455,193 
Treasury stock, at cost (930 and 443 shares at December 31, 2017 and 2016, respectively)(33,425) (13,261)
Treasury stock, at cost; 2,561 shares at December 31, 2020 and 2019Treasury stock, at cost; 2,561 shares at December 31, 2020 and 2019(119,143)(119,143)
Retained earnings142,229
 9,671
Retained earnings469,558 400,047 
Accumulated other comprehensive income (loss)(112) 1
Accumulated other comprehensive incomeAccumulated other comprehensive income40 152 
Total stockholders’ equity562,527
 449,383
Total stockholders’ equity819,677 736,742 
Total liabilities and stockholders’ equity$1,253,957
 $1,186,881
Total liabilities and stockholders’ equity$2,353,507 $1,931,646 
See accompanying notes to consolidated financial statements.
38

                        

AMN HEALTHCARE SERVICES, INC.
 
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands, except per share amounts)
 
Years Ended December 31, Years Ended December 31,
2017 2016 2015 202020192018
Revenue$1,988,454
 $1,902,225
 $1,463,065
Revenue$2,393,714 $2,222,107 $2,136,074 
Cost of revenue1,344,035
 1,282,501
 993,702
Cost of revenue1,601,936 1,478,642 1,439,691 
Gross profit644,419
 619,724
 469,363
Gross profit791,778 743,465 696,383 
Operating expenses:     Operating expenses:
Selling, general and administrative399,700
 398,472
 319,531
Selling, general and administrative549,747 508,030 452,318 
Depreciation and amortization32,279
 29,620
 20,953
Depreciation and amortization92,766 58,520 41,237 
Total operating expenses431,979
 428,092
 340,484
Total operating expenses642,513 566,550 493,555 
Income from operations212,440
 191,632
 128,879
Income from operations149,265 176,915 202,828 
Interest expense, net, and other19,677
 15,465
 7,790
Interest expense, net, and other57,742 28,427 16,143 
Income before income taxes192,763
 176,167
 121,089
Income before income taxes91,523 148,488 186,685 
Income tax expense60,205
 70,329
 39,198
Income tax expense20,858 34,500 44,944 
Net income$132,558
 $105,838
 $81,891
Net income$70,665 $113,988 $141,741 
     
Other comprehensive income (loss):     Other comprehensive income (loss):
Foreign currency translation and other(98) 267
 75
Foreign currency translation and other(112)263 
Cash flow hedge, net of income taxes(15) (83) 98
Other comprehensive income (loss)(113) 184
 173
Other comprehensive income (loss)(112)263 
     
Comprehensive income$132,445
 $106,022
 $82,064
Comprehensive income$70,553 $113,989 $142,004 
     
Net income per common share:     Net income per common share:
Basic$2.77
 $2.21
 $1.72
Basic$1.49 $2.44 $2.99 
Diluted$2.68
 $2.15
 $1.68
Diluted$1.48 $2.40 $2.91 
Weighted average common shares outstanding:     Weighted average common shares outstanding:
Basic47,807
 47,946
 47,525
Basic47,424 46,704 47,371 
Diluted49,430
 49,267
 48,843
Diluted47,690 47,593 48,668 
     
 
See accompanying notes to consolidated financial statements.


39

                        

AMN HEALTHCARE SERVICES, INC.
 
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Years Ended December 31, 2017, 20162020, 2019 and 20152018
(in thousands)
 
Common StockAdditional
Paid-in
Capital
Treasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total
Common Stock 
Additional
Paid-in
Capital
 Treasury Stock Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Income (Loss) Total SharesAmountSharesAmount
Shares Amount Shares Amount 
Balance, December 31, 201446,639
 $466
 $434,529
 
 $
 $(178,058) $(356) $256,581
Balance, December 31, 2017Balance, December 31, 201748,411 $484 $453,351 (930)$(33,425)$142,229 $(112)$562,527 
Repurchase of common stock into treasuryRepurchase of common stock into treasury— — — (1,236)(67,013)— — (67,013)
Equity awards vested and exercised, net of shares withheld for payroll taxes1,070
 11
 (8,256) 
 
 
 
 (8,245)Equity awards vested and exercised, net of shares withheld for payroll taxes398 (11,436)— — — — (11,432)
Excess income tax benefits from equity awards vested and exercised
 
 7,176
 
 
 
 
 7,176
Cumulative-effect adjustment from adoption of the new revenue recognition standard, net of taxCumulative-effect adjustment from adoption of the new revenue recognition standard, net of tax— — — — — 2,089 — 2,089 
Share-based compensation
 
 10,284
 
 
 
 
 10,284
Share-based compensation— — 10,815 — — — — 10,815 
Comprehensive income
 
 
 
 
 81,891
 173
 82,064
Comprehensive income— — — — — 141,741 263 142,004 
Balance, December 31, 201547,709
 $477
 $443,733
 
 $
 $(96,167) $(183) $347,860
Balance, December 31, 2018Balance, December 31, 201848,809 $488 $452,730 (2,166)$(100,438)$286,059 $151 $638,990 
Repurchase of common stock into treasury
 
 
 (443) (13,261) 
 
 (13,261)Repurchase of common stock into treasury— — — (395)(18,705)— — (18,705)
Equity awards vested and exercised, net of shares withheld for payroll taxes346
 4
 (5,785) 
 
 
 
 (5,781)Equity awards vested and exercised, net of shares withheld for payroll taxes474 (13,778)— — — — (13,773)
Excess income tax benefit from equity awards vested and exercised
 
 3,144
 
 
 
 
 3,144
Share-based compensation
 
 11,399
 
 
 
 
 11,399
Share-based compensation— — 16,241 — — — — 16,241 
Comprehensive income
 
 
 
 
 105,838
 184
 106,022
Comprehensive income— — — — — 113,988 113,989 
Balance, December 31, 201648,055
 $481
 $452,491
 (443) $(13,261) $9,671
 $1
 $449,383
Repurchase of common stock into treasury
 
 
 (487) (20,164) 
 
 (20,164)
Balance, December 31, 2019Balance, December 31, 201949,283 $493 $455,193 (2,561)$(119,143)$400,047 $152 $736,742 
Equity awards vested and exercised, net of shares withheld for payroll taxes356
 3
 (9,377) 
 
 
 
 (9,374)Equity awards vested and exercised, net of shares withheld for payroll taxes331 (6,932)— — — — (6,929)
Cumulative-effect adjustment from adoption of the credit loss standard, net of taxCumulative-effect adjustment from adoption of the credit loss standard, net of tax— — — — — (1,154)— (1,154)
Share-based compensation
 
 10,237
 
 
 
 
 10,237
Share-based compensation— — 20,465 — — — — 20,465 
Comprehensive income (loss)
 
 
 
 
 132,558
 (113) 132,445
Comprehensive income (loss)— — — — — 70,665 (112)70,553 
Balance, December 31, 201748,411
 $484
 $453,351
 (930) $(33,425) $142,229
 $(112) $562,527
Balance, December 31, 2020Balance, December 31, 202049,614 $496 $468,726 (2,561)$(119,143)$469,558 $40 $819,677 
 
See accompanying notes to consolidated financial statements.


40

                        

AMN HEALTHCARE SERVICES, INC.
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
 Years Ended December 31,
 202020192018
Cash flows from operating activities:
Net income$70,665 $113,988 $141,741 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization94,187 58,520 41,237 
Non-cash interest expense and other4,349 1,984 (4,841)
Write-off of fees on credit facilities and senior notes4,956 594 574 
Change in fair value of contingent consideration4,900 7,178 (2,400)
Increase in allowance for credit losses and sales credits6,535 6,275 9,006 
Provision for deferred income taxes(21,628)913 (667)
Share-based compensation20,465 16,241 10,815 
Net loss on deferred compensation balances1,646 
Loss on disposal or sale of fixed assets4,322 484 117 
Amortization of discount on investments(109)(298)(202)
Non-cash lease expense(589)— 
Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable(7,338)28,278 (1,453)
Accounts receivable, subcontractor(1,271)(22,571)(9,131)
Income taxes receivable(412)(4,464)15,099 
Prepaid expenses(1,342)774 4,465 
Other current assets2,322 2,847 (1,259)
Other assets3,220 (12,751)5,239 
Accounts payable and accrued expenses5,562 1,925 17,154 
Accrued compensation and benefits25,856 32,758 10,252 
Other liabilities41,640 (6,090)(8,980)
Deferred revenue(1,119)(1,806)319 
Restricted investments balance78 (92)
Net cash provided by operating activities256,826 224,862 226,993 
Cash flows from investing activities:
Purchase and development of fixed assets(37,702)(35,218)(35,206)
Purchase of investments(48,311)(26,309)(33,824)
Proceeds from maturity of investments32,800 32,135 25,000 
Purchase of equity investments(6,100)
Proceeds from sale of equity investment527 
Purchase of convertible promissory notes(490)(779)(750)
Payments to fund deferred compensation plan(7,171)(12,507)(9,917)
Cash paid for acquisitions, net of cash and restricted cash received(476,491)(247,906)(217,360)
Cash paid for other intangibles(1,400)(1,240)(1,180)
Cash received for working capital adjustments for prior year acquisitions66 
Net cash used in investing activities(538,172)(291,824)(279,337)

41
 Years Ended December 31,
 2017 2016 2015
Cash flows from operating activities:     
Net income$132,558
 $105,838
 $81,891
Adjustments to reconcile net income to net cash provided by operating activities:     
Depreciation and amortization32,279
 29,620
 20,953
Non-cash interest expense and other2,231
 2,416
 1,934
Change in fair value of contingent consideration184
 (24) (330)
Increase in allowances for doubtful accounts and sales credits10,339
 12,008
 6,684
Provision for deferred income taxes5,607
 (9,424) 12,677
Share-based compensation10,237
 11,399
 10,284
Excess tax benefit from equity awards vested and exercised
 (3,351) (7,449)
Loss on disposal or sale of fixed assets227
 69
 4
Amortization of discount on investments(127) 
 
Changes in assets and liabilities, net of effects from acquisitions:     
Accounts receivable(18,858) (58,700) (75,653)
Accounts receivable, subcontractor8,221
 1,542
 (22,365)
Income taxes receivable(15,537) 6,469
 7,867
Prepaid expenses(2,316) (455) (2,915)
Other current assets(934) (13,938) (5,409)
Other assets(5,406) (3,562) (4,785)
Accounts payable and accrued expenses(7,862) 17,705
 29,611
Accrued compensation and benefits13,430
 19,142
 11,888
Other liabilities(8,442) 8,147
 (2,103)
Deferred revenue(548) 732
 1,313
Restricted cash, cash equivalents and investments balance(40,021) 6,218
 (7,784)
Net cash provided by operating activities115,262
 131,851
 56,313
Cash flows from investing activities:     
Purchase and development of fixed assets(26,529) (21,956) (27,010)
Purchase of investments(15,096) (13,152) 
Proceeds from maturity of investments20,301
 2,000
 
Change in restricted cash, cash equivalents and investments balance1,915
 999
 
Equity investment(2,000) 
 (1,000)
Payments to fund deferred compensation plan(10,537) (6,911) (3,004)
Cash paid for acquisitions, net of cash received
 (216,494) (84,081)
Cash paid for other liabilities, working capital adjustments and holdback liability for prior year acquisitions(1,500) (1,848) (990)
Net cash used in investing activities(33,446) (257,362) (116,085)

                        

Years Ended December 31,
202020192018
Cash flows from financing activities:     Cash flows from financing activities:
Capital lease repayments
 (7) (4)
Payments on term loans(44,063) (167,813) (7,500)Payments on term loans(228,125)(150,000)
Proceeds from term loan
 75,000
 
Proceeds from term loan250,000 150,000 
Payments on revolving credit facility
 (206,500) (25,000)Payments on revolving credit facility(245,000)(221,000)(75,000)
Proceeds from revolving credit facility
 124,000
 89,500
Proceeds from revolving credit facility245,000 101,000 195,000 
Proceeds from senior notes
 325,000
 
Proceeds from senior notes552,000 300,000 
Redemption of senior notesRedemption of senior notes(333,330)
Repurchase of common stock(20,164) (13,261) 
Repurchase of common stock(18,705)(67,013)
Payment of financing costs
 (6,561) 
Payment of financing costs(11,508)(5,223)(2,331)
Earn-out payments for prior acquisitions(3,677) (900) 
Earn-out payments for prior acquisitions(10,622)(5,700)(1,713)
Proceeds from termination (payment on reduction) of derivative contract85
 (238) 
Proceeds from exercise of equity awards
 
 3,663
Cash paid for shares withheld for taxes(9,374) (5,781) (11,908)Cash paid for shares withheld for taxes(6,929)(13,773)(11,432)
Excess tax benefit from equity awards vested and exercised
 3,351
 7,449
Net cash provided by (used in) financing activities(77,193) 126,290
 56,200
Net cash provided by financing activitiesNet cash provided by financing activities211,486 136,599 37,511 
Effect of exchange rate changes on cash(98) 267
 75
Effect of exchange rate changes on cash(112)263 
Net increase (decrease) in cash and cash equivalents4,525
 1,046
 (3,497)
Cash and cash equivalents at beginning of year10,622
 9,576
 13,073
Cash and cash equivalents at end of year$15,147
 $10,622
 $9,576
Net increase (decrease) in cash, cash equivalents and restricted cashNet increase (decrease) in cash, cash equivalents and restricted cash(69,972)69,638 (14,570)
Cash, cash equivalents and restricted cash at beginning of yearCash, cash equivalents and restricted cash at beginning of year153,962 84,324 98,894 
Cash, cash equivalents and restricted cash at end of yearCash, cash equivalents and restricted cash at end of year$83,990 $153,962 $84,324 
Supplemental disclosures of cash flow information:     Supplemental disclosures of cash flow information:
Cash paid for interest (net of $188, $174 and $264 capitalized in 2017, 2016 and 2015, respectively)$17,936
 $8,057
 $5,806
Cash paid for amounts included in the measurement of operating lease liabilitiesCash paid for amounts included in the measurement of operating lease liabilities$20,052 $17,817 $— 
Cash paid for interest (net of $389, $536 and $460 capitalized in 2020, 2019 and 2018, respectively)Cash paid for interest (net of $389, $536 and $460 capitalized in 2020, 2019 and 2018, respectively)$22,652 $23,730 $21,283 
Cash paid for income taxes$73,746
 $73,366
 $33,132
Cash paid for income taxes$46,258 $37,747 $30,593 
Acquisitions:      Acquisitions:
Fair value of tangible assets acquired in acquisitions, net of cash received$
 $18,703
 $26,771
Fair value of tangible assets acquired in acquisitions, net of cash and restricted cash receivedFair value of tangible assets acquired in acquisitions, net of cash and restricted cash received$35,733 $29,660 $24,026 
Goodwill
 136,101
 50,227
Goodwill268,971 157,036 97,910 
Intangible assets
 89,064
 34,237
Intangible assets228,000 107,580 122,110 
Liabilities assumed
 (21,474) (22,954)Liabilities assumed(56,213)(31,148)(16,586)
Holdback provision
 (1,830) (1,500)
Earn-out liabilities
 (4,070) (2,700)Earn-out liabilities(15,222)(10,100)
Net cash paid for acquisitions$
 $216,494
 $84,081
Net cash paid for acquisitions$476,491 $247,906 $217,360 
Supplemental disclosures of non-cash investing and financing activities:     Supplemental disclosures of non-cash investing and financing activities:
Purchase of fixed assets recorded in accounts payable and accrued expenses$2,962
 $2,134
 $3,337
Purchase of fixed assets recorded in accounts payable and accrued expenses$3,103 $2,301 $1,706 
See accompanying notes to consolidated financial statements.


42

                        

AMN HEALTHCARE SERVICES, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017, 20162020, 2019 and 20152018
(in thousands, except per share amounts)
 
(1) Summary of Significant Accounting Policies
 
(a) General
 
AMN Healthcare Services, Inc. was incorporated in Delaware on November 10, 1997. AMN Healthcare Services, Inc. and its subsidiaries (collectively, the “Company”) provide healthcare workforce solutions and staffing services at acute and sub-acute care hospitals and other healthcare facilities throughout the United States.
On March 11, 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus, also known as COVID-19, a global pandemic. Due to the pandemic, there has been uncertainty and disruption in the global economy and significant volatility of financial markets. The Company is closely monitoring the impact of the pandemic, which continues to evolve, and its effects and risks on our operations, liquidity, financial condition and financial results. The Company also implemented remote-work arrangements effective mid-March 2020 and, to date, transitioning to a remote-work environment has not had a material adverse impact on the Company’s ability to continue to operate its business, financial reporting process or internal controls and procedures.
 
(b) Principles of Consolidation
 
The accompanying consolidated financial statements include the accounts of AMN Healthcare Services, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
 
(c) Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to asset impairment,goodwill and indefinite-lived intangible assets, professional liability reserve, contingent liabilities such as legal accruals, for self-insurance and compensation and related benefits, contingencies and litigation, and income taxes. The Company bases these estimates on the information that is currently available and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from those estimates under different assumptions or conditions.
The estimates used for, but not limited to, determining the collectability of accounts receivable, fair value of long-lived assets, and goodwill could be impacted by the COVID-19 pandemic. While the full impact of COVID-19, including the duration and severity of the pandemic, remains unknown, the Company has made appropriate estimates based on the facts and circumstances available as of the reporting date. Specifically, the Company continues to monitor the impacts of the pandemic on its customers’ liquidity and capital resources and, therefore, the Company’s ability to collect, or the timeliness of collection of accounts receivable. The impact of COVID-19 did not have a material effect on the Company’s estimates as of December 31, 2020. These estimates may change as new events occur and additional information is obtained. See additional information below regarding the allowance for credit losses for accounts receivable.
 
(d) Cash and Cash Equivalents
 
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents include currency on hand, deposits with financial institutions and highly liquid investments.
 
(e) Restricted Cash, Cash Equivalents and Investments
 
Restricted cash and cash equivalents primarily represent cash and money market funds on deposit with financial institutions and investments represents commercial paper that serves as collateral for the Company’s outstanding letters of credit and captive insurance subsidiary claim payments. See Note (4)(3), “Fair Value Measurement” and Note (8), “Notes Payable and Credit Agreement” for additional information.
43

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets and related notes to the amounts presented in the accompanying consolidated statements of cash flows.
 December 31, 2020December 31, 2019
Cash and cash equivalents$29,213 $82,985 
Restricted cash and cash equivalents (included in other current assets)18,626 18,393 
Restricted cash, cash equivalents and investments61,347 62,170 
Total cash, cash equivalents and restricted cash and investments109,186 163,548 
Less restricted investments(25,196)(9,586)
Total cash, cash equivalents and restricted cash$83,990 $153,962 
(f) Fixed Assets
 
The Company records furniture, equipment, leasehold improvements and internal-usecapitalized software at cost less accumulated amortization and depreciation. The Company records equipment acquired under capitalfinance leases at the present value of the future minimum lease payments. The Company capitalizes major additions and improvements, and it expenses maintenance and repairs when incurred. The Company calculates depreciation on furniture, equipment and technology and software using the straight-line method based on the estimated useful lives of the related assets (three to ten years). The Company amortizesdepreciates leasehold improvements and equipment obtained under capitalfinance leases over the shorter of the term of the lease or their estimated useful lives. The Company includes depreciation of equipment obtained under capitalfinance leases with depreciation expense in the accompanying consolidated financial statements.
 
The Company capitalizes costs it incurs to develop internal-use software during the application development stage. Application development stage costs generally include costs associated with internal-use software configuration, coding, installation and testing. The Company also capitalizes costs of significant upgrades and enhancements that result in additional functionality, whereas it expenses as incurred costs for maintenance and minor upgrades and enhancements. The Company amortizes capitalized costs using the straight-line method over three to ten years once the software is ready for its intended use.
 
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison

of the carrying amount of an asset group to the future undiscounted net cash flows that are expected to be generated by the asset group. If such asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. The Company reports assets to be disposed of at the lower of the carrying amount or fair value less costs to sell.
 
(g) Leases

The Company recognizes operating lease right-of-use assets and liabilities at commencement date based on the present value of the future minimum lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet in accordance with the short-term lease recognition exemption. The Company applies the practical expedient to not separate lease and non-lease components for all leases that qualify. Lease expense is recognized on a straight-line basis over the lease term. See Note (5), “Leases,” for additional information.

(h) Goodwill
 
The Company records as goodwill the portion of the purchase price that exceeds the fair value of net assets of entities acquired. The Company evaluates goodwill annually for impairment at the reporting unit level and whenever circumstances occur indicating that goodwill may be impaired. The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines that it is more likely than not that the fair value of the reporting unit is greater than its carrying amount, the quantitative impairment test is unnecessary. The performance ofIf the quantitative impairment test involves a two-step process. The first step ofreporting unit does not pass the test involves comparing the fair value of the Company’s reporting units withqualitative assessment, then the reporting unit’s carrying amount, including goodwill. The Company generally determines the fair value of its reporting units using a combination of the income approach (using discounted future cash flows) and the market valuation approach. If the carrying amount of a Company’s reporting unit exceedsis compared to its fair value, the Company performs the second step of the test to determine the amount of impairment loss. The second step of the test involves comparing the implied fair value of the Company’s reporting unit’s goodwill with the carrying amount of that goodwill.value. The amount by which the carrying value of the goodwill exceeds its implied fair value if any, is recognized as an impairment loss.
 
(h)(i) Intangible Assets
 
Intangible assets consist of identifiable intangible assets acquired through acquisitions. Identifiable intangible assetsacquisitions, which include tradenames and trademarks, customer relationships, non-compete agreements, staffing databases, developed technology and acquired technology.non-compete agreements. The fair value of
44

identifiable intangible assets are determined using either the income approach (relief-from-royalty method or multi-period excess earnings method) or the cost approach (replacement cost method). The Company amortizes intangible assets, other than tradenames and trademarks with an indefinite life, using the straight-line method over their useful lives. The Company amortizes non-compete agreements using the straight-line method over the lives of the related agreements. The Company reviews for impairment intangible assets with estimable useful lives whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
 
The Company does not amortize indefinite-lived tradenames and trademarks and instead reviews them for impairment annually. The Company may first perform a qualitative assessment to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company determines that it is more likely than not that the indefinite-lived intangible asset is not impaired, no quantitative fair value measurement is necessary. If a quantitative fair value measurement calculation is required for an indefinite-lived intangible asset, the Company compares its fair value with its carrying amount. If the carrying amount exceeds the fair value, the Company records the excess as an impairment loss.
(i)(j) Insurance Reserves
 
The Company maintains an accrual for professional liability that is included in accounts payable and accrued expenses and other long-term liabilities in the consolidated balance sheets. The expense is included in the selling, general and administrative expenses in the consolidated statement of comprehensive income. The Company determines the adequacy of this accrual by evaluating its historical experience and trends, loss reserves established by the Company’s insurance carriers, management and third-party administrators, and independent actuarial studies. The Company obtains actuarial studies on a semi-annual basis that use the Company’s actual claims data and industry data to assist the Company in determining the adequacy of its reserves each year. For periods between the actuarial studies, the Company records its accruals based on loss rates provided in the most recent actuarial study and management’s review of loss history and trends. In November 2012, the Company established a captive insurance subsidiary, which primarily provides coverage, on an occurrence basis, for professional liability within its nurse and allied solutions segment. Liabilities include provisions for estimated losses incurred but not yet reported (“IBNR”), as well as provisions for known claims. IBNR reserve estimates involve the use of assumptions that are primarily based upon historical loss experience, industry data and other actuarial assumptions. The Company maintains excess insurance coverage through a commercial carrier for losses above the per occurrence retention.


The Company maintains an accrual for workers compensation, which is included in accrued compensation and benefits and other long-term liabilities in the consolidated balance sheets. The expense relating to healthcare professionals is included in cost of revenue, while the expense relating to corporate employees is included in the selling, general and administrative expenses in the consolidated statement of comprehensive income. The Company determines the adequacy of this accrual by evaluating its historical experience and trends, loss reserves established by the Company’s insurance carriers and third-party administrators, and independent actuarial studies. The Company obtains actuarial studies on a semi-annual basis that use the

Company’s payroll and historical claims data, as well as industry data, to determine the appropriate reserve for both reported claims and IBNR claims for each policy year. For periods between the actuarial studies, the Company records its accruals based on loss rates provided in the most recent actuarial study.


OnIn December 31, 2017, the Company transferred the legacy liabilities in amount of $31,639 related to its self-insured retention portion of both the workers compensation and locum tenens solutions segmentbusiness professional liability to its captive insurance subsidiary. This transaction had no impact onThese legacy liabilities follow the amount of the recorded liabilitiessame accounting policies as described in the consolidated balance sheet as of December 31, 2017.paragraphs above.
 
(j)(k) Revenue Recognition

Revenue primarily consists of fees earned from the temporary staffing and permanent placement of healthcare professionals, executives, and executivesleaders (clinical and operational). The Company also generates revenue from its software as well as from the Company’s software-as-a-service (SaaS)a service (“SaaS”)-based technologies, including its vendor management systems (VMS) and scheduling software, and outsourced workforce services, including language interpretation and recruitment process outsourcing. The Company recognizes revenue when control of its scheduling software.services is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Revenue from temporary staffing services is recognized as the services are rendered by theclinical and non-clinical healthcare professional.professionals. Under the Company’s managed services program (“MSP”) arrangements, the Company manages all or a part of a customer’s supplemental workforce needs utilizing its own poolnetwork of healthcare professionals along with those of third-party subcontractors, and revenuesubcontractors. Revenue and the related direct costs under MSP arrangements are recorded in accordance with the accounting guidance on reporting revenue gross as a principal versus net as an agent. When the Company uses subcontractors and acts as an agent, revenue is recorded net of the related subcontractor’s expense. Revenue from recruitmentpermanent placement and permanent placementoutsourced workforce services is recognized as the services are provided and upon successful placements. Therendered.
45

Depending on the arrangement, the Company’s SaaS-based revenue is recognized either as the services are rendered or ratably over the applicable arrangement’s service period. FeesSee additional information below regarding the Company’s revenue disaggregated by service type.
The Company’s customers are primarily billed as services are rendered. Any fees billed in advance of being earned are recorded as deferred revenue. While payment terms vary by the type of customer and the services rendered, the term between invoicing and when payment is due is not significant. During the years ended December 31, 2020 and 2019, previously deferred revenue recognized as revenue was $11,729 and $9,972, respectively.
The Company recognizes assets from incremental costs to obtain a contract with a customer and costs incurred to fulfill a contract with a customer, which are deferred and amortized using the portfolio approach on a straight line basis over the average period of benefit consistent with the timing of transfer of services to the customer. Aggregate expense for these costs was $11,208 and $11,369 for the years ended December 31, 2020 and 2019, respectively.
(k)The Company has elected to apply the following practical expedients and optional exemptions related to contract costs and revenue recognition:
Recognize incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred. These costs are recorded within selling, general and administrative expenses.
Recognize revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company’s services completed to date.
Exemptions from disclosing the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which revenue is recognized in the amount of consideration to which the Company has a right to invoice for services performed and (iii) contracts for which variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation.

(l) Accounts Receivable
 
The Company records accounts receivable at the invoiced amount. Accounts receivable are non-interest bearing. The Company maintains an allowance for doubtful accountsexpected credit losses based on the Company’s historical write-off experience, and an assessment of its customers’ financial conditions and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. See additional information below regarding the Company’s adoption of the credit loss standard effective January 1, 2020.
The following table provides a reconciliation of activity in the allowance for credit losses for accounts receivable:
2020
Balance as of January 1,$3,332 
Adoption of the credit loss standard, cumulative-effect adjustment to retained earnings1,334 
Provision for expected credit losses4,428 
Amounts written off charged against the allowance(2,051)
Balance as of December 31,$7,043 
The Company also maintains a salesreclassified its allowance for accounts receivable in the prior year’s consolidated balance sheet to reserve for potential credits issuedconform to customers, which is based on the Company’s historical experience.current year presentation. The Company has not experienced material bad debts or sales adjustments during the past three years.prior year balance of accounts receivable (net of allowances) remains unchanged.


(l)(m) Concentration of Credit Risk
 
The majority of the Company’s business activity is with hospitals located throughout the United States. Credit is extended based on the evaluation of each entity’s financial condition. One customer primarily within the Company’s nurse and allied solutions segment comprised approximately 13%14%, 11%13% and 11%13% of the consolidated revenue of the Company for the fiscal years ended December 31, 2017, 20162020, 2019 and 2015,2018, respectively.
The Company’s cash and cash equivalents and restricted cash, cash equivalents and investments accounts are financial instruments that are exposed to concentration of credit risk. The Company maintains most of its cash, cash equivalents and investment balances with high-credit quality and federally insured institutions. However, restricted cash equivalents and investment balances may be invested in a non-federally insured money market account and commercial paper. As of December 31, 20172020 and 2016,2019, there were $64,315$61,347 and $31,287,$62,170, respectively, of restricted cash, cash equivalents and
46

investments, a portion of which was invested in a non-federally insured money market fund and commercial paper. See Note (4)(3), “Fair Value Measurement,” for additional information.


(m)(n) Income Taxes
 
The Company records income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period the changes are enacted. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income, and tax-planning strategies in making this assessment. The Company recognizes the effect of income tax positions only if it is more likely than not that such positions will be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in

the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.
 
(n)(o) Fair Value of Financial Instruments
 
The carrying amounts of the Company’s cash equivalents and restricted cash equivalents and investments approximate their respective fair values due to the short-term nature and liquidity of these financial instruments. The fair value of the Company’s equity investment is determined by using prices for identical or similar investments of the same issuer, which is more fully described in Note (3), “Fair Value Measurement.” As it relates to the Company’s 2027 Notes and 2029 Notes (as defined in Note (8) and Note (3) below), which were issued in October 2016 with a fixed rate of 5.125%respectively, below), fair value disclosure is detailed in Note (4)(3), “Fair Value Measurement.”See Note (8), “Notes Payable and Credit Agreement,” for additional information. The fair value of the long-term portion of the Company’s insurance accruals cannot be estimated because the Company cannot reasonably determine the timing of future payments.
 
(o)(p) Share-Based Compensation
 
The Company accounts for its share-based employee compensation plans by expensing the estimated fair value of share-based awards on a straight-line basis over the requisite employee service period, which typically is the vesting period.period, except for awards granted to retirement-eligible employees, which are expensed on an accelerated basis. Restricted stock units (“RSUs”) typically vest at the end ofover a three-year vesting period, however, 33% of the awards may vest on the 13th month anniversary of the grant date and 34% on the second anniversary of the grant date if certain performance targets are met.period. Share-based compensation cost of RSUs is measured by the market value of the Company’s common stock on the date of grant, and the Company records share-based compensation expense only for those awards that are expected to vest. Performance restricted stock units (“PRSUs”) primarily consist of PRSUs that contain a performance conditionconditions dependent on defined targets of the Company’s adjusted EBITDA, margin during the third year of the three-year vesting period, with a range of 0% to 175%200% of the target amount granted to be issued under the award. Share-based compensation cost for these PRSUs is measured by the market value of the Company’s common stock on the date of grant, and the amount recognized is adjusted for estimated achievement of the performance conditions. A limited amount of PRSUs contain a market condition dependent upon the Company’s relative and absolute total shareholderstockholder return over a three-year period, with a range of 0% to 175% of the target amount granted to be issued under the award. Share-based compensation cost for these PRSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the performancemarket conditions.
 
(p)(q) Net Income per Common Share
Share-based awards to purchase 20, 1641, 43 and 923 shares of common stock for the years ended December 31, 2017, 20162020, 2019 and 2015,2018, respectively, were not included in the calculation of diluted net income per common share because the effect of these instruments was anti-dilutive.
47

The following table sets forth the computation of basic and diluted net income per common share for the years ended December 31, 2017, 20162020, 2019 and 2015,2018, respectively:
 
 Years Ended December 31,
 202020192018
Net income$70,665 $113,988 $141,741 
Net income per common share - basic$1.49 $2.44 $2.99 
Net income per common share - diluted$1.48 $2.40 $2.91 
Weighted average common shares outstanding - basic47,424 46,704 47,371 
Plus dilutive effect of potential common shares266 889 1,297 
Weighted average common shares outstanding - diluted47,690 47,593 48,668 
 Years Ended December 31,
 2017 2016 2015
Net income$132,558
 $105,838
 $81,891
      
Net income per common share - basic$2.77
 $2.21
 $1.72
Net income per common share - diluted2.68
 2.15
 1.68
      
Weighted average common shares outstanding - basic47,807
 47,946
 47,525
Plus dilutive effect of potential common shares1,623
 1,321
 1,318
Weighted average common shares outstanding - diluted49,430
 49,267
 48,843


(q)(r) Segment Information
 
The Company’s operating segments are identified in the same manner as they are reported internally and used by the Company’s chief operating decision maker for the purpose of evaluating performance and allocating resources. Effective March 8, 2020, the Company modified its reportable segments. The Company has threepreviously utilized 3 reportable segments:segments, which it identified as follows: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. In light of the Company’s recent acquisitions and organizational changes to better align its organizational structure with its strategy and operations, the Company’s management reorganized its reportable segments to better reflect how the business is evaluated by the chief operating decision maker. Beginning in the first quarter of 2020, the Company has disclosed the following 3 reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. The nurse and allied solutions segment consists ofincludes the Company’s travel nurse allied, localstaffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and rapid response staffingrevenue cycle solutions businesses. The locum tenensphysician and leadership solutions segment consists ofincludes the Company’s locum tenens staffing, business. The other workforce solutions segment consists of the following Company businesses (i) physician permanent placement services, (ii)

healthcare interim leadership staffing, and executive search, and physician permanent placement businesses. The technology and workforce solutions segment includes the Company’s language interpretation services, (iii) vendor management systems, (iv)workforce optimization, recruitment process outsourcing, (v) education, (vi) medical codingcredentialing, and related consulting, and (vii) workforce optimization services.flex pool management businesses.
The Company’s chief operating decision maker relies on internal management reporting processes that provide revenue and operating income by reportable segment for making financial decisions and allocating resources. Segment operating income represents income before income taxes plus depreciation, amortization of intangible assets, share-based compensation, interest expense, net, and other, and unallocated corporate overhead. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, asset information by segment is not prepared or disclosed.


The following table, which includes reclassified prior period amounts to conform to the new segment reporting structure, provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes:
48

Years Ended December 31, Years Ended December 31,
2017 2016 2015 202020192018
Revenue     Revenue
Nurse and allied solutions$1,238,543
 $1,185,095
 $953,253
Nurse and allied solutions$1,699,311 $1,562,588 $1,431,018 
Locum tenens solutions430,615
 424,242
 385,091
Other workforce solutions319,296
 292,888
 124,721
Physician and leadership solutionsPhysician and leadership solutions466,622 562,762 617,488 
Technology and workforce solutionsTechnology and workforce solutions227,781 96,757 87,568 
$1,988,454
 $1,902,225
 $1,463,065
$2,393,714 $2,222,107 $2,136,074 
Segment operating income     Segment operating income
Nurse and allied solutions$182,792
 $161,779
 $123,969
Nurse and allied solutions$232,005 $219,862 $201,866 
Locum tenens solutions51,422
 58,757
 48,011
Other workforce solutions81,154
 77,450
 40,390
Physician and leadership solutionsPhysician and leadership solutions62,342 71,378 86,077 
Technology and workforce solutionsTechnology and workforce solutions93,212 43,899 41,373 
315,368
 297,986
 212,370
387,559 335,139 329,316 
Unallocated corporate overhead60,412
 65,335
 52,254
Unallocated corporate overhead123,642 83,463 74,436 
Depreciation and amortization32,279
 29,620
 20,953
Depreciation and amortization92,766 58,520 41,237 
Depreciation (included in cost of revenue)Depreciation (included in cost of revenue)1,421 
Share-based compensation10,237
 11,399
 10,284
Share-based compensation20,465 16,241 10,815 
Interest expense, net, and other19,677
 15,465
 7,790
Interest expense, net, and other57,742 28,427 16,143 
Income before income taxes$192,763
 $176,167
 $121,089
Income before income taxes$91,523 $148,488 $186,685 
 
(r)The following tables present the Company’s revenue disaggregated by service type:
Year Ended December 31, 2020
Nurse and Allied SolutionsPhysician and Leadership SolutionsTechnology and Workforce SolutionsTotal
Temporary staffing$1,699,311 $408,228 $$2,107,539 
Permanent placement58,394 58,394 
Outsourced workforce134,468 134,468 
SaaS-based technologies93,313 93,313 
Total revenue$1,699,311 $466,622 $227,781 $2,393,714 

Year Ended December 31, 2019
Nurse and Allied SolutionsPhysician and Leadership SolutionsTechnology and Workforce SolutionsTotal
Temporary staffing$1,562,588 $482,984 $$2,045,572 
Permanent placement79,778 79,778 
Outsourced workforce16,096 16,096 
SaaS-based technologies80,661 80,661 
Total revenue$1,562,588 $562,762 $96,757 $2,222,107 

Year Ended December 31, 2018
Nurse and Allied SolutionsPhysician and Leadership SolutionsTechnology and Workforce SolutionsTotal
Temporary staffing$1,431,018 $543,117 $$1,974,135 
Permanent placement74,371 74,371 
Outsourced workforce15,042 15,042 
SaaS-based technologies72,526 72,526 
Total revenue$1,431,018 $617,488 $87,568 $2,136,074 
49


(s) Recently Adopted Accounting Pronouncements
In MarchFebruary 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting StandardsStandard Update (“ASU”) 2016-09, “Stock Compensation - Improvements2016-02, “Leases.” This standard requires organizations that lease assets to Employee Share-Based Payment Accounting.”recognize the assets and liabilities created by those leases. The guidance attemptsstandard also requires disclosures to simplifyhelp investors and other financial statement users better understand the accounting for share-based payment transactions in several areas, including the following: income tax consequences, classification of awards as either equity or liabilities, forfeitures, expected term,amount, timing, and statementuncertainty of cash flows classification.arising from leases. A modified retrospective transition approach is required, applying the standard to all leases existing at the date of initial application. In addition, the FASB has also issued several amendments to the standard, which clarify certain aspects of the guidance, including an optional transition method for adoption of this standard, which allows organizations to initially apply the new requirements at the effective date, recognize a cumulative effect adjustment to the opening balance of retained earnings, and continue to apply the legacy guidance in Accounting Standards Codification (“ASC”) 840, Leases, including its disclosure requirements, in the comparative periods presented. The new standard provides a number of optional practical expedients in transition. The Company elected the ‘package of practical expedients’, which permits organizations not to reassess under the new standard prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect to use the hindsight practical expedient to determine the lease term or evaluate impairment for existing leases.
The Company adopted ASU 2016-02 effective January 1, 2019, using the optional transition method described above. The Company recognized the cumulative effect of adopting this guidance as an adjustment as of the effective date, primarily related to the recognition of lease liabilities of $114,807 and corresponding right-of-use assets of $99,525 for existing operating leases. The Company also derecognized existing deferred rent liabilities of $15,302. These adjustments had no effect on opening retained earnings and prior periods were not retrospectively adjusted and continue to be reported in accordance with ASC 840. The new standard also provides practical expedients for an organization’s ongoing accounting. The Company elected the short-term lease recognition exemption and the practical expedient to not separate lease and non-lease components for all leases that qualify. The adoption did not have a material effect on the Company’s results of operations.
In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments.” The FASB also issued a series of other ASUs, which update ASU 2016-13 (collectively, the “credit loss standard”). This new standard introduces new accounting models for determining and recognizing credit losses on certain financial instruments based on an estimate of current expected credit losses. The Company adopted this pronouncement prospectively beginningstandard effective January 1, 2017. Accordingly,2020 using the priormodified retrospective transition method. The Company recognized the cumulative effect of adopting this guidance as an adjustment to the opening balance of retained earnings of $1,154, net of tax, primarily related to its allowance for credit losses for accounts receivable. Prior period hasamounts are not been adjusted and the primary effectsretrospectively adjusted. The impact of the adoption of the new standard was not material to the Company’s consolidated financial statements. The Company expects the impact to be immaterial on an ongoing basis.
In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Further, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. The Company adopted this standard effective January 1, 2020 and the adoption did not have a material effect on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement.” The standard modifies the current period are as follows:

disclosure requirements on fair value measurements. The Company recorded$5,449 of tax benefits within income tax expense for 2017 relatedadopted this standard effective January 1, 2020. Refer to the excess tax benefit on share-based compensation. Prior to adoption, this amount would have been recorded as additional paid-in capital;
information regarding fair value measurements in Note (3), “Fair Value Measurement.”
The Company continued to estimate the number of awards expected to be forfeited in accordance with its existing accounting policy, which is to estimate forfeitures when recording share-based compensation expense;
The Company excluded the excess tax benefits from the assumed proceeds available to repurchase shares in the computation of its diluted earnings per share for 2017. The effect of this change on its diluted earnings per share was not significant; and
For 2017, cash flows related to excess tax benefits were classified as an operating activity.


There were no other material impacts to the Company'sCompany’s consolidated financial statements as a result of adopting thisthese updated standard.standards.

50

                        

(2) Business CombinationsAcquisitions
As set forth below, the Company completed six6 acquisitions from January 1, 20152018 through December 31, 2017.2020. The Company accounted for each acquisition using the acquisition method of accounting. Accordingly, it recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. For eachSince the applicable date of acquisition, the Company did not incur any materialhas revised the allocation of the purchase price to the tangible and intangible assets acquired and liabilities assumed based on analysis of information that has been made available through December 31, 2020. The allocations will continue to be updated through the measurement period, if necessary. The Company recognizes acquisition-related costs.costs in selling, general and administrative expenses in the consolidated statements of comprehensive income.
Peak Provider SolutionsStratus Video Acquisition
On June 3, 2016,February 14, 2020, the Company completed its acquisition of Peak Provider Solutions (“Peak”), whichStratus Video, a remote video interpreting company that provides healthcare interpretation via remote medical coding, case managementvideo, over the phone, and consulting solutions to hospitals and physician medical groups nationwide. The addition of Peak has expanded the Company’s workforce solutions and enables the Company to offer services in coding diagnosis and procedure codes, which is critical to clinical quality reporting and the financial health of healthcare organizations.onsite in-person, all supported by proprietary technology platforms. The initial purchase price of $52,125 included (1) $51,645$485,568 consisted entirely of cash consideration paid upon acquisition. The acquisition was funded primarily through (1) borrowings under the Company’s $400,000 secured revolving credit facility (the “Senior Credit Facility”), provided for under a credit agreement (the “New Credit Agreement”), and (2) a contingent earn-out paymentthe Second Amendment (as defined in Note (8) below) to the New Credit Agreement, which provided $250,000 of upadditional available borrowings to $3,000 with an estimated fair value of $480 as of the acquisition date.Company. The contingent earn-out payment was based onNew Credit Agreement and the operating results of Peak for the year ended December 31, 2016, which resultedSecond Amendment are more fully described in no earn-out payment. As the acquisition was not considered significant, pro forma information has not been provided.Note (8), “Notes Payable and Credit Agreement.” The results of PeakStratus Video have been included in the Company’s othertechnology and workforce solutions segment since the date of acquisition. During the thirdsecond quarter of 2016,2020, an additional $275$99 of cash consideration was paid to the selling shareholders for the final working capital settlement. The Company incurred $11,467 of acquisition-related costs during the year ended December 31, 2020 as a result of its acquisition of Stratus Video.
The allocation of the $52,400$485,667 purchase price, which included the additional cash consideration paid for the final working capital settlement, consisted of (1) $5,658 $44,909of fair value of tangible assets acquired, which included $9,176 cash received, (2) $9,346$56,213 of liabilities assumed, (3) $19,220$228,000 of identified intangible assets, and (4) $36,868$268,971 of goodwill, noneof which $10,182 is expected to be deductible for tax purposes. The intangible assets acquired have a weighted average useful life of approximately seventeen years. The following table summarizes the fair value and useful life of each intangible asset acquired as of the acquisition date:
Fair ValueUseful Life
(in years)
Identifiable intangible assets
Customer Relationships$171,000 20
Tradenames and Trademarks40,000 5 - 10
Developed Technology16,000 5
Interpreter Database1,000 4
$228,000 
During the third quarter of 2020, the Company revised the estimated useful lives for the tradenames and trademarks intangible assets as a result of its plan to rebrand the language interpretation business. Based on this change in circumstances since the date of acquisition, the Company determined that the remaining useful lives of the assets are five years and will amortize the remaining value on a straight-line basis over the remaining useful life. The Company will continue to evaluate the remaining useful lives of other intangible assets impacted by its brand consolidation efforts.
Approximately $116,054 of revenue and $20,164 of income before income taxes of Stratus Video were included in the consolidated statement of comprehensive income for the year ended December 31, 2020. The following summary presents unaudited pro forma consolidated results of operations of the Company as if the Stratus Video and Advanced (as defined below) acquisitions had occurred on January 1, 2019, which gives effect to certain adjustments, including incremental acquisition-related costs of $25,311, of which $14,468 was reclassified from the year ended December 31, 2020, amortization of intangible assets of $15,014, and interest expense of $6,722 for the year ended December 31, 2019. The unaudited pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisitions been consummated as of the date indicated, nor is it necessarily indicative of the Company’s future operating results.
51

Years Ended December 31,
20202019
Revenue$2,407,586 $2,383,405 
Income from operations165,196 145,069 
Net income81,422 85,154 
b4health Acquisition
On December 19, 2019, the Company completed its acquisition of B4Health, LLC (“b4health”), an innovative technology company and a leading provider of a web-based internal float pool management solution and vendor management system for healthcare facilities. The initial purchase price of $23,006 included (1) $19,906 cash consideration paid upon acquisition and (2) a contingent earn-out payment of up to $12,000 with an estimated fair value of $3,100 as of the acquisition date. The contingent earn-out payment is based on the operating results of b4health for the twelve months ending December 31, 2020. The results of b4health have been included in the Company’s technology and workforce solutions segment since the date of acquisition. During the first quarter of 2020, $66 was returned to the Company for the final working capital settlement.
The allocation of the $22,940 purchase price, which was reduced by the final working capital settlement and finalized during the fourth quarter of 2020, consisted of (1) $1,169 of fair value of tangible assets acquired, which included $222 cash received, (2) $823 of liabilities assumed, (3) $9,000 of identified intangible assets, and (4) $13,594 of goodwill, all of which is deductible for tax purposes. The fair value of intangible assets primarily includes $7,600$3,000 of trademarks and $11,500developed technology, $4,000 of customer relationships, and $2,000 of trademarks with a weighted average useful life of approximately thirteenseven years.
HealthSource Global StaffingAdvanced Acquisition
On January 11, 2016,June 14, 2019, the Company completed its acquisition of HealthSource Global StaffingAdvanced Medical Personnel Services, Inc. (“HSG”Advanced”), which provides labor disruptiona national healthcare staffing company that specializes in placing therapists and rapid response staffing. The acquisition helps the Company expand its service lines and provide clients with rapid response staffing services.nurses across multiple settings. The initial purchase price of $8,511$211,743 included (1) $2,799$201,121 cash consideration paid upon acquisition funded through cash-on-hand, net of cash received, and settlement of the pre-existing relationship between AMN and HSG, (2) $2,122 cash holdback for potential indemnification claims, and (3) a tiered contingent earn-out payment of up to $4,000$20,000 with an estimated fair value of $3,590$10,622 as of the acquisition date. The contingent earn-out payment is comprised of (A) up to $2,000 based on the operating results of HSGAdvanced for the year ended December 31, 2016, of which, $1,930 was paid in March 2017, and (B) up to $2,000 based on the operating results of HSG for the yeartwelve months ending December 31, 2017. As2019, which was settled in full during the first quarter of 2020. The acquisition is not considered significant, pro forma information has not been provided.was funded primarily through (1) borrowings under the Senior Credit Facility and (2) the First Amendment (as defined in Note (8) below) to the New Credit Agreement, which provided $150,000 of additional available borrowings to the Company. The results of HSGAdvanced have been included in the Company’s nurse and allied solutions segment since the date of acquisition. During the third quarter of 2016, the final working capital settlement resulted in $292 due from2019, an additional $73 of cash consideration was paid to the selling shareholders to the Company, which was settled through a reduction to a cash holdback.
The allocation of the $8,219 purchase price, which was reduced by the final working capital settlement, consisted of (1) $1,025 of fair value of tangible assets acquired, (2) $3,698 of liabilities assumed, (3) $3,944 of identified intangible assets, and (4) $6,948 of goodwill, none of which is deductible for tax purposes. The intangible assets include the fair value of trademarks, customer relationships, staffing databases, and covenants not to compete with a weighted average useful life of approximately eight years.
B.E. Smith Acquisition
On January 4, 2016, the Company completed its acquisition of B.E. Smith (“BES”), a full-service healthcare interim leadership placement and executive search firm, for $162,232 in cash, net of cash received, and settlement of the pre-existing relationship between AMN and BES. BES places interim leaders and executives across all healthcare settings, including acute care hospitals, academic medical and children’s hospitals, physician practices, and post-acute care providers. The acquisition provides the Company additional access to healthcare executives and enhances its integrated services to hospitals, health systems, and other healthcare facilities across the nation. The results of BES have been included in the Company’s other workforce solutions segment since the date of acquisition. During the second quarter of 2016, $524 was returned to the Company for the final working capital settlement.
The allocation of the $161,708$211,816 purchase price, which was reduced byincluded the additional cash consideration paid for the final working capital settlement and was finalized during the second quarter of 2020, consisted of (1) $11,953$29,020 of fair value of tangible assets acquired, which included $2,497 cash and restricted cash received, (2) $7,272$28,772 of liabilities assumed, (3) $65,900$91,700 of identified intangible assets, and (4) $91,127$119,868 of goodwill, most of which $57,236 is deductible for tax purposes. The intangible assets acquired have a weighted

average useful life of approximately fifteennine years. The following table summarizes the fair value and useful life of each intangible asset acquired:
52

   Fair Value Useful Life
     (in years)
Identifiable intangible assets    
 Tradenames and Trademarks $26,300
 20
 Customer Relationships 25,700
 12
 Staffing Database 13,000
 10
 Non-Compete Agreements 900
 5
   $65,900
  
Fair ValueUseful Life
(in years)
Identifiable intangible assets
Customer Relationships$68,000 10
Tradenames and Trademarks10,000 5
Staffing Database10,300 10
Developed Technology3,400 3
$91,700 

Onward HealthcareSilversheet Acquisition
On January 7, 2015,30, 2019, the Company completed its acquisition of Onward Healthcare, including its two wholly-owned subsidiaries, Locum LeadersSilversheet, Inc. (“Silversheet”), which provides innovative software and Medefis (collectively, “OH”),services to reduce the complexities and challenges of the credentialing process for approximately $76,643 inclinicians and healthcare organizations. The initial purchase price of $31,676 included (1) $30,176 cash consideration paid upon acquisition, funded by cash-on-hand andprimarily through borrowings under the Company’s Revolver. Onward HealthcareSenior Credit Facility, and (2) a contingent earn-out payment of up to $25,000 with an estimated fair value of $1,500 as of the acquisition date. The contingent earn-out payment is a national nursebased on (A) up to $6,000 based on the operating results of Silversheet for the twelve months ending December 31, 2019, which resulted in no earn-out payment, and allied healthcare staffing firm, Locum Leaders is a national locum tenens provider, and Medefis is a provider(B) up to $19,000 based on the operating results of a SaaS-based vendor management systemSilversheet for healthcare facilities. The acquisition helps the Company to expand its service lines and its supply and placement capabilities of healthcare professionals to its clients.twelve months ending December 31, 2020. The results of Onward Healthcare areSilversheet have been included in the Company’s technology and workforce solutions segment since the date of acquisition.
The allocation of the $31,676 purchase price, which was finalized during the first quarter of 2020, consisted of (1) $2,826 of fair value of tangible assets acquired, which included $651 cash received, (2) $1,567 of liabilities assumed, (3) $6,880 of identified intangible assets, and (4) $23,537 of goodwill, NaN of which is deductible for tax purposes. The fair value of intangible assets primarily includes $5,300 of developed technology and $1,500 of trademarks with a weighted average useful life of approximately eight years.
MedPartners Acquisition

On April 9, 2018, the Company completed its acquisition of MedPartners HIM (“MedPartners”), which provides case management, clinical documentation improvement, medical coding and registry services to hospitals and physician medical groups nationwide. The initial purchase price of $200,933 included (1) $196,533 cash consideration paid upon acquisition, funded through borrowings under the Senior Credit Facility, (2) a contingent earn-out payment of up to $20,000 with an estimated fair value of $4,400 as of the acquisition date. The contingent earn-out payment is based on (A) up to $10,000 based on the operating results of MedPartners for the twelve months ending December 31, 2018, which resulted in no earn-out payment, and (B) up to $10,000 based on the operating results of MedPartners for the six months ending June 30, 2019, which resulted in no earn-out payment. The results of MedPartners have been included in the Company’s nurse and allied solutions segment the results of Locum Leaders are included in the Company’s locum tenens solutions segment, and the results of Medefis are included in the Company’s other workforce solutions segment, in each case, since the date of acquisition. During the third quarter of 2018, $222 was returned to the Company for the final working capital settlement.
The allocation of the $76,643$200,711 purchase price, which was reduced by the final working capital settlement and finalized during the second quarter of 2019, consisted of (1) $25,216$28,508 of fair value of tangible assets acquired, (including $21,313 of accounts receivable),which included $8,403 cash received, (2) $22,275$11,933 of liabilities assumed, (including $11,113 of accounts payable and accrued expenses), (3) $30,219$103,000 of identified intangible assets, and (4) $43,483$81,136 of goodwill, a portionall of which is deductible for tax purposes. The intangible assets include the fair value of tradenames and trademarks, customer relationships, staffing database, acquired technologies, and non-compete agreements. Thehad a weighted average useful life of the acquired intangible assets is approximately elevensixteen years. The following table summarizes the fair value and useful life of each intangible asset acquired:
Fair ValueUseful Life
(in years)
Identifiable intangible assets
Tradenames and Trademarks$46,000 20
Customer Relationships57,000 12
$103,000 
53

   Fair Value Useful Life
     (in years)
Identifiable intangible assets    
 Tradenames and Trademarks $8,100
 3 - 15
 Customer Relationships 17,600
 10 - 15
 Staffing Database 2,600
 5
 Acquired Technologies 1,700
 8
 Non-Compete Agreements 219
 2
   $30,219
  
Of the $43,483 allocated to goodwill, $23,032, $5,241 and $15,210 were allocated to the Company’s nurse and allied solutions, locum tenens solutions and other workforce solutions segments, respectively.

Other Acquisitions
During 2015,the third quarter of 2019, the Company had two additional acquisitions: MillicanSolutionsshortened the estimated useful life for the tradenames and trademarks intangible asset as a result of its plan to rebrand the revenue cycle solutions business. Based on this change in circumstances since the date of acquisition, the Company determined that the remaining useful life of this asset was five years and began amortizing its remaining value on a straight-line basis over the remaining useful life.
Phillips DiPisa and Leaders For Today Acquisition
On April 6, 2018, the Company completed its acquisition of 2 related entities, Phillips DiPisa and Leaders For Today (“Millican”)PDA” and The First String Healthcare (“TFS”“LFT”), withwhich offer a totalrange of leadership staffing and permanent placement solutions for the healthcare industry. The initial purchase price of $11,638.

(3) Derivative Instruments
In April 2015, the Company entered into$35,968 included (1) $30,268 cash consideration paid upon acquisition, funded through cash on hand, and (2) a contingent earn-out payment of up to $7,000 with an interest rate swap agreement to minimize its exposure to interest rate fluctuations on $100,000 of its outstanding variable rate debt under one of its Term Loans whereby the Company pays a fixed

rate of 0.983% per annum and receives a variable rate equal to floating one-month LIBOR. The agreement would have expired on March 30, 2018.

In connection with the Company’s issuance of $325,000 aggregate principal amount of 5.125% Senior Notes due 2024 (the “Notes”) and the use of a portion of the proceeds thereof to repay $138,438 of certain indebtedness under the Term Loans on October 3, 2016, the Company reduced the interest rate swap notional amount to $40,000 in the fourth quarter of 2016. As a result, $238 was recorded to interest expense reflecting the settlement amount with the counterparty to reduce the notional amount. See additional information in Note (8), “Notes Payable and Credit Agreement.” At December 31, 2016, the interest rate swap agreement had aestimated fair value of $24,$5,700 as of the acquisition date. The contingent earn-out payment is based on the operating results of PDA and LFT for the twelve months ending December 31, 2018, which was settled in full during the second quarter of 2019. The results of PDA and LFT have been included in the Company’s physician and leadership solutions segment since the date of acquisition. During the third quarter of 2018, $465 was returned to the Company for the final working capital settlement.
The allocation of the $35,503 purchase price, which was reduced by the final working capital settlement and finalized during the second quarter of 2019, consisted of (1) $4,389 of fair value of tangible assets acquired, which included $351 cash received, (2) $4,779 of liabilities assumed, (3) $19,110 of identified intangible assets, and (4) $16,783 of goodwill, all of which is included in other assets in the audited consolidated balance sheet as of December 31, 2016.deductible for tax purposes. The Company had formally documented the hedging relationship and accounted for this arrangement as a cash flow hedge. On May 3, 2017, the Company terminated the remaining interest rate swap after further repayment of the Term Loans. As a result, $85 was received upon termination of the contract.

The Company recognizes all derivatives on the balance sheet at fair value based on quotes from an independent pricing service. Gains or losses resulting from changes in the values of the arrangement are recorded in other comprehensive income, netintangible assets includes $5,400 of tax, until the hedged item is recognized in earnings. The Company also formally assesses, both at the hedge’s inceptiontrademarks, $8,000 of customer relationships and on an ongoing basis, whether the derivative instrument that is used in the hedging transaction is highly effective in offsetting changes in fair values or cash flows$5,710 of the hedged item. When it is determined thatstaffing databases with a derivative instrument is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the Company discontinues hedge accounting prospectively and recognizes subsequent changes in market value in earnings.weighted average useful life of approximately twelve years.


(4)(3) Fair Value Measurement
 
Fair value represents the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which the Company would conduct a transaction, in addition to the assumptions that market participants would use when pricing the related assets or liabilities, including non-performance risk.


A three-level hierarchy prioritizes the inputs to valuation techniques used to measure fair value and requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of the fair value hierarchy are as follows:
 
Level 1—Quoted prices in active markets for identical assets or liabilities.
 
Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.


Assets and Liabilities Measured on a Recurring Basis
 
The Company’s restricted cash equivalents that serve as collateral for the Company’s outstanding letters of credit typically consist of money market funds that are measured at fair value based on quoted prices, which are Level 1 inputs.


AsThe Company’s obligation under its deferred compensation plan is measured at fair value based on quoted market prices of December 31, 2017, the participants’ elected investments, which are Level 1 inputs. The deferred compensation plan is more fully described in Note (9), “Retirement Plans.”

The Company’s restricted cash equivalents and investments that serve as collateral for the Company’s captive insurance company consist of commercial paper that is measured at observable market prices for identical securities that are traded in less active markets, which are Level 2 inputs. Of the $28,708$58,345 commercial paper issued and outstanding as of December 31, 2017, $6,0742020, $25,196 had original maturities greater than three months, which were considered available-for-sale securities. As of December 31, 2016,2019, the Company had $25,610$59,243 commercial paper issued and outstanding, of which $11,152$9,586 had original maturities greater than three months and were considered available-for-sale securities.
The Company’s interest rate swap was measured at fair value using a discounted cash flow analysis that included the contractual terms, including the period to maturity, and Level 2 observable market-based inputs, including interest rate curves. The fair value of the swap was determined by netting the discounted future fixed cash receipts payments and the discounted expected variable cash receipts. The variable cash receipts were based on an expectation of future interest rates (forward curves) derived from observable market interest rate yield curves. The valuation also considered credit risk adjustments that

were necessary to reflect the probability of default by the counterparty or the Company, which were considered Level 3 inputs. On May 3, 2017, the Company terminated the remaining interest rate swap.

The Company’s contingent consideration liabilities are measured at fair value using probability-weighted discounted cash flow analysis or a simulation-based methodology for the acquired companies, which are Level 3 inputs. The Company
54

recognizes changes to the fair value of its contingent consideration liabilities in selling, general and administrative expenses in the consolidated statements of comprehensive income.
The following tables present information about the above-referenced assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value:
Fair Value Measurements as of December 31, 2017 Fair Value Measurements as of December 31, 2020
Assets (Liabilities)Total 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)Assets (Liabilities)TotalQuoted Prices in
Active Markets
for Identical
Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Money market funds$2,713
 $2,713
 $
 $
Money market funds$2,198 $2,198 $$
Deferred compensationDeferred compensation(97,184)(97,184)
Commercial paper28,708
 
 28,708
 
Commercial paper58,345 58,345 
Acquisition contingent consideration liabilities(2,070) 
 
 (2,070)Acquisition contingent consideration liabilities(8,000)(8,000)
 
 Fair Value Measurements as of December 31, 2019
Assets (Liabilities)TotalQuoted Prices in
Active Markets
for Identical
Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Money market funds$2,508 $2,508 $$
Deferred compensation(81,064)(81,064)
Commercial paper59,243 59,243 
Acquisition contingent consideration liabilities(23,100)(23,100)
 Fair Value Measurements as of December 31, 2016
Assets (Liabilities)Total 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)
Money market funds$4,627
 $4,627
 $
 $
Commercial paper25,610
 
 25,610
 
Interest rate swap asset24
 
 24
 
Acquisition contingent consideration liabilities(6,816) 
 
 (6,816)
Level 3 Information
The following table sets forth a reconciliation of changes in the fair value of contingent consideration liabilities classified as Level 3 in the fair value hierarchy:
 20202019
Balance as of January 1,$(23,100)$(7,700)
Settlement of PDA and LFT contingent consideration liability for year ended December 31, 20187,000 
Settlement of Advanced contingent consideration liability for year ended December 31, 201920,000 
Contingent consideration liability from Silversheet acquisition on January 30, 2019(1,500)
Contingent consideration liability from Advanced acquisition on June 14, 2019(10,622)
Contingent consideration liability from b4health acquisition on December 19, 2019(3,100)
Change in fair value of contingent consideration liability from MedPartners acquisition700 
Change in fair value of contingent consideration liability from Silversheet acquisition1,500 
Change in fair value of contingent consideration liability from Advanced acquisition(9,378)
Change in fair value of contingent consideration liability from b4health acquisition(4,900)
Balance as of December 31,$(8,000)$(23,100)

As of December 31, 2020 and 2019, the fair value measurement of contingent consideration liabilities for b4health and Advanced, respectively, was based on actual operating results of the acquired company.

55

 2017 2016
Balance as of January 1,$(6,816) $(3,770)
Settlement of TFS earn-out for year ended
December 31, 2015

 1,000
Contingent consideration earn-out liability from
HSG acquisition on January 11, 2016

 (3,590)
Change in fair value of contingent consideration earn-out liabilities from Avantas, TFS and HSG acquisitions(184) (456)
Settlement of TFS earn-out for year ended
December 31, 2016
3,000
 
Settlement of HSG earn-out for year ended
December 31, 2016
1,930
 
Balance as of December 31,$(2,070) $(6,816)

Assets Measured on a Non-Recurring Basis
 
The Company applies fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to its goodwill, indefinite-lived intangible assets, long-lived assets, and equity method investment.investments.
The Company evaluates goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill or indefinite-lived intangible assets might be impaired. The Company determines the fair value of its reporting units based on a combination of inputs, including the market capitalization of the Company, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. The Company determines the fair value of its indefinite-lived intangible assets using the income approach (relief-from-royalty method) based on Level 3 inputs.

The Company’s equity investment represents an investment in a non-controlled corporation without a readily determinable market value. The Company has elected to measure the investment at cost minus impairment, if any, plus or minus changes resulting from observable price changes. The fair value is determined by using quoted prices for identical or similar investments of the same issuer, which are Level 2 inputs. The Company recognizes changes to the fair value of its equity investment in interest expense, net, and other in the consolidated statements of comprehensive income.
The balance of the equity investment classified as Level 2 in the fair value hierarchy was $15,449 as of both December 31, 2020 and 2019. There were no changes to the fair value of the equity investment recognized during the years ended December 31, 2020 and 2019, respectively.


There were no triggering events identified, no indication of impairment of the Company’s goodwill, indefinite-lived intangible assets, long-lived assets, or equity investments, and 0 impairment charges recorded during the three years ended December 31, 20172020 requiring such measurements.
Other Fair Value Measurement Disclosuresof Financial Instruments


The Company is required to disclose the fair value of financial instruments thatfor which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets for which it is practicable to estimate that value. As of December 31, 2017, the Company’s Notes have a carrying amount of $325,000 and an estimatedsheets. The fair value of $335,156. Quotedthe Company’s 5.125% senior notes due 2024 (the “2024 Notes”), the 2027 Notes (as defined in Note (8) below), and 4.000% senior notes due 2029 (the “2029 Notes”) was estimated using quoted market prices in active markets for identical liabilities, based inputs (level 1) were used to estimate fair value.which are Level 1 inputs. The Notes were issued in October 2016carrying amounts and have a fixed rate of 5.125%. As of December 31, 2016, the Company's Notes approximated theirestimated fair value as there had been no changes in available rates for similar debt sinceof the date of issuance. See additional information2024 Notes, the 2027 Notes and the 2029 Notes, which are more fully described in Note (8), “Notes Payable and Credit Agreement.Agreement, are presented in the following table:

As of December 31, 2020As of December 31, 2019
Carrying
Amount
Estimated
Fair Value
Carrying
Amount
Estimated
Fair Value
2024 Notes$$$325,000 $337,188 
2027 Notes500,000 521,250 300,000 301,500 
2029 Notes350,000 357,000 
The fair value of the Company’s long-term self-insurance accruals cannot be estimated as the Company cannot reasonably determine the timing of future payments.
(5)
56

(4) Goodwill and Identifiable Intangible Assets
As of December 31, 20172020 and 2016,2019, the Company had the following acquired intangible assets:
 
As of December 31, 2017 As of December 31, 2016 As of December 31, 2020As of December 31, 2019
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Intangible assets subject to amortization:           Intangible assets subject to amortization:
Staffing databases$19,826
 $(7,693) $12,133
 $19,826
 $(5,633) $14,193
Staffing databases$36,836 $(16,706)$20,130 $35,836 $(13,369)$22,467 
Customer relationships136,759
 (60,764) 75,995
 136,759
 (50,309) 86,450
Customer relationships444,839 (122,105)322,734 273,839 (94,206)179,633 
Tradenames and trademarks61,369
 (16,757) 44,612
 61,369
 (12,139) 49,230
Tradenames and trademarks166,269 (58,299)107,970 126,269 (33,545)92,724 
Non-compete agreements1,697
 (958) 739
 1,697
 (678) 1,019
Non-compete agreements6,371 (3,402)2,969 4,117 (2,035)2,082 
Acquired technology8,730
 (4,513) 4,217
 8,730
 (3,298) 5,432
Acquired technology36,430 (14,722)21,708 20,430 (8,262)12,168 
$228,381
 $(90,685) $137,696
 $228,381
 $(72,057) $156,324
$690,745 $(215,234)$475,511 $460,491 $(151,417)$309,074 
Intangible assets not subject to amortization:           Intangible assets not subject to amortization:
Tradenames and trademarks    $89,400
     $89,400
Tradenames and trademarks$89,400 $89,400 
    $227,096
     $245,724
$564,911 $398,474 
 
Aggregate amortization expense for intangible assets was $18,628$63,817 and $18,310$36,493 for the years ended December 31, 20172020 and 2016,2019, respectively. Based on the current amount of intangibles subject to amortization, the estimated future amortization expense as of December 31, 20172020 is as follows:
Amount
Year ending December 31, 2021$61,234 
Year ending December 31, 202260,351 
Year ending December 31, 202358,694 
Year ending December 31, 202452,161 
Year ending December 31, 202539,199 
Thereafter203,872 
$475,511 
 
57
 Amount
Year ending December 31, 2018$17,555
Year ending December 31, 201916,827
Year ending December 31, 202013,889
Year ending December 31, 202111,899
Year ending December 31, 202211,640
Thereafter65,886
 $137,696

                        

In connection with the reorganization of its reportable segments effective March 8, 2020, the Company reassigned the goodwill balances to the reporting units, the composition of which changed under the reorganized reportable segments, using the relative fair value reallocation approach. The Company performed a goodwill impairment test at the reporting unit level both immediately before and after the reorganization. The Company determined the fair values of its reporting units using a combination of the income approach (using discounted future cash flows) and the market valuation approach. Based on the results of this testing, the Company determined that the fair values of its reporting units were each greater than their respective carrying values both before and after the reorganization. Therefore, there was 0 impairment loss recognized during the year ended December 31, 2020.
The following table, which includes reclassified prior period amounts to conform to the new segment reporting structure, summarizes the activity related to the carrying value of goodwill by reportable segment:
Nurse and Allied
Solutions
Physician and Leadership
Solutions
Technology and Workforce SolutionsTotal
Balance, January 1, 2019$224,454 $163,362 $50,690 $438,506 
Goodwill adjustment for MedPartners acquisition23 23 
Goodwill adjustment for PDA and LFT acquisition(14)(14)
Goodwill from Silversheet acquisition23,537 23,537 
Goodwill from Advanced acquisition119,839 119,839 
Goodwill from b4health acquisition13,660 13,660 
Balance, December 31, 2019344,316 163,348 87,887 595,551 
Goodwill adjustment for Advanced acquisition29 29 
Goodwill adjustment for b4health acquisition(66)(66)
Goodwill from Stratus Video acquisition268,971 268,971 
Reallocation due to change in segments(5,330)(10,548)15,878 
Balance, December 31, 2020$339,015 $152,800 $372,670 $864,485 
Accumulated impairment loss as of December 31, 2019 and 2020$154,444 $60,495 $$214,939 

58
 
Nurse and Allied
Solutions
 
Locum Tenens
Solutions
 Other Workforce Solutions Total
Balance, January 1, 2016$95,309
 $19,743
 $89,727
 $204,779
Goodwill from BES acquisition
 
 91,127
 91,127
Goodwill from HSG acquisition8,147
 
 
 8,147
Goodwill from Peak acquisition
 
 36,827
 36,827
Goodwill adjustment for Onward acquisition850
 
 
 850
Goodwill adjustment for TFS acquisition
 
 24
 24
Balance, December 31, 2016104,306
 19,743
 217,705
 341,754
Goodwill adjustment for HSG acquisition(1,199) 
 
 (1,199)
Goodwill adjustment for Peak acquisition
 
 41
 41
Balance, December 31, 2017$103,107
 $19,743
 $217,746
 $340,596
Accumulated impairment loss as of
December 31, 2016 and 2017
$154,444
 $53,940
 $6,555
 $214,939


                        

(5) Leases

The Company leases certain office facilities, data centers, and equipment under various operating leases. The Company’s short-term leases (with initial lease terms of 12 months or less) are primarily related to housing arrangements for healthcare professionals on assignment. Most leases include one or more options to renew, with renewal terms that can extend the lease term up to 10 years. Certain leases also include options to terminate the leases within 3 years.

The components of lease expense were as follows:
Years Ended December 31,
20202019
Operating lease cost$20,176 $18,725 
Short-term lease cost8,702 20,112 
Variable and other lease cost2,526 2,880 
Net lease cost$31,404 $41,717 
Rent expense under operating leases (with initial lease terms in excess of one year) was $21,402 for the year ended December 31, 2018.

The maturities of lease liabilities as of December 31, 2020 were as follows: 
Operating Leases
Years ending December 31,
2021$19,108 
202218,552 
202318,207 
202417,030 
202515,160 
Thereafter18,733 
Total lease payments106,790 
Less imputed interest(13,958)
Present value of lease liabilities$92,832 

Supplemental cash flow information related to leases was as follows: 
Years Ended December 31,
20202019
Cash paid for amounts included in the measurement of operating lease liabilities (operating cash flows)$20,052 $17,817 

The weighted average remaining lease term and discount rate as of December 31, 2020 and 2019 were as follows:
December 31,
20202019
Weighted average remaining lease term6 years7 years
Weighted average discount rate4.8 %4.8 %

The Company uses its incremental borrowing rate as the discount rate to measure its lease liabilities. The incremental borrowing rate is determined for each operating lease based on the Company’s borrowing capabilities over a similar term of the lease arrangement, which is estimated by utilizing the Company’s credit rating and the effects of full collateralization.

59

(6) Balance Sheet Details
 
The consolidated balance sheets detail is as follows as of December 31, 2017 and 2016:follows:
 
 December 31,
 20202019
Other current assets:
        Restricted cash and cash equivalents$18,626 $18,393 
        Income taxes receivable6,591 5,984 
        Other15,592 16,069 
Other current assets$40,809 $40,446 
Fixed assets:
Furniture and equipment$47,355 $37,315 
Software220,971 191,050 
Leasehold improvements9,600 9,367 
277,926 237,732 
Accumulated depreciation(161,752)(132,900)
Fixed assets, net$116,174 $104,832 
Accounts payable and accrued expenses:
Trade accounts payable$28,089 $26,985 
Subcontractor payable79,364 75,562 
Accrued expenses37,849 36,344 
Loss contingencies7,613 6,146 
Professional liability reserve8,897 7,925 
Other6,069 3,178 
Accounts payable and accrued expenses$167,881 $156,140 
Accrued compensation and benefits:
Accrued payroll$59,721 $47,381 
Accrued bonuses and commissions34,514 22,613 
Accrued travel expense1,998 2,459 
Health insurance reserve5,590 4,019 
Workers compensation reserve10,244 8,782 
Deferred compensation97,184 81,064 
Other4,163 4,614 
Accrued compensation and benefits$213,414 $170,932 
Other current liabilities:
Acquisition related liabilities$8,000 $20,000 
Other2,938 5,302 
Other current liabilities$10,938 $25,302 
Other long-term liabilities:
Workers compensation reserve$20,930 $18,291 
Professional liability reserve31,997 34,606 
Unrecognized tax benefits5,447 5,431 
Other49,533 3,485 
Other long-term liabilities$107,907 $61,813 

60
 As of December 31,
 2017 2016
Other current assets:   
        Restricted cash and cash equivalents25,506
 20,271
        Income taxes receivable15,898
 361
        Other9,589
 13,975
Other current assets$50,993
 $34,607
    
Fixed assets:   
Furniture and equipment$29,494
 $25,582
Technology and software132,770
 112,405
Leasehold improvements9,056
 6,832
 171,320
 144,819
Accumulated depreciation(97,889) (84,865)
Fixed assets, net$73,431
 $59,954
    
Accounts payable and accrued expenses:   
Trade accounts payable$31,420
 $33,392
Subcontractor payable41,786
 51,973
Accrued expenses40,403
 37,251
Professional liability reserve7,672
 10,254
Other9,038
 4,642
Accounts payable and accrued expenses$130,319
 $137,512
    
Accrued compensation and benefits:   
Accrued payroll$33,923
 $30,917
Accrued bonuses and commissions19,489
 26,992
Accrued travel expense3,256
 2,972
Accrued health insurance reserve3,658
 3,189
Accrued workers compensation reserve8,553
 8,406
Deferred compensation49,330
 32,690
Other3,214
 2,827
Accrued compensation and benefits$121,423
 $107,993
    
Other current liabilities:   
Acquisition related liabilities2,599
 6,921
Other2,547
 9,690
Other current liabilities$5,146
 $16,611
    
Other long-term liabilities:   
Workers compensation reserve$19,074
 $18,708
Professional liability reserve38,964
 37,338
Deferred rent14,744
 13,274
Unrecognized tax benefits5,270
 8,464
Other1,227
 4,312
Other long-term liabilities$79,279
 $82,096

                        

(7) Income Taxes
 
The provision for income taxes from operations for the years ended December 31, 2017, 20162020, 2019 and 20152018 consists of the following:
 
 Years Ended December 31,
 202020192018
Current income taxes:
Federal$32,673 $25,255 $33,564 
State9,813 8,332 12,047 
Total42,486 33,587 45,611 
Deferred income taxes:
Federal(15,092)625 (1,372)
State(6,536)288 705 
Total(21,628)913 (667)
Provision for income taxes from operations$20,858 $34,500 $44,944 
 Years Ended December 31,
 2017 2016 2015
Current income taxes:     
Federal$45,899
 $68,312
 $22,552
State8,699
 11,441
 3,969
Total54,598
 79,753
 26,521
Deferred income taxes:     
Federal1,754
 (9,115) 8,896
State3,853
 (309) 3,781
Total5,607
 (9,424) 12,677
Provision for income taxes from operations$60,205
 $70,329
 $39,198
Total income tax expense for the years ended December 31, 2017, 2016 and 2015 was allocated as follows:
 Years Ended December 31,
 2017 2016 2015
Provision for income taxes from operations$60,205
 $70,329
 $39,198
Shareholders’ equity, for compensation expense for tax purposes in excess of amounts recognized for financial reporting purposes
 (3,144) (7,176)
 $60,205
 $67,185
 $32,022
The Company’s income tax expense differs from the amount that would have resulted from applying the federal statutory rate of 35%21% for 2020, 2019 and 2018 to pretax income from operations because of the effect of the following items during the years ended December 31, 2017, 20162020, 2019 and 2015:2018:
 Years Ended December 31,
 202020192018
Tax expense at federal statutory rate$19,220 $31,253 $39,272 
State taxes, net of federal benefit4,161 6,810 9,902 
Non-deductible expenses3,621 3,840 2,956 
Share-based compensation(2,311)(4,770)(4,343)
Unrecognized tax benefit(78)(207)413 
Other, net(3,755)(2,426)(3,256)
Income tax expense from operations$20,858 $34,500 $44,944 
61
 Years Ended December 31,
 2017 2016 2015
Tax expense at federal statutory rate$67,467
 $61,658
 $42,381
State taxes, net of federal benefit7,880
 7,597
 5,260
Non-deductible expenses3,849
 3,656
 3,505
Share-based compensation(4,889) 
 
Corporate tax rate change impact on deferred income taxes(14,039) 
 
Unrecognized tax benefit(1,175) 379
 (11,464)
Other, net1,112
 (2,961) (484)
Income tax expense from operations$60,205
 $70,329
 $39,198

                        

The adoption of ASU 2016-09, “Stock Compensation - Improvements to Employee Share-Based Payment Accounting” in the first quarter of 2017, resulted in recording a $5,449 reduction in income tax expense for the year ended December 31, 2017. Prior to adoption, this amount wouldCertain reclassifications have been recorded as additional paid-in capital.
made to the prior year’s presentation of deferred tax assets in order to conform to the current year presentation. There is no change to the prior year total deferred tax assets. The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are presented below as of the years ended December 31, 20172020 and 2016:2019:
 
 December 31,
20202019
Deferred tax assets:
Stock compensation$6,198 $5,848 
Deferred compensation24,604 20,564 
Accrued bonus7,607 4,294 
Accrued payroll taxes12,445 60 
Accrued expenses18,185 14,218 
Operating lease liabilities23,826 27,206 
Net operating losses9,557 3,448 
Loss contingencies6,459 
Other989 570 
Total deferred tax assets$109,870 $76,208 
Deferred tax liabilities:
Intangibles$(126,833)$(71,646)
Fixed assets(25,252)(22,896)
Operating lease right-of-use assets(19,933)(23,234)
Other(5,057)(5,050)
Total deferred tax liabilities$(177,075)$(122,826)
Net deferred tax liabilities$(67,205)$(46,618)
 Years Ended December 31,
 2017 2016
Deferred tax assets:   
Stock compensation$7,723
 $11,954
Deferred compensation12,949
 13,079
Accrued expenses11,343
 35,499
Deferred rent4,033
 5,492
Net operating losses2,650
 5,756
Other4,904
 6,576
Total deferred tax assets$43,602
 $78,356
Deferred tax liabilities:   
Intangibles$(51,551) $(78,201)
Fixed assets(15,750) (18,847)
Other(3,297) (2,545)
Total deferred tax liabilities$(70,598) $(99,593)
Valuation allowance$(40) $(183)
Net deferred tax liabilities$(27,036) $(21,420)
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management believes it is more likely than not that the Company will realize the benefits of its deferred tax assets, net of the recorded valuation allowance.assets.
 
The amount of federal net operating losses (“NOL”) carryforward that is available for use in years subsequent to December 31, 20172020 is $11,250,$41,430, primarily related to the Stratus Video acquisition, which is setbegins to expire by 2029.2030. The amount of state NOL carryforward that is available for use in years subsequent to December 31, 20172020 is $4,749,$16,631, primarily related to the Stratus Video acquisition, which is setbegins to expire at various dates between 2018 and 2032.by 2021. The Stratus Video acquisition is more fully described in Note (2), “Acquisitions.”
A summary of the changes in the amount of unrecognized tax benefits (excluding interest and penalties) for 2017, 20162020, 2019 and 20152018 is as follows:
 
2017 2016 2015202020192018
Beginning balance of unrecognized tax benefits$6,842
 $6,537
 $22,890
Beginning balance of unrecognized tax benefits$4,937 $4,393 $4,663 
Additions based on tax positions related to the current year513
 
 
Additions based on tax positions related to the current year667 588 475 
Additions based on tax positions of prior years731
 868
 395
Additions based on tax positions of prior years255 990 753 
Reductions due to lapse of applicable statute of limitation(949) (563) (214)Reductions due to lapse of applicable statute of limitation(943)(1,034)(547)
Settlements(2,474) 
 (16,534)Settlements— (951)
Ending balance of unrecognized tax benefits$4,663
 $6,842
 $6,537
Ending balance of unrecognized tax benefits$4,916 $4,937 $4,393 
 
At December 31, 2017,2020, if recognized, approximately $4,613$4,616 net of $831 of temporary differences would affect the effective tax rate (including interest)interest and penalties).
 
The Company recognizes interest related to unrecognized tax benefits in income tax expense. The Company had approximately $606, $1,622$530, $493 and $1,544$467 of accrued interest related to unrecognized tax benefits at December 31, 2017, 20162020, 2019 and 2015,2018, respectively. The amount of interest expense (benefit) recognized in 2017, 20162020, 2019 and 20152018 was $(1,016), $78$37, $26 and $(4,272)$(139), respectively.

62

The Company is subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of December 31, 2017,2020, the Company is no longer subject to state, local or foreign examinations by tax authorities for tax years before 2006,2011, and the Company is no longer subject to U.S. federal income or payroll tax examinations for tax years before 2013. The Company’s tax years 2007, 2008, 2009 and 2010 had been under audit by the Internal Revenue Service (“IRS”) for

several years and the Company received a final determination from the IRS in July 2015 on both the Revenue Agent Report (“RAR”) adjustments and Employment Tax Examination Report (“ETER”) assessments, effectively settling these audits with the IRS.

The IRS conducted and completed a separate audit of the Company’s 2011 and 2012 tax years that focused on income and employment tax issues similar to those raised in the 2007 through 2010 examination. The IRS completed its audit during the quarter ended March 31, 2015, and issued its RAR and ETER to the Company with proposed adjustments2017. Prior to the Company’s taxable incomeacquisition of Advanced, on June 14, 2019, Advanced was under an IRS audit for 2011 and 2012 and net operating loss carryforwards from 2010 and assessmentsthe years 2011-2013 for additionalvarious payroll tax liabilities and penalties for 2011 and 2012matters related to the Company’s treatment of certain non-taxable per diem allowances and travel benefits. The Company filed a Protest LetterThis audit was completed and an assessment was issued for both the RAR and ETER$8,300 in April 2015.July 2018. The Company received a final determination from the IRS in November 2017 on both2019 for $1,300. The Company is indemnified by Advanced for the 2011 and 2012 RAR adjustments and ETER assessments, respectively, effectively settling these audits with the IRSpotential contingent liability for $2,000 (including interest) during the fourth quarter of 2017. As a result, the Company recorded federal income tax benefits of approximately $800 during the quarter ended December 31, 2017 as the settlement was less than the previously recorded uncertain tax position reserve.all pre-acquisition open years. The Advanced acquisition is more fully described in Note (2), “Acquisitions.”


The IRS began an audit of the Company’s 2013 tax year during the quarter ended June 30, 2015. The Company believes its indemnification by Advanced for all pre-acquisition years and its reserve for unrecognized tax benefits and contingent tax issues isare adequate with respect to all open years. Notwithstanding the foregoing, the Company could adjust its provision for income taxes and contingent tax liability based on future developments.


Tax Cuts and JobsCARES Act


On December 22, 2017,March 27, 2020, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax CutsCoronavirus Aid, Relief, and JobsEconomic Security Act (the “Tax“CARES Act”). The Tax Act makes broad was enacted and complex changessigned into law in response to the U.S.COVID-19 pandemic. Among other things, the CARES Act contains significant business tax code,provisions, including but not limited to, reducing the U.S. federal corporate tax rate from 35 percent to 21 percent.a deferral of payment of employer payroll taxes and an employer retention credit for employer payroll taxes.

Tax Act changes that affect the Company in 2017 are primarily tax rate changes on certain deferred tax assets (“DTAs”) and deferred tax liabilities (“DTLs”).


The Tax Act also establishes new tax laws that will affect 2018 and beyond, including, but not limited to, (1) reductionCompany deferred payment of the U.S. federal corporate tax rate; (2) the repealemployer’s share of the domestic production activity deduction; (3) limitations on the deductibilitypayroll taxes of certain executive compensation;$48,249, which is included in accrued compensation and (4) limitations on various entertainmentbenefits and meals deductions.

The SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimateother long-term liabilities in the financial statements.

In connection with the Company's initial analysisconsolidated balance sheet as of the impact of the Tax Act, the Company recorded a discrete net tax benefit of $14,039 in the quarter ended December 31, 2017. This net benefit primarily consists2020, with half of a net benefit forsuch taxes to be paid by the corporate rate reduction onend of 2021 and the Company's existing deferredother half to be paid by the end of 2022. The Company claimed an employee retention employment tax assets and liabilities.credit of $1,183.


The Company's accounting for the following elements of the Tax Act is incomplete. However, the Company was able to make reasonable estimates of certain effects and, therefore, recorded provisional adjustments for items impacting executive compensation and accounting methods.
(8) Notes Payable and Credit Agreement


(a) The Companys Credit Agreement and Related Credit Facilities

Credit Agreement Prior to February 9, 2018
The Company is party to a credit agreement (as amended to date, the “Credit Agreement”) with several lenders in respect of three credit facilities (the “Credit Facilities”), including (A) a $275,000 revolver facility (the “Revolver”), which includes a $40,000 sublimit for the issuance of letters of credit and a $20,000 sublimit for swingline loans, (B) a $150,000 secured term loan facility (the “Original Term Loan”) and (C) a $75,000 secured term loan facility (the “Second Term Loan,” and together with the Original Term Loan, the “Term Loans”). The maturity dates of the Revolver and the Original Term Loan, on the one

hand, and the Second Term Loan, on the other hand, are April 18, 2019 and January 4, 2021, respectively. The Company fully repaid all amounts under the Original Term Loan and Second Term Loan in 2016 and 2017, respectively.
On September 19, 2016, the Company entered into another amendment to the Credit Agreement (the “Second Amendment”), which, among other things, permits the Company to increase the commitments that may be obtained under the Credit Agreement by the amount of certain prepayments made thereunder. Accordingly, the Credit Agreement provides that the Company may from time to time obtain an increase in the Revolver or obtain additional term loans or both in an aggregate principal amount not to exceed $125,000 plus the amount of certain prepayments of Credit Facilities (including $138,438 of prepayments of the Term Loans made by the Company on October 3, 2016) subject to, among other conditions, the arrangement of additional commitments with financial institutions reasonably acceptable to the Company and the administrative agent.
The Revolver carries an unused fee of 0.25% to 0.35% per annum and each standby letter of credit issued under the Revolver is subject to a letter of credit fee ranging from 1.50% to 2.25% per annum of the average daily maximum amount available to be drawn under the standby letter of credit, in each case, depending on the Company’s consolidated leverage ratio, as calculated quarterly in accordance with the Credit Agreement. The Second Term Loan was subject to amortization of principal of 5.00% per year of the original loan amount, which was $3,750 per annum, and payable in equal quarterly installments. Borrowings under the Second Term Loan and Revolver bear interest at floating rates, at the Company’s option, based upon either LIBOR plus a spread of 1.50% to 2.25% or a base rate plus a spread of 0.50% to 1.25%. The applicable spread is determined quarterly based upon the Company’s consolidated leverage ratio.
The Credit Agreement contains various customary affirmative and negative covenants, including restrictions on incurrence of additional indebtedness, declaration and payment of dividends, dispositions of assets, consolidation into another entity, and allowable investments. Additionally, there are financial covenants based on the Company’s consolidated leverage ratio and interest coverage ratio as calculated in accordance with the Credit Agreement. The payment obligations under the Credit Agreement may be accelerated upon the occurrence of defined events of default. Additionally, the Credit Agreement no longer requires (as was originally set forth in the original Credit Agreement) the Company to make mandatory prepayments under any of the credit facilities provided thereunder with the proceeds of extraordinary receipts and excess cash flow when certain financial conditions were present. The Credit Facilities are secured by substantially all of the assets of the Company and the common stock or equity interests of its domestic subsidiaries.
In connection with the First Amendment, the Company incurred $632 in fees paid to lenders and other third parties, of which $448 was capitalized and amortized to interest expense on a pro rata basis over the remaining term of the Revolver and the term of the Second Term Loan and the remaining amount was recorded as interest expense during the year ended December 31, 2016. The Company incurred de minimis costs in connection with the Second Amendment.
The Revolver is available for working capital, capital expenditures, permitted acquisitions and general corporate purposes of the Company. At December 31, 2017, with $19,320 of outstanding letters of credit collateralized by the Revolver, there was $255,680 of available credit under the Revolver.

New Credit Agreement
On February 9, 2018, the Company entered into a credit agreement (the “Newthe New Credit Agreement”)Agreement with several lenders to provide for athe $400,000 secured revolving credit facility (the “SeniorSenior Credit Facility”)Facility to replace its then-existing credit facilities. On June 14, 2019, the Company entered into the first amendment to the New Credit Agreement.Agreement (the “First Amendment”) to provide for, among other things, a $150,000 secured term loan credit facility (the “Term Loan”). The Company used the proceeds from the Term Loan, together with a drawdown of a portion of the Senior Credit Facility, includesto complete its acquisition of Advanced, as more fully described in Note (2), “Acquisitions.” The Company fully repaid all amounts under the Term Loan in 2019.

On February 14, 2020, the Company entered into the second amendment to the New Credit Agreement (the “Second Amendment”) to provide for, among other things, a $50,000 sublimit for$250,000 secured term loan credit facility (the “Additional Term Loan”). The Second Amendment (together with the issuanceNew Credit Agreement and the First Amendment, collectively, the “Amended Credit Agreement”) extended the maturity date of letters of credit and a $50,000 sublimit for swingline loans.the Senior Credit Facility to be coterminous with the Additional Term Loan. The obligations of the Company under the NewAmended Credit Agreement and the Senior Credit Facility are secured by substantially all of the assets of the Company. The Company used the proceeds from the Additional Term Loan, together with a drawdown of a portion of the Senior Credit Facility, to complete its acquisition of Stratus Video, as more fully described in Note (2), “Acquisitions.”

In connection with the Second Amendment, the Company incurred $4,144 in fees paid to lenders and other third parties, which were capitalized and are being amortized to interest expense over the term of the Credit Facilities (as defined below). In addition, $1,681 of unamortized financing fees incurred in connection with obtaining the New Credit Agreement and First Amendment will continue to be amortized to interest expense over the term of the Credit Facilities.

Borrowings under the Senior Credit Facility and the Additional Term Loan (together, the “Credit Facilities”) bear interest at floating rates, at the Company’s option, based upon either LIBOR plus a spread of 1.00% to 2.00%1.75% or a base rate plus a spread of 0.00% to 1.00%0.75%. The applicable spread is determined quarterly based upon the Company’s consolidated net leverage ratio.ratio (as calculated per the Amended Credit Agreement). The Additional Term Loan is subject to amortization of principal of 2.50% per year for the first year of the term and 5.00% per year thereafter, payable in equal quarterly installments. The Senior Credit Facility, which includes a $75,000 sublimit for the issuance of letters of credit and a $75,000 sublimit for swingline loans, is available for working capital, capital expenditures, permitted acquisitions and general corporate purposes. The maturity date of the Credit Facilities is February 14, 2025.
63

At December 31, 2020, with $21,910 of outstanding letters of credit collateralized by the Senior Credit Facility, is February 9, 2023.there was $378,090 of available credit under the Senior Credit Facility. The interest rate for the Additional Term Loan was 1.65% on a LIBOR basis as of December 31, 2020.


(b) The Company’s 5.125%s 4.625% Senior Notes Due 20242027
On October 3, 2016,August 13, 2020, the Company completed the issuance and sale of $325,000an additional $200,000 aggregate principal amount of 4.625% senior notes due 2027 (the “New 2027 Notes”), which were issued at a price of 101.000% of the aggregate principal amount. The New 2027 Notes which mature onwere issued pursuant to the existing indenture, dated as of October 1, 2024.2019, under which the Company previously issued $300,000 aggregate principal amount of 4.625% senior notes due 2027 (the “Existing 2027 Notes” and together with the New 2027 Notes, the “2027 Notes”). The New 2027 Notes will be treated as a single series with the Existing 2027 Notes and will have the same terms (other than issue price, issue date and the date from which interest accrues) as those of the Existing 2027 Notes. Interest on the 2027 Notes is fixed at 5.125%4.625% and payable semi-annually in arrears on April 1 and October 1 of each year, commencing October 1, 2020 with respect to the New 2027 Notes. The aggregate principal amount of the 2027 Notes matures on October 1, 2027.
With proceeds from the New 2027 Notes and cash on hand, the Company (1) repaid $200,000 of its indebtedness under the Additional Term Loan and (2) paid $2,620 of fees and expenses related to the issuance of the New 2027 Notes, which were recorded as a reduction of the notes payable balance and are being amortized to interest expense over the remaining term of the 2027 Notes.

(c) The Companys 4.000% Senior Notes Due 2029
On October 20, 2020, the Company completed the issuance of $350,000 aggregate principal amount of the 2029 Notes, which mature on April 1, 2017.15, 2029. Interest on the 2029 Notes is fixed at 4.000% and payable semi-annually in arrears on April 15 and October 15 of each year, commencing April 15, 2021. With the proceeds from the 2029 Notes and cash generated from operations, the Company (1) repaid $131,250redeemed all of Original Term Loan indebtedness,its outstanding $325,000 aggregate principal amount of the 2024 Notes on November 4, 2020, (2) repaid $7,188paid $9,857 consisting of existing Second Term Loan indebtedness,the associated redemption premium and accrued and unpaid interest on the 2024 Notes, (3) repaid $182,500$40,000 under the Revolver,Senior Credit Facility and (4) paid $6,113 ofincurred $4,744 in fees and expenses related to the issuance and sale of the 2029 Notes, which were recorded as a reduction of the notes payable balance and are being amortized to interest expense over the term of the 2029 Notes.

In addition, the Company wrote off $2,992 of unamortized financing fees incurred in connection with the issuance of the 2024 Notes, which was recognized in interest expense, net, and other in the consolidated statements of comprehensive income for the year ended December 31, 2020.
The indenture governing the 2029 Notes contains covenants that, among other things, restrict the ability of the Company to:
sell assets,
pay dividends or make other distributions on capital stock, or make payments in respect of subordinated indebtedness or make other restricted payments,
make certain investments,
incur or guarantee additional indebtedness or issue preferred stock,
create or permit to exist, certain liens,
enter into agreements that restrict dividends or other payments from restricted subsidiaries,
consolidate, merge or transfer all or substantially all of its assets,
engage in transactions with affiliates, and
create unrestricted subsidiaries.
These covenants are subject to a number of important exceptions and qualifications. The indenture governing the 2029 Notes contains affirmative covenants and events of default that are customary for indentures governing high yield securities. The 2029 Notes and the related guarantees thereof are not subject to any registration rights agreements.
(c)
64

(d) Debt Balances


Outstanding debt balances as of December 31, 20172020 and 20162019 consisted of the following:
As of December 31,
As of December 31,20202019
Additional Term LoanAdditional Term Loan$21,875 $
2017 2016
Second Term Loan
 44,063
Notes325,000
 325,000
2024 Notes2024 Notes325,000 
2027 Notes2027 Notes500,000 300,000 
2029 Notes2029 Notes350,000 
Total debt outstanding325,000
 369,063
Total debt outstanding871,875 625,000 
Less unamortized fees(5,157) (6,121)
Less unamortized fees and premiumLess unamortized fees and premium(9,226)(7,841)
Less current portion of notes payable
 (3,750)Less current portion of notes payable(4,688)
Long-term portion of notes payable$319,843
 $359,192
Long-term portion of notes payable$857,961 $617,159 


The aggregate principal amount2024 Notes, which were redeemed by the Company during the fourth quarter of 2020, were issued in October 2016 and had a fixed interest rate of 5.125%. The Company repaid its outstanding indebtedness under the Notes mature on October 1, 2024.Additional Term Loan in January 2021. Additionally, in February 2021, the Company borrowed $25,000 under the Senior Credit Facility in the ordinary course of business.
(d)(e) Letters of Credit
 
At December 31, 2017,2020, the Company maintained outstanding standby letters of credit totaling $21,976$24,064 as collateral in relation to its professional liability insurance agreements, workers compensation insurance agreements and a corporate office lease agreement. Of the $21,976$24,064 outstanding letters of credit, the Company has collateralized $2,656$2,154 in cash and cash equivalents and the remaining amount has been$21,910 is collateralized by the Revolver.Senior Credit Facility. Outstanding standby letters of credit at December 31, 20162019 totaled $15,379.$19,752.
 
(9) Retirement Plans
 
The Company maintains the AMN Services 401(k) Retirement Savings Plan (the “AMN Plan”), which the Company believes complies with the IRC Section 401(k) provisions. The AMN Plan covers all employees that meet certain age and other eligibility requirements. An annualA discretionary matching contribution is determined by the Compensation and Stock Plan Committee of the Board of DirectorsCompany each year. Employer contribution expenses incurred under the AMN Plan were $4,486, $5,010$4,256, $5,516 and $1,618$5,250 for the years ended December 31, 2017, 20162020, 2019 and 2015,2018, respectively.
 
The Company has a deferred compensation plan for certain executives and key employees (the “Plan”). The Plan is not intended to be tax qualified and is an unfunded plan. The Plan is composed of deferred compensation and all related income and losses attributable thereto. Discretionary matching contributions to the Plan are made that vest incrementally so that the employee is fully vested in the match following five years of employment with the Company. Under the Plan, participants can defer up to 80% of their base salary, 90% of their bonus and 100% of their vested RSUs or vested PRSUs. An annualA discretionary matching contribution is determined by the Compensation and Stock Plan Committee of the Board of DirectorsCompany each year. Employer contributions under the Plan were $4,545, $3,032$2,845, $5,551 and $974$4,708 for the years ended December 31, 2017, 20162020, 2019 and 2015,2018, respectively. In connection with the administration of the Plan, the Company has purchased company-owned life insurance policies insuring the lives of certain officers and key employees. The cash surrender value of these policies was $48,145$98,161 and $32,190$79,515 at December 31, 20172020 and 2016,2019, respectively. The cash surrender value of these insurance policies is included in other assets in the consolidated balance sheets.
 
(10) Capital Stock
 
(a) Preferred Stock
 
The Company has 10,000 shares of preferred stock authorized for issuance in one or more series (including preferred stock designated as Series A Conditional Convertible Preferred Stock), at a par value of $0.01$0.01 per share.At December 31, 20172020 and 2016, no 2019, 0shares of preferred stock were outstanding.


(b) Treasury Stock
 
On November 1, 2016, the Company’s Board of Directors approved a share repurchase program under which the Company may repurchase up to $150,000 of its outstanding common stock. The amount and timing of the purchases will depend on a number of factors including the price of the Company’s shares, trading volume, Company performance, Company
65

liquidity, general economic and market conditions and other factors that the Company’s management believes are relevant. The share repurchase program does not require the purchase of any minimum number of shares and may be suspended or discontinued at any time.


The Company intends to make all repurchases and to administer the plan in accordance with applicable laws and regulatory guidelines, including Rule 10b-18 of the Exchange Act, and in compliance with its debt instruments. Repurchases
may be made from cash on hand, free cash flow generated from the Company’s business or from the Company’s Revolver.Senior Credit Facility. Repurchases may be made from time to time through open market purchases or privately negotiated transactions. Repurchases may also be made pursuant to one or more plans established pursuant to Rule 10b5-1 under the Exchange Act whichthat would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insiderthe Company’s securities trading restrictions.policy.


During 2017,the year ended December 31, 2020, the Company did 0t repurchase any shares of its common stock. During the year ended December 31, 2019, the Company repurchased 487395 shares of its common stock at an average price of $41.41$47.30 per share, resulting in an aggregate purchase price of $20,164. During 2016, the Company repurchased 443 shares of its common stock at an average price of $29.88 per share, resulting in an aggregate purchase price of $13,261.$18,705.


(11) Share-Based Compensation
 
(a) Equity Award Plans
 
Equity Plan
 
The Company established the AMN Healthcare Equity Plan (as amended or amended and restated from time to time, the “Equity Plan”), which has been approved by the Company’s stockholders. At the time of the Equity Plan’s original adoption in 2006, equity awards, based on the Company’s common stock, could be issued for a maximum of 723 shares plus the number of shares of common stock underlying any grants under the Stock Option Plan (under which there are no longer any outstanding awards) that were forfeited, canceled or terminated (other than by exercise) from and after the effective date of the Equity Plan. Pursuant to the Equity Plan, stock options and stock appreciation rights (“SARs”) granted have a maximum contractual life of

ten years and have exercise prices that will be determined at the time of grant, which will be no less than fair market value of the underlying common stock on the date of grant. Any shares to be issued under the Equity Plan will be issued by the Company from authorized but unissued common stock or shares of common stock reacquired by the Company. On April 18, 2007, April 9, 2009, April 18, 2012 and April 28,19, 2017, the Company amended the Equity Plan, with stockholder approval, to increase the number of shares authorized under the Equity Plan by 3,000,, 1,850,, 2,400 and 1,400, respectively. At As of December 31, 20172020 and 2016, respectively, 3,2442019, 2,830 and 1,9332,930 shares of common stock were reserved for future grants under the Equity Plan.Plan, respectively.
 
Other Plans
 
From time to time, the Company grants, and has granted, key employees inducement awards outside of the Equity Plan (collectively, “Other Plans”), which have recently consisted of SARs, options or RSUs. Although these awards are not made under the Equity Plan, the key terms and conditions of the grant are typically the same as equity awards made under the Equity Plan.


Additionally, in February 2014, the Company established the 2014 Employment Inducement Plan, which reserves for issuance 200 shares of common stock for prospective employees of the Company. As of December 31, 2017, 2002020, 179 shares of common stock remained available for future grants under the 2014 Employment Inducement Plan.
 
66

(b) Share-Based Compensation
 
Restricted Stock Units
 
RSUs and PRSUs (subject to a PRSU being earned) granted under the Equity Plan generally entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company’s common stock. The following table summarizes RSU and PRSU activity for non-vested awards for the years ended December 31, 2017, 20162020, 2019 and 2015:2018:
Number of SharesWeighted Average
Grant Date
Fair Value per
Share
Number of Shares 
Weighted Average
Grant Date
Fair Value per
Share
Unvested at January 1, 20151,575
 $11.95
Unvested at January 1, 2017Unvested at January 1, 2017855 $30.98 
Granted—RSUs203
 $22.43
Granted—RSUs279 $53.73 
Granted—PRSUs (1)616
 $13.58
Granted—PRSUs (1)266 $35.28 
Vested(1,081) $9.13
Vested(499)$23.04 
Canceled/forfeited/expired(76) $15.45
Canceled/forfeited/expired(83)$42.32 
Unvested at December 31, 20151,237
 $16.73
Unvested at December 31, 2018Unvested at December 31, 2018818 $43.84 
Granted—RSUs180
 $32.65
Granted—RSUs191 $54.99 
Granted—PRSUs (1)361
 $20.88
Granted—PRSUs (1)201 $48.32 
Vested(641) $14.90
Vested(400)$35.46 
Canceled/forfeited/expired(62) $22.57
Canceled/forfeited/expired(52)$41.09 
Unvested at December 31, 20161,075
 $22.14
Unvested at December 31, 2019Unvested at December 31, 2019758 $52.45 
Granted—RSUs166
 $40.73
Granted—RSUs271 $60.02 
Granted—PRSUs (1)317
 $27.51
Granted—PRSUs (1)155 $64.59 
Vested(637) $16.88
Vested(283)$49.18 
Canceled/forfeited/expired(66) $30.02
Canceled/forfeited/expired(184)$53.84 
Unvested at December 31, 2017855
 $30.98
Unvested at December 31, 2020Unvested at December 31, 2020717 $58.88 
 
(1) PRSUs granted included both the PRSUs granted during the year at the target amount and the additional shares of prior period granted PRSUs vested during the year in excess of the target shares.


As of December 31, 2017,2020, there was $11,679$16,972 unrecognized compensation cost related to non-vestedunvested RSUs and PRSUs. The Company expects to recognize such cost over a period of 1.81.7 years. As of December 31, 20172020 and 2016,2019, the aggregate intrinsic value of the RSUs and PRSUs outstanding was $42,103$48,945 and $41,317,$47,242, respectively.



Stock Options and SARs
 
Stock options entitle the holder to purchase, at the end of a vesting period, a specified number of shares of the Company’s common stock at a price per share set at the date of grant. SARs entitle the holder to receive, at the end of a vesting period, shares of the Company’s common stock equal in value to the difference between the exercise price of the SAR, which is set at the date of grant, and the fair market value of the Company’s common stock on the date of exercise.
67

A summary of stock option and SAR activity under the Stock Option Plan and the Equity Plan and Other Plans are as follows:
Stock Option Plan Equity Plan and Other Plans Number
Outstanding
Weighted-
Average
Exercise Price
per Share
Number
Outstanding
 
Weighted-
Average
Exercise Price
per Share
 
Number
Outstanding
 
Weighted-
Average
Exercise Price
per Share
Outstanding at December 31, 2014245
 $14.93
 948
 $10.61
Outstanding at December 31, 2017Outstanding at December 31, 2017262 $8.81 
Granted
 $
 
 $
Granted$
Exercised(245) $14.93
 (615) $10.79
Exercised(35)$10.12 
Canceled/forfeited/expired
 $
 (1) $24.95
Canceled/forfeited/expired$
Outstanding at December 31, 2015
 $
 332
 $10.26
Outstanding at December 31, 2018Outstanding at December 31, 2018227 $8.61 
Granted
 $
 
 $
Granted$
Exercised
 $
 (44) $13.69
Exercised(215)$8.67 
Canceled/forfeited/expired
 $
 (2) $18.03
Canceled/forfeited/expired$
Outstanding at December 31, 2016
 $
 286
 $9.67
Outstanding at December 31, 2019Outstanding at December 31, 201912 $7.51 
Granted
 $
 
 $
Granted$
Exercised
 $
 (24) $18.85
Exercised(12)$7.51 
Canceled/forfeited/expired
 $
 
 $
Canceled/forfeited/expired$
Outstanding at December 31, 2017
 $
 262
 $8.81
Vested and expected to vest at December 31, 2017
 $
 262
 $8.81
Exercisable at December 31, 2017
 $
 262
 $8.81
Outstanding at December 31, 2020Outstanding at December 31, 2020$
Vested and expected to vest at December 31, 2020Vested and expected to vest at December 31, 2020$
Exercisable at December 31, 2020Exercisable at December 31, 2020$
 
As of December 31, 2017, all SARs were fully vested, and2020, there were no0 stock options or SARs outstanding. The total intrinsic value of stock options and SARs exercised was $555, $877$828, $9,177 and $10,505$1,535 for 2017, 20162020, 2019 and 2015,2018, respectively. At As of December 31, 2017 and 2016,2019, the total intrinsic value of stock options and SARs outstanding and exercisable was $10,674 and $8,247, respectively.$645.


Share-Based Compensation
 
Total share-based compensation expense for the years ended December 31, 2017, 20162020, 2019 and 20152018 was as follows:
 
Years Ended December 31, Years Ended December 31,
2017 2016 2015 202020192018
Share-based employee compensation, before tax$10,237
 $11,399
 $10,284
Share-based employee compensation, before tax$20,465 $16,241 $10,815 
Related income tax benefits(3,985) (4,423) (3,990)Related income tax benefits(5,321)(4,223)(2,812)
Share-based employee compensation, net of tax$6,252
 $6,976
 $6,294
Share-based employee compensation, net of tax$15,144 $12,018 $8,003 
 


(12) Commitments and Contingencies
(a) Legal

From time to time, the Company is involved in various lawsuits, claims, investigations, and proceedings that arise in the
ordinary course of business. These matters typically relate to professional liability, tax, payroll,compensation, contract, competitor disputes and employee-related matters and include individual and collectiveclass action lawsuits, as well as inquiries and investigations by governmental agencies regarding the Company’s employment and compensation practices. Additionally, some of the Company’s clients may also

become subject to claims, governmental inquiries and investigations, and legal actions relating to services provided by the Company’s healthcare professionals. Depending upon the particular facts and circumstances, the Company may also be subject to indemnification obligations under its contracts with such clients relating to these matters.

The Company accrues for contingencies and records a liability when management believes an adverse outcome from a loss contingency is both probable and the amount, or a range, can be reasonably estimated. Significant judgment is required to determine both probability of loss and the estimated amount. The Company reviews its loss contingencies at least quarterly and adjusts its accruals and/or disclosures to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, or other new information, as deemed necessary. The most significant matters for which the Company has established loss contingencies are class actions related to wage and hour claims under California and Federal law. Specifically, among other claims in these lawsuits, it is alleged that certain expense reimbursements should be considered wages and included in the regular rate of pay for purposes of calculating overtime rates,rates.

68

On May 26, 2016, former travel nurse Verna Maxwell Clarke filed a complaint against AMN Services, LLC, in California Superior Court in Los Angeles County. The Company removed the case to the United States District Court for the Central District of California (Case No. 2:16-cv-04132-DSF-KS) (the “Clarke Matter”). The complaint asserts that, due to the Company’s per diem adjustment practices, traveling nurses’ per diem benefits should be included in their regular rate of pay for the purposes of calculating their overtime compensation; and that employeesthe Company’s wage statements do not comply with the requirements of California law. On June 26, 2018, the Court denied the plaintiffs’ Motion for Summary Judgment in its entirety, and granted the Company’s Motion for Summary Judgment with respect to the Plaintiffs’ per diem and overtime claims. The plaintiffs filed an appeal of the judgment relating to the per diem claims with the Ninth Circuit Court of Appeals. On February 8, 2021, a three-judge panel of the Ninth Circuit Court of Appeals issued an opinion that reversed the district court’s granting of the Company’s Motion for Summary Judgment and remanded the matter to the district court instructing the district to enter partial summary judgment in favor of the Plaintiffs. The Company intends to appeal the Ninth Circuit’s decision and continue to defend the lawsuit vigorously.

On May 2, 2019, former travel nurse Sara Woehrle filed a complaint against AMN Services, LLC, and Providence Health System – Southern California in California Superior Court in Los Angeles County. The Company removed the case to the United States District Court for the Central District of California (Case No. 2:19-cv-05282 DSF-KS). The complaint asserts that, due to the Company’s per diem adjustment practices, traveling nurses’ per diem benefits should be included in their regular rate of pay for the purposes of calculating their overtime compensation. The Complaint also alleges that the putative class members were not affordeddenied required breaks ormeal periods, denied proper overtime compensation, were not compensated for all time worked. Whileworked, including reporting time and training time, and received non-compliant wage statements. The case was stayed pending a decision by the 9th circuit in the Clarke Matter.

The Company believes that its wage and hour practices, including those associated with the cases described above, conform with the applicable law in all material respects, litigation is always subject torespects. However, because of the recent ruling by the 9th Circuit of Appeals, the inherent uncertainty of litigation, and the Company is not able to reasonably predict if any matter will be resolved in a manner that is materially adverse to the Company, it recorded an increase to its accruals established in connection with the matters described above amounting to $20,000 during the fourth quarter of 2020. In addition, while the Company continues to believe that it has meritorious defenses against the suits described above, the ultimate resolution of these matters could result in a loss of up to $15,000, excluding interest and penalties, in excess of the amounts currently accrued. For all other matters, the Company is unable to currently estimate the possible loss or range of loss beyond the amounts already accrued.

With regards to outstanding loss Loss contingencies accrued as of December 31, 2017, which2020 are included in accounts payable and accrued expenses and other long-term liabilities in the consolidated balance sheet, the Company believes that such matters will not, either individually or in the aggregate, have a material adverse effect on its business, consolidated financial position, results of operations, or cash flows.sheets.
 
(b) Leases
The Company leases certain office facilities and equipment under various operating leases. The Company recognizes rent expense on a straight-line basis over the lease term. Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) as of December 31, 2017 are as follows:
  
Operating
Leases
Years ending December 31,  
2018 $16,962
2019 16,969
2020 16,913
2021 16,969
2022 16,777
Thereafter 66,439
Total minimum lease payments $151,029
Rent expense under operating leases was $20,529, $18,793, and $15,940 for the years ended December 31, 2017, 2016 and 2015, respectively.

(13) Quarterly Financial Data (Unaudited)
 
 Year Ended December 31, 2020
 First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Total Year
 (In thousands, except per share data)
Revenue$602,461 $608,351 $551,631 $631,271 $2,393,714 
Gross profit$202,066 $197,540 $184,633 $207,539 $791,778 
Net income$12,965 $22,325 $26,067 $9,308 $70,665 
Net income per share from:
Basic$0.27 $0.47 $0.55 $0.20 $1.49 
Diluted$0.27 $0.47 $0.55 $0.19 $1.48 

 Year Ended December 31, 2019
 First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Total Year
 (In thousands, except per share data)
Revenue$532,441 $535,177 $567,597 $586,892 $2,222,107 
Gross profit$176,759 $179,542 $190,031 $197,133 $743,465 
Net income$34,122 $28,869 $23,515 $27,482 $113,988 
Net income per share from:
Basic$0.73 $0.62 $0.50 $0.59 $2.44 
Diluted$0.71 $0.61 $0.49 $0.58 $2.40 

69
 Year Ended December 31, 2017
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 Total Year
 (In thousands, except per share data)
Revenue$495,169
 $489,803
 $494,406
 $509,076
 $1,988,454
Gross profit$161,776
 $161,012
 $159,539
 $162,092
 $644,419
Net income$32,008
 $31,255
 $28,128
 $41,167
 $132,558
Net income per share from:         
Basic$0.67
 $0.65
 $0.59
 $0.86
 $2.77
Diluted$0.65
 $0.63
 $0.57
 $0.84
 $2.68


                        

Net income for the fourth quarter of 2017 included a discrete net tax benefit of $14,039 in connection with the Company's initial analysis of the impact of the Tax Act. See Note (7), “Income Taxes,” for additional information.
 Year Ended December 31, 2016
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 Total Year
 (In thousands, except per share data)
Revenue$468,002
 $473,729
 $472,636
 $487,858
 $1,902,225
Gross profit$151,898
 $154,753
 $154,467
 $158,606
 $619,724
Net income$25,869
 $26,322
 $27,296
 $26,351
 $105,838
Net income per share from:         
Basic$0.54
 $0.55
 $0.57
 $0.55
 $2.21
Diluted$0.53
 $0.53
 $0.55
 $0.54
 $2.15
Item 9.Changes In and Disagreements With Accountants on Accounting and Financial Disclosure
Item 9.    Changes In and Disagreements With Accountants on Accounting and Financial Disclosure
 
None.
 
Item 9A.Controls and Procedures
Item 9A.    Controls and Procedures
 
(1) Evaluation of Disclosure Controls and Procedures
 
We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of December 31, 20172020 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
 
(2) Management’s Annual Report on Internal Control over Financial Reporting
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Based on the framework set forth in Internal Control—Integrated Framework (2013), management concluded that our internal control over financial reporting was effective as of December 31, 2017.2020.


A registrant may omit an assessment of an acquired business’s internal control over financial reporting from the registrant’s assessment of its internal control; however, such an exclusion may not extend beyond one year from the date of the acquisition, nor may such assessment be omitted from more than one annual management report on internal control over financial reporting. We acquired Stratus Video (the “acquired entity”) during 2020, and we excluded from the assessment of the effectiveness of our internal control over financial reporting as of December 31, 2020, the acquired entity’s internal control over financial reporting associated with total assets of $537.1 million (of which $483.1 million represents goodwill and intangible assets included within the scope of the assessment) and total revenues of $116.1 million included in our consolidated financial statements as of and for the year ended December 31, 2020.

The effectiveness of our internal control over financial reporting as of December 31, 20172020 has been audited by KPMG LLP, an independent registered public accounting firm, as stated in its report, which we include herein.
 
(3) Changes in Internal Control Over Financial Reporting
 
There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 20172020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
70

                        

(4) Report of Independent Registered Public Accounting Firm
 
TheTo the Stockholders and Board of Directors
AMN Healthcare Services, Inc.:
 
Opinion on Internal Control Over Financial Reporting
We have audited AMN Healthcare Services, Inc. and subsidiaries’ (the "Company")Company) internal control over financial reporting as of December 31, 2017,2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017,2020, based on criteria established in Internal Control - Integrated Framework (2013)issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB")(PCAOB), the consolidated balance sheets of the Company as of December 31, 20172020 and 2016, and2019, the related consolidated statements of comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2017,2020, and the related notes (collectively, the "consolidatedconsolidated financial statements")statements), and our report dated February 16, 201826, 2021 expressed an unqualified opinion on those consolidated financial statements.
The Company acquired Stratus Video, during 2020, and management excluded from its assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2020, Stratus Video’s internal control over financial reporting associated with total assets of $537.1 million (of which $483.1 million represents goodwill and intangible assets included within the scope of the assessment) and total revenues of $116.1 million included in the consolidated financial statements of the Company as of and for the year ended December 31, 2020. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Stratus Video
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

71

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
/s/ KPMG LLP
 
San Diego, California
February 16, 201826, 2021


72

                        

Item 9B.Other Information
None.Item 9B.    Other Information
 
On February 22, 2021, Michael M.E. Johns, M.D., a member of the Board of Directors (the “Board”) of AMN Healthcare Services, Inc. (the “Company”), provided notice to the Company that he does not intend to stand for re-election as a director of the Company upon expiration of his current term at the Company’s 2021 annual meeting (the “2021 Annual Meeting”). Dr. Johns has served as a valuable director on the Board for 12 years and his decision to retire was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

As a result of Dr. Johns’ decision not to stand for re-election, on February 25, 2021 the Board approved decreasing the size of the Board to eight members, effective upon the election of the Company’s directors at the 2021 Annual Meeting.
PART III
 
Item 10.Directors, Executive Officers and Corporate Governance
Item 10.    Directors, Executive Officers and Corporate Governance
 
Information required by this item, other than the information below concerning our Code of Ethics for Senior Financial Officers and stockholder recommended nominations, is incorporated by reference to the Proxy Statement to be distributed in connection with our Annual Meeting of Stockholders currently scheduled to be held on April 18, 201821, 2021 (the “2018“2021 Annual Meeting Proxy Statement”) under the headings “Election of Directors—Our Director Nominees, for the Board of Directors,” “Executive Compensation Disclosure—Non-Director Executive Officers,Disclosure,” “Security Ownership and Other Matters—Section 16(a) Beneficial Ownership Reporting Compliance,” the table set forth in “Corporate Governance—Committees of the Board” identifying, among other things, members of our Board committees, and “Corporate Governance—Committees of the Board.”
 
We have adopted a Code of Ethics for Senior Financial Officers that applies to our principal executive officer, principal financial officer, and principal accounting officer or any person performing similar functions, which we post on our website in the “Corporate Governance” link located at www.amnhealthcare.com/investors. We intend to publish any amendment to, or waiver from, the Code of Ethics for Senior Financial Officers on our website. We will provide any person, without charge, a copy of such Code of Ethics upon written request, which may be mailed to 12400 High Bluff Drive, Suite 100, San Diego, California 92130, Attn: Corporate Secretary.
 
There have been no material changes to the procedures by which stockholders may recommend nominees to our Board since we last disclosed information related to such procedures.
 
Item 11.Executive Compensation
Item 11.    Executive Compensation
 
Information required by this item is incorporated by reference to the 20182021 Annual Meeting Proxy Statement under the headings “Compensation, Discussion and Analysis,” “Executive Compensation Disclosure,” “Director Compensation and Stock Ownership Guidelines,” “Corporate Governance—Board Role InEnterprise Risk Oversight,” “Corporate Governance—Committees of the Board—Compensation Committee—Compensation Committee Interlocks and Insider Participation,” and “Compensation Committee Report.Report on Executive Compensation.
 
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
 
Information required by this item, other than the information below concerning our equity compensation plans, is incorporated by reference to the 20182021 Annual Meeting Proxy Statement under the headings “Security Ownership and Other Matters—Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information atManagement.”

The following table sets forth information as of December 31, 2017.2020 regarding compensation plans under which our equity securities are authorized for issuance.

73

(a)(b)(c)
Number of Securities
to be Issued upon Exercise of Outstanding Options, Warrants and Rights(1)
 
Weighted-Average Exercise Price of Outstanding Options, Warrants, and Rights ($)
 
Numbers of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column(a))(2)

Plan Category
Equity compensation plans approved by security holders696,200 $—2,829,752 
Equity compensation plans not approved by security holders (3)
20,944 179,056 
    
Total717,144 $—3,008,808 

(1) Includes RSUs and PRSUs. As of December 31, 2020, there were no stock options or SARs outstanding. The weighted-average exercise price set forth in this table excludes the effect of RSUs and PRSUs, which have no exercise price.
(2) Under the Equity Plan, each share (a) tendered or held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding with respect to an award, or (b) subject to SARs that are not issued in connection with the settlement of the SARs on exercise thereof, is made available to be re-awarded. For PRSUs, we consider the maximum number of shares that may be issued under the award to be outstanding upon grant. When the number of PRSUs that have been earned are determined, we true-up the actual number of shares that were awarded and return the unearned shares into shares available for issuance. This figure does not include shares underlying our Equity Plan that are forfeited, canceled or terminated after December 31, 2020. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (11), Share-Based Compensation.
(3) On occasion, we have made employee award inducement equity grants to key employees outside of the Equity Plan. Although these awards were made outside of the Equity Plan, the key terms and conditions of each grant are the same in all material respects as equity awards made under the Equity Plan. Additionally, in 2014, the Board adopted the Company’s 2014 Employment Inducement Plan under which we may issue up to 200,000 shares of our common stock to prospective employees. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (11), Share-Based Compensation.”

Item 13.Certain Relationships and Related Transactions, and Director Independence
Item 13.    Certain Relationships and Related Transactions, and Director Independence
 
Information required by this item is incorporated by reference to the 20182021 Annual Meeting Proxy Statement under the headings “Corporate Governance—Board Policy onPolicies and Procedures Governing Conflicts of Interest and Related Party Transactions,” “Corporate Governance—Director Independence,” and “Corporate Governance—Committees of the Board.”
 
Item 14.Principal Accounting Fees and Services
Item 14.    Principal Accounting Fees and Services
 
Information required by this item is incorporated by reference to the 20182021 Annual Meeting Proxy Statement under the heading “Ratification of the Selection of Independent Registered Public Accounting Firm.”
74

                        

PART IV
 
Item 15.Exhibits and Financial Statement Schedules
Item 15.    Exhibits and Financial Statement Schedules
 
(a) Documents filed as part of the report.
 
(1) Consolidated Financial Statements
 
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 20172020 and 20162019
Consolidated Statements of Comprehensive Income for the years ended December 31, 2017, 20162020, 2019
and 20152018
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2017, 20162020, 2019 and 20152018
Consolidated Statements of Cash Flows for the years ended December 31, 2017, 20162020, 2019 and 20152018
Notes to Consolidated Financial Statements
 
(2) Financial Statement Schedules
 
All schedules have been omitted because the required information is presented in the financial statements or notes thereto, the amounts involved are not significant or the schedules are not applicable.
 
(3) Exhibits
75

                        



Exhibit
Number
Description
2.1
2.2
3.12.3 
2.4 
2.5 
3.1 
3.2
3.3
4.1
4.2
10.14.3 
4.4 
4.5 
10.1 
10.2
First Amendment to Credit Agreement, dated as of January 4, 2016,June 14, 2019, by and among AMN Healthcare, Inc., as borrower, AMN Healthcare Services, Inc.the guarantors party thereto, AMN Services, LLC, O’Grady-Peyton International (USA), Inc., AMN Staffing Services, LLC, Merritt, Hawkins & Associates, LLC, AMN Healthcare Allied, Inc., Staff Care, Inc., AMN Allied Services, LLC, Rx Pro Health, LLC, Nursefinders, LLC, Linde Health Care Staffing, Inc., Shiftwise, Inc., The First String Healthcare, Inc., MillicanSolutions, LLC, Avantas, LLC, Onward Healthcare, LLC, Locum Leaders, Inc., and Medefis, Inc., as guarantors, the lenders identified on the signature pages thereto, as lenders, and SunTrust Bank, as administrative agent (Incorporated by reference to Exhibit 10.2 of4.1 to the Registrant’s AnnualQuarterly Report on Form 10-K10-Q for the yearquarter ended December 31, 2015,June 30, 2019, filed with the SEC on February 24, 2016)August 7, 2019).
10.3
10.4
76

10.5
Exhibit
Number

Description
10.5 
10.6
10.7
10.8

Exhibit
Number
10.9 
Description
10.9
10.10
10.11
10.12
10.13
10.14
10.15
10.16
10.17
10.18
10.19
10.20
77

10.21
Exhibit
Number

Description
10.21 
10.22
10.23 
10.24 
10.25 
10.26 
10.27 
10.28 
10.29 
10.30 
10.31 
10.32 
10.2310.33 
10.2410.34 

Exhibit
Number
10.35 
Description
10.25
10.26
10.27
10.28
78

Exhibit
Number
Description
10.29
10.36 
21.110.37 
10.38 
10.39 
10.40 
10.41 
21.1 
23.1
31.1
31.2
32.1
32.2
101.INS
XBRL Instance Document.*
101.SCH
XBRL Taxonomy Extension Schema Document.*
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB
XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document.*



*Filed herewith.
*Filed herewith.
**Incorporated by reference to the applicable exhibit of the Registrant’s Current Report on Form 8-K dated April 12, 2006, filed with the SEC on April 14, 2006.
***Incorporated by reference to the applicable exhibit of the Registrant’s Current Report on Form 8-K dated February 12, 2008, filed with the SEC on February 12, 2008.

Item 16.    Form 10-K Summary
None.

79

                        

SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
AMN HEALTHCARE SERVICES, INC.
/S/    SUSAN R. SALKA
Susan R. Salka

President and Chief Executive Officer
 
Date: February 16, 201826, 2021
 


Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated and on February 16, 2018.26, 2021.
 
/S/    SUSAN R. SALKA
Susan R. Salka

Director, President and Chief Executive Officer

(Principal Executive Officer)
/S/    BRIAN M. SCOTT
/S/    BRIAN M. SCOTT
Brian M. Scott

Chief Accounting Officer,

Chief Financial Officer and Treasurer

(Principal Accounting and Financial Officer)
/S/    DOUGLAS D. WHEAT
/S/    DOUGLAS D. WHEAT
Douglas D. Wheat

Director and Chairman of the Board
/S/    MARK G. FOLETTA
Mark G. Foletta
Director
/S/    MARKS/    TERI G. FOLETTAONTENOT
MarkTeri G. Foletta
Fontenot
Director
Director/S/    R. JEFFREY HARRIS
R. Jeffrey Harris
Director
/S/    R.MICHAEL M.E. JEFFREY HARRISOHNS
Michael M.E. Johns
Director
R. Jeffrey Harris
Director/S/    DAPHNE E. JONES
Daphne E. Jones
Director
/S/    MICHAEL M.E. JOHNSARTHA H. MARSH
Martha H. Marsh
Director
Michael M.E. Johns
Director/S/    SYLVIA TRENT-ADAMS
/S/    MARTHA H. MARSH
Martha H. Marsh
Sylvia Trent-Adams
Director
/S/    ANDREW M. STERN
Andrew M. Stern
Director
/S/    PAUL E. WEAVER
Paul E. Weaver
Director


65
80